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ABSTRACT IN ENGLISH 
Methylmalonic acidurias represent a group of rare inborn errors of metabolism caused by deficient 
activity of the mitochondrial enzyme methylmalonyl-CoA mutase (MUT). Deficiency of MUT results 
either from defects of the MUT apoenzyme itself, which is encoded by the MUT gene, or from defects 
of the intracellular synthesis of its cofactor, 5-deoxyadenosylcobalamin, and leads to the accumula-
tion of methylmalonic acid and other toxic metabolites. Methylmalonic aciduria (MMAuria) typically 
presents in early infancy with life-threatening metabolic decompensations. Most surviving patients 
show failure to thrive and develop chronic renal failure linked to tubulointerstitial nephritis. Moreo-
ver, approximately half of them suffer from severe neurological impairment such as an extrapyram-
idal movement disorder. Although the symptoms observed in MMAuria are thought to be the result 
of the accumulation of toxic intermediary products, knowledge concerning pathomechanisms is 
scarce, and the evidence base and efficacy of current treatment strategies is not satisfactory. A fun-
damental limitation for pathophysiological studies is that durable animal models of MMAuria have 
not been established, i.e. full knockout mice display neonatal lethality. 
Given the severe phenotypic and pathological outcomes of MMAuria there is an imminent need to 
explore the pathomechanisms of MMAuria and search for novel therapeutic approaches. In this PhD 
thesis, this problem is tackled by 1) characterizing a cohort of MMAuria patients regarding their mu-
tations and biochemical properties; 2) investigating functional consequences of MUT missense mu-
tations on enzyme activity, cofactor binding, structural protein integrity, and thermal stability; 3) in-
vestigating the effect of the cobalamin cofactor of MUT and of screening-derived small molecule 
chaperones on MUT protein stability and enzymatic activity; and 4) validation and characterization 
of novel conditional Mut knock-out and constitutive Mut knock-in mice in order to study the recapit-
ulation of MMAuria in these models. 
The analysis of MMAuria patients revealed a very diverse cohort with regard to mutations and mu-
tation types, enzymatic and biochemical properties, and clinical phenotype. Further detailed analy-
sis of 23 missense mutations derived from this cohort, allowed an in-depth categorization of these 
mutations into various classes of biochemical defects, identifying specific missense mutations which 
were judged to be of value in pursuing the aims of two follow-up studies: 
i. Identification of missense mutations that produce an unstable protein allowed addition of 
MMAuria to the list of misfolding disorders. We established MUT as a suitable candidate for 
pharmacological chaperone screening in which identified small molecules that can rescue 
unstable MUT protein via stabilization. 
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ii. A missense allele which correlates to low residual enzyme activity and to an intermediate 
MMAuria clinical phenotype was selected in order to generate a novel knock-in mouse 
model which was successfully validated as an accurate model recapitulating human MMAu-
ria and which may be further utilized as a tool in future studies on pathomechanisms and 
treatment of MMAuria.  
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ABSTRACT IN GERMAN 
Methylmalonazidurien bilden eine Gruppe im Bereich der seltenen angeborenen Stoffwechselstö-
rungen und sind durch einen Mangel des mitochondrialen Enzyms Methylmalonyl-CoA Mutase 
(MUT; codiert durch das MUT Gen) verursacht. Die Defizienz dieses Enzyms rührt entweder von ei-
nem Defekt im Apoenzym MUT selbst oder von einem Defekt in der intrazellulären Synthese des 
essenziellen Kofaktors Adenosylcobalamin her. Durch die Fehlfunktion des MUT-Enzyms kommt es 
zur Akkumulation von Methylmalonsäure und anderen Metaboliten, welche sich toxisch auf den Or-
ganismus auswirken. Methylmalonazidurien präsentieren sich typischerweise im Säuglingsalter mit 
lebensbedrohlichen metabolischen Entgleisungen. Die meisten Patienten, welche diese initiale Krise 
überleben, leiden unter Gedeihstörungen und entwickeln basierend auf einer tubulo-interstitiellen 
Nephritis ein chronisches Nierenversagen. Bei der Hälfte der überlebenden Patienten entwickeln 
sich zudem schwere neurologische Defekte mit extrapyramidalen Bewegungsstörungen. Obwohl 
vermutet wird, dass die Akkumulation von toxischen Stoffwechselzwischenprodukten zu den 
schweren Krankheitsfolgen führt, mangelt es an präzisem, evidenzbasiertem Wissen bezüglich der 
Pathomechanismen und die heutigen Therapieansätze zeitigen nur unbefriedigende Ergebnisse. 
Eine fundamentale Limitation der Erforschung der Methylmalonazidurie stellen dabei fehlende Tier-
modelle dar, welche eine Langzeituntersuchung von phänotypischen Krankheitsaspekten erlauben 
würden. 
Angesichts des schweren Krankheitsbildes der Methylmalonazidurie besteht dringender Bedarf an 
Forschungsprojekten, welche die Grundlage zur Entwicklung von neuartigen Therapien legen. In 
dieser Dissertation verfolgen verschiedene Subprojekte dieses Ziel: 1) Charakterisierung einer Ko-
horte von Methylmalonazidurie-Patienten hinblicklich des Genotyps und biochemischer Eckdaten; 
2) Untersuchung der funktionalen Konsequenzen von MUT missense Mutationen auf die Enzymakti-
vität, Kofaktoraffinität, Proteinstabilität und Thermostabilität der Genprodukte; 3) Bestimmung des 
Effekts des Cobalamin-Kofaktors und anderer Chaperonmoleküle auf die Enzymaktivität und Stabili-
tät von MUT; 4) Validierung und Charakterisierung von neuen konditionalen Mut knock-out und kon-
stitutiven Mut knock-in Mausmodellen. 
Die Analyse der Patienten-Kohorte ergab ein diverses Portfolio von verschiedenen MUT Mutationen 
mit unterschiedlichen Auswirkungen auf die biochemischen Eigenschaften des Enzyms. Die detail-
lierte Untersuchung von 23 missense Mutationen erlaubte deren Verwendung in weiterführenden 
Studien: 
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i. Aufgrund der Beschreibung von instabilen missense Mutanten, konnte die Methylmalonazi-
durie als Fehlfaltungs-Krankheit kategorisiert werden. Dies erlaubte ein spezifisches Scree-
ning nach Chaperonmolekülen und deren Validierung als Stabilisatoren von MUT. 
ii. Die Identifikation einer mittelschweren missense Mutation erlaubte die Entwicklung eines 
überlebungsfähigen Mausmodells, welches zahlreiche Aspekte der menschlichen Methyl-
malonazidurie rekapituliert und sich als wertvollen Forschungsgegenstand zukünftiger Stu-
dien im Bereich der Pathomechanismen und Therapieformen der Methylmalonazidurie an-
bietet. 
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1 INTRODUCTION 
1.1 MUTATION IS THE ORIGIN OF GENETIC DISEASE 
Variation in the genomic sequence occurs within and among populations. In Homo sapiens sapiens 
the similarity among all individuals regarding their DNA sequence has always thought to be around 
99.9%. Recently, this number has been corrected and lowered to 99.5% (Redon, et al., 2006). A num-
ber which is actually surprisingly low, when considering the similarity between the DNA sequences 
from chimps (Pan troglodytes) and humans, which accounts for about 98% depending on the com-
parison method (Britten, 2002; Chimpanzee-Sequencing-Consortium, 2005; Wildman, et al., 2003). 
The overall similarity to mice was found to be around 90% (Church, et al., 2009; Gunter and Dhand, 
2002). When it comes to the coding part of the DNA, the genes, it is even more surprising how similar 
organisms from different species are at the genetic level. As a matter of fact, it is estimated that all 
life forms on our planet share about 50% of their genes – a phenomenon explained by universal 
common ancestry (Theobald, 2010). On the one hand it is striking that life on earth is based on such 
similar genetic material, on the other hand individuals from the same species are, genetically spoken, 
surprisingly different from each other. 
Traits of individuals are influenced by environmental factors and their genetic background. This is 
why genetic variation plays an important role in life. During evolution stochastic changes in the DNA 
of organisms were crucial for the development of all life forms. The new variants were subjected to 
selection processes, which lead to the evolution of the genetic material and subsequently to the 
genesis of new traits and finally novel species. The reasons why variation in DNA occurs are not dis-
cussed here. But this process of random genetic changes is not limited to ancient times – it is still 
ongoing and the human genome is still evolving. Genetic changes are partly responsible for pheno-
typic variation but go unnoticed in many cases. However, in some cases a variant can cause a mal-
function of a gene which is relevant to the health of the organism. In other words, certain variants 
can occasionally cause disease in humans. In this case, the variants are referred to as mutations. 
Mutations and their nomenclature are complex. There are not only simple base pair exchanges, but 
rather several different ways how DNA can be changed, modified, and rearranged. They are exten-
sively discussed in this thesis. Often traits are only partially influenced by a single DNA change and a 
combination of many changes in different genes are required to make an individual more vulnerable 
to be affected by a specific disease, e.g. diabetes type II. Several genetic factors have been identified 
in diabetes type II (such as TCF7L2 (Gloyn, et al., 2009) or ABCC8 (Thomas, et al., 1995)), which makes 
it a polygenetic disorder. Often polygenetic diseases are also influenced by environmental factors 
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such as toxins or lifestyle. By contrast, a class of completely different disorders, which are solely de-
termined by one single gene, exists. 
Mutations in genes, which are of vital important to the integrity of a specific pathway in the organ-
ism, can directly cause disease. In this case, mutations in other genes or the presence of certain en-
vironmental factors play a subordinate role and are usually not necessary at all. Such diseases are 
known as single-gene disorders and are accordingly inherited in a Mendelian manner. If these genes 
are part of a metabolic pathway this group of disorders is referred to as the inborn errors of metab-
olism (IEMs). 
1.2 INBORN ERRORS OF METABOLISM 
IEMs constitute a group of diseases which are characterized by the deficiency of function of a single 
gene and the consequences of this malfunction on the metabolism of a patient. These consequences 
can be very various depending on the affected gene and the clinical phenotype can vary with differ-
ent organs or organ systems being affected. The difference of the affected genes themselves and 
additionally their distinct expression in different cell types and tissues provide an explanation for the 
heterogeneity of IEMs. This chapter tries to summarize general aspects of IEMs related to clinical 
phenotype, diagnosis and treatment without asserting to claim complete coverage of this topic. 
1.2.1 Background 
Single IEMs are often rare and only found in very few patients. This might be due to the high number 
of genes (estimate of the total number of genes in Homo sapiens: 21,000 (Pennisi, 2012)) which can 
be affected; with each defective gene resulting in a specific disease. In countries without high rates 
of consanguinity, another important factor contributing to the rarity of IEMs is the autosomal reces-
sive inheritance pattern. Also the low likelihood that a random mutation actually has a deleterious 
effect on the function of the gene product contributes to the low prevalence of single IEMs. The rarity 
of these disorders hinders the formation of large stakeholder groups and public awareness of IEMs 
is sparse. As a consequence, public funds are only seldom allocated to the research of rare diseases. 
In addition, the scientific community is faced with many new disorders, which are currently discov-
ered at a high frequency, making those novel disorders so far mostly unexplored. Also metabolic 
clinicians become aware of new metabolic diseases since patients survive with acute and supportive 
care which improved significantly over the last few decades. Together, the novelty of many IEMs and 
the financial limitation of research efforts leads to numerous open questions in the understanding 
of these disorders. 
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Unsolved problems related to IEMs remain a challenge, especially in the view of the prevalence of all 
IEMs together. It is estimated that overall IEM incidence accounts to about 1:2,000 (Applegarth, et 
al., 2000; Hutchesson, et al., 1998) which is comparable to diabetes type II incidence in adolescents 
(D'Adamo and Caprio, 2011). This indicates that the sum of IEMs is very relevant to the public health 
system, impacting on quality of life of many patients and also causing considerable healthcare costs. 
1.2.2 Pathophysiological mechanisms 
At the beginning of the early 20th century Archibald Garrod fomulated the term inborn error of me-
tabolism during his work on the inherited disease alkaptonuria (Garrod, 1902). Based on Garrod’s 
studies George Beadle and Edward Tatum developed the “one gene-one enzyme” concept, in which 
each gene produces one enzyme which is in turn responsible for a specific step in a metabolic path-
way (Beadle and Tatum, 1941). From a present-day perspective this seems to be an oversimplifica-
tion to describe the relation of genes and proteins, but it was the first scientific endeavour into a field 
which is today known as molecular biology (Horowitz, et al., 2004). 
This simplified concept can be used to summarize the pathophysiology in different IEMs. According 
to Saudubray et al. (Saudubray, et al., 2012) there are three pathophysiological groups which are 
useful from a diagnostic perspective: 
i. Disorders that give rise to intoxication. This group of disorders is characterized by a meta-
bolic reaction which is massively reduced in its throughput which consequently leads to the 
accumulation of intermediary metabolites of the affected pathway. The accumulating me-
tabolites cause intoxication-like clinical characteristics, such as vomiting and lethargy at on-
set. Usually these metabolites have been identified but their molecular mode of action of 
how they harmfully interfere with the normal metabolism of the cell is often not known. Typ-
ically, disorders of this group (organic acidurias, urea cycle defects, amino acid disorders etc.) 
are characterized by unproblematic intrauterine development and a symptom-free interval 
after birth. 
ii. Disorders involving energy metabolism. Deficiencies in energy production or utilization can 
be caused by cytoplasmic and mitochondrial defects, with the latter being more severe. Pro-
cesses involving glycolysis, gluconeogenesis, glycogen metabolism, mitochondrial respira-
tory chain, mitochondrial transporters, fatty acid oxidation and several others can be af-
fected in this group of disorders. Diagnosis is very difficult and requires specialized biochem-
ical as well as genetic investigations. 
iii. Disorders involving complex molecules. In this group the synthesis or catabolism of com-
plex molecules of different kinds are impaired. Examples are lysosomal storage disorders, 
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peroxisomal disorders, congenital disorders of glycosylation, disorders of cholesterol synthe-
sis and several others. Many of these diseases are usually detectable on the genetic level and 
are mostly not amenable to treatment in the acute phase. 
1.2.3 Clinical picture 
IEMs show a great variation of clinical symptoms with regard to timing and characteristics. Therefore, 
this section only summarizes some general clinical aspects of IEMs and groups them in three forms 
of early-onset, late-onset with acute crisis, and chronic/progressive (Saudubray, et al., 2012). 
Striking early symptoms can entail antenatal and neonatal malformations, dysplasias and functional 
manifestations such as growth retardation. But it needs to be born in mind, that most often these 
specific symptoms are not present and the detection of a metabolic disorder in a neonate is chal-
lenging. This is due to the general and unspecific nature of the symptoms such as respiratory distress, 
hypotonia, poor suckling reflex, vomiting, diarrhoea, dehydration, lethargy and seizures. Often neu-
rological symptoms and poor feeding are the very first signs. High ammonia levels (hyperammone-
mia) can give rise to hypotonia and encephalopathy with subsequent seizures. Cardiac and liver fo-
cused diseases can present with hepatomegaly and hypertrophic cardiomyopathy with cardiac fail-
ure. Previous siblings having died during the neonatal period may give rise to the suspicion of an 
IEM. 
Later onset forms of IEMs often manifest with an acute crisis often precipitated by an intercurrent 
infection which can reoccur during later exacerbations of the disease. An acute crisis can present 
with striking symptoms depending on the underlying disorder. Vomiting, acidosis, and neurological 
symptoms (e.g. lethargy, coma, metabolic stroke, attacks of ataxia) are seen in crises of organic acid-
urias. Even acute psychiatric symptoms can be observed, e.g. in mild forms of ornithine transcarbam-
ylase deficiency. 
Chronic and progressive forms of IEM often present with symptoms which worsen over time and are 
very difficult to treat. These disorders often show neurological features which lead to very severe 
clinical pictures, making the patient completely dependent on community or home care. Symptoms 
may include developmental delay, mental retardation, neurological deterioration and psychiatric 
signs. Often the situation is complicated by episodes of epileptic seizures. 
1.2.4 Diagnostic methods 
The suspicion of an IEM should lead to initial laboratory investigations to determine the diagnosis as 
soon as possible since specific treatment based on the diagnosis may be required in the acute phase. 
Laboratory support of the diagnosis is often essential because many IEMs show only general clinical 
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symptoms. Since IEMs cause disturbed metabolism, many traces of the impaired metabolic pro-
cesses, such as increased or decreased metabolite levels, can be detected in body fluids of patients. 
A specific metabolic pattern often points to a concrete disease or at least a disease group, which can 
be further evaluated by biochemical methods, often including enzymatic assays. Genetic tests are 
mostly used as a final confirmation of the defective gene although in some cases, genetic analysis is 
even applied in parallel to first-line diagnostics. Additionally, more general measurements, such as 
ketone bodies, blood gases, blood pH, anion gap, ammonia, lactate etc., are also needed in order to 
help decisions regarding acute patient management. 
Newborn screening (NBS) allows early detection of diseases. In most parts of the world, where NBS 
is in place, the vast majority of the diseases included in NBS belong to the group of IEMs. This diag-
nostic tool is very helpful to detect disorders before they manifest with an acute clinical crisis. Even 
though the Wilson’s criteria provide useful guidelines (Wilson and Jungner, 1968), it is hotly debated 
which diseases should be included in these screenings and the number of diseases included in new-
born screening programs varies greatly between countries. Recently, the possibility of complement-
ing this metabolic screening by genetic methods such as whole genome or exome sequencing has 
been discussed (Ross, et al., 2013). This brings into play more ethical considerations regarding the 
collection of information which is not completely understood, in many cases not clinically relevant, 
and for which no informed consent of the neonate exists (Mayer, et al., 2011). Many of the available 
diagnostic tools can also be applied to the unborn child during prenatal diagnosis, implying similar 
ethical issues. 
1.2.5 Classical treatment 
Different inborn errors of metabolism are treated in very specific ways and the vast number of dif-
ferent diseases complicates a uniform summary of treatment approaches. Therefore, this section is 
limited to a few basic principles which apply to the treatment of IEMs. 
1.2.5.1 Supportive/symptomatic treatment 
In the acute phase, nearly all IEMs require supportive care even if there is an established disease-
specific treatment procedure available. Supportive treatment includes ventilator or cardiac support 
as well as correction of hydration and electrolyte status (Saudubray, et al., 2012). 
1.2.5.2 Dietary treatment 
Since many metabolites derive from food intake, the modulation of the latter can influence the 
throughput of certain metabolic pathways. For example in the case of intoxication-type disorders, 
where toxic metabolites accumulate, it is desirable to minimize the substrate of this pathway in order 
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to maintain levels of toxic metabolites as low as possible. This is possible via a reduction of the intake 
of specific diet components, e.g. a reduction of protein in the diet of patients suffering from an amino 
acid disorder. Also an increase of some nutrients (often the products of the deficient enzymes) may 
be necessary, e.g. as in the case of glycogen-storage disorder where hypoglycaemia is prevented by 
frequent intake of carbohydrates. 
More importantly, dietary management should prevent catabolism by aggressive promotion of 
anabolism. This is especially crucial in the acute phase, when an increased breakdown (catabolism) 
of protein leads to metabolic decompensation as observed in organic acidurias. High glucose infu-
sions combined with insulin under continuous monitoring of blood glucose and lactate levels are 
used to promote sufficient anabolism (Baumgartner, et al., 2014). As soon as the clinical condition of 
the patient allows it, enteral feeding should be reinitiated to provide energy to meet metabolic de-
mands and maintain an anabolic state. 
1.2.5.3 Detoxification of metabolites 
In the acute phase of certain IEMs accumulating metabolites reach levels which are exceeding nor-
mal ranges by far. These high concentrations of metabolites can be lowered by applying scavenger 
molecules. These carrier molecules are capable of binding accumulating metabolites and makinkg 
them innocuous. Subsequently the carrier is excreted together with the toxic metabolite. One exam-
ple is carnitine which can bind accumulating propionyl-coenzyme A (propionyl-CoA) in methylma-
lonic aciduria. In this case, carnitine is not only given to scavenge propionyl-CoA but also to replenish 
the carnitine levels. Other examples are benzoate and phenylbutyrate in urea cycle disorders to scav-
enge amino acids in order to lower ammonia levels. Benzoate is conjugated with glycine to generate 
hippurate; phenylbutyrate is converted to phenylacetate which then conjugates with glutamine to 
generate phenylacetylglutamine (Haberle, et al., 2012). Both conjugate products are excreted in the 
urine. 
In the acute phase, toxic metabolites can be lowered not only by scavengers but also by applying 
methods of hemofiltration. Veno-venous hemodiafiltration is recommended for children and infants, 
while haemodialysis should be employed in adults for extracorporeal detoxification (Baumgartner, 
et al., 2014). 
1.2.5.4 Enzyme replacement therapy 
IEMs are usually caused by a gene defect which leads to the production of a dysfunctional protein or 
even no protein at all. The missing or dysfunctional protein can be replaced via different methods in 
the application of enzyme replacement therapy (ERT). This approach has shown recent success for 
lysosomal storage diseases (LSDs) (Ohashi, 2012; Parenti, et al., 2013) such as Gaucher disease, Fabry 
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disease, Pompe disease, and for some types of mucopolysaccharidosis. In ERT recombinantly pro-
duced enzymes are supplemented mostly via the intravenous route. The main issue of this concept-
wise simple method is the limited possibility of treating neurological symptoms since the blood-
brain barrier prevents the recombinant enzyme crossing into and subsequently fulfilling its function 
in the brain. This drawback of ERT has recently been circumvented by intrathecal application of the 
recombinant protein, but only with partial success (Dickson, et al., 2007). In general, ERT is more suc-
cessful in slowing down the progression of symptoms when started early in the disease course and 
in patients with mild disease limited to organs that are well accessible to the intravenously applied 
enzyme. The results in more severely affected patients or patients, which have a disease which is far 
progressed, are often discouraging, suggesting that commencement of ERT intervention should be 
at as young an age as possible (Harmatz, 2015). However, the efficacy of ERT is debated since long-
term outcome studies are still lacking and measures to monitor outcome (surrogate markers) are 
controversial. 
Although recombinant protein production is a routine procedure nowadays, it remains a sophisti-
cated task to purify protein of high quality. The process requires numerous purification steps in order 
to achieve a high yield and concentration of the protein of interest and also to avoid contamination 
with other substances. For clinical application of recombinant proteins, the product has to meet a 
catalogue of requirements, making this process complex and intricate. Therefore, great investments 
in research and development of these drugs are required. The exceptionally big proportion of devel-
opment costs over the number of potential patients, which is very low for all IEMs, may explain the 
expensive prices of these drugs. Hence, despite some clinical improvements, which have been ob-
served in LSD patients under ERT, this innovative approach still suffers from pitfalls regarding costs 
and efficacy. 
1.2.5.5 Organ and hematopoietic cell transplantation 
The approach of ERT is based on the idea to substitute the dysfunctional mutant protein, encoded 
by a defective gene, with functional wild-type protein. Since ERT has its inherent problems, other 
solutions are needed. It is possible to not only substitute the enzyme itself but also to replace a com-
plete organ in order to supply the patient with cells of sufficient protein (often enzyme) function to 
cope with the demand of the defective metabolic pathway. Often the liver or the hematopoietic 
system is transplanted in order to achieve higher levels of enzyme activity. However, this treatment 
strategy also has its drawbacks: If the defective enzyme is also expressed in the brain, metabolites 
which accumulate within the brain and cannot cross the blood-brain barrier will not be processed 
by the enzyme in the transplanted organ and remain trapped in the brain. Also immunosuppressive 
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therapy, which is required after transplantation, has its intrinsic problems and may negatively influ-
ence the quality of life of patients. 
1.2.5.6 Substrate reduction 
Substrate reduction therapy (SRT) is currently used in glycogen-storage disorders and LSDs. In this 
approach small molecules inhibit crucial steps in the production of toxic metabolites which would 
otherwise accumulate. Consequently, the concentration of these toxic metabolites can be lowered 
in the patient’s body fluids and tissues. SRT small molecules can cross the blood-brain barrier but 
they are considered to be less effective than ERT and can show significant neurological side effects, 
e.g. as observed in miglustat treatment (Machaczka, et al., 2012). 
1.2.5.7 Protein enhancement with chaperones 
Mutations, especially of the missense type, can cause a structurally unstable protein. After aggrega-
tion, the protein is consequently degraded by the proteasomal degradation system. In addition to 
the naturally occurring chaperone proteins, such as Hsp60, Hsp70 and Hsp90, there is a growing 
number of drugs which mimic this chaperone function in order to improve the stability and function 
of mutant proteins in various ways. These molecules are known as pharmacological chaperones 
(PCs) in the case of small molecules, or chemical chaperones which are usually osmolytes. These 
compounds have the purpose of interfering with the degradation process of the mutant proteins in 
the following ways: 
i. Chaperones can support the folding process of a mutant proteins. 
ii. Chaperones can stabilize mutant protein and protect it from being degraded. 
iii. Chaperones can support the disposal of already degraded and aggregated mutant proteins. 
Studies on the famous mutant protein ΔPhe508 cystic fibrosis transmembrane conductance regula-
tor show that the application of osmolytes can be successful and can support the stabilization of the 
protein and promote the trafficking of the transmembrane channel to the cell membrane (Welch 
and Brown, 1996). Even before that, glycerol was known to stabilize protein confirmations in vitro 
(Gekko and Timasheff, 1981). Although successful, these chemical chaperone molecules are not ideal 
candidates for clinical application. This is due to the high concentration at which they need to be 
applied and their unspecific mode of action of stabilization of proteins. As a consequence, harmful 
effects on other protein (off-target) are possible and raise the concern of side effects. 
Therefore, more specific molecules are needed. These compounds are known as pharmacological 
chaperones (PCs) and are small, target-specific small molecules which exert a stabilizing effect on 
the protein of interest. This allows the application of lower dosages and minimization of off-target 
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effects. In the search for PCs, in vitro screening approaches are applied (Pey, et al., 2008). In the clinical 
context, these molecules have been most successfully tested in LSDs (Boyd, et al., 2013; Fan, 2008; 
Parenti, et al., 2014). 
More information on chaperone therapy in MMAuria, is considered in chapter 5 of this thesis. 
1.3 BRANCHED‐CHAIN ORGANIC ACIDURIAS 
The branched-chain amino acids are leucine, isoleucine, and valine, all characterized by the epo-
nymic branched side chain. Other amino acids, which also have a branched side chain, exist but are 
not proteogenic. In the breakdown of these amino acids, specific enzymes can be defective, leading 
to different types of IEMs. Still, these diseases are quite similar to each other, not only regarding their 
biochemical background but also their clinical signs. They can present with early-onset, late-onset 
with recurrent crises or in a chronic/progressive form. Because of their common features and due to 
the accumulation of characteristic organic acids in the urine they are categorized within the group 
of organic acidurias. Diagnosis can be accomplished by the analysis of acylcarnitine and organic acid 
profiles. The most commonly encountered organic acidurias are maple syrup urine disease (MSUD), 
isovaleric aciduria (IVA), propionic aciduria (PA), and methylmalonic aciduria (MMAuria). 
1.3.1 Maple syrup urine disease, isovaleric aciduria, propionic aciduria 
MSUD is known for the characteristic maple syrup odour of the urine of the patients and shows a 
prevalence of 1:225,000 (Carleton, et al., 2010). The amino acids valine, isoleucine, leucine and alloi-
soleucine are elevated in plasma caused by a deficiency of the branched-chain alpha-keto acid de-
hydrogenase complex. In comparison to other organic acidurias, no activated CoA compounds are 
generated, hence the acylcarnitine profile is usually not changed. There is usually a less severe aci-
dosis and degree of hyperammonemia, key traits of many organic acidurias, possibly attributable to 
the absence of accumulating CoA molecules. The molecular background of MSUD is quite complex 
and involves a number of proteins encoded by four genes which are all inherited in a recessive man-
ner. Involved proteins comprising the branched-chain alpha-keto acid dehydrogenase complex are 
the subunits E1α, E1β, E2, and E3, which are encoded by the genes BCKDHA, BCKDHB, DBT, and DLD. In 
addition, the deficiency of E3 leads to a malfunction of pyruvate dehydrogenase complex which con-
verts pyruvate to acetyl-CoA. The clinical aspects of the disease include progressive encephalopathy 
in the acute phase of severe forms starting a few days after birth or a developmental delay with var-
ious neurological symptoms in milder forms. The acute treatment involves glucose and insulin ad-
ministration in order to promote protein anabolism. The long-term treatment focuses on diet mod-
ification with a reduced intake of protein to control the plasma values of leucine, isoleucine and va-
line. 
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IVA is the rarest organic aciduria discussed in this section with an incidence of about 1:250,000 in the 
United States. Deficiency of isovaleryl-CoA dehydrogenase is the cause of IVA and leads to the accu-
mulation of isovaleryl-CoA derivatives, including free isovaleric acid. The enzyme is expressed in the 
mitochondrion and it transfers electrons to the respiratory chain via the electron transfer flavopro-
tein. While accumulating isovaleryl-CoA conjugates with carnitine to build isovalerylcarnitine, alter-
native pathways are activated which leads to the accumulation of 3-hydroxyisovaleric acid and N-
isovalerylgylcine. Since the reaction catalysed by isovaleryl-CoA dehydrogenase represents an early 
step in leucine metabolism, no other amino acid pathways are affected in IVA. The underlying gene 
is IVD, mutations of which are inherited in an autosomal recessive manner. The clinical course can be 
acute with onset in the neonatal period (Newman, et al., 1967) or chronic intermittent with recurrent 
crises (Tanaka, et al., 1966). Treatment is based on carnitine supplementation and glycine medica-
tion, since glycine can conjugate with isovaleric acid with subsequent excretion of the conjugate. In 
addition, the diet is modified in order to lower the leucine intake. 
PA is caused by a deficiency of propionyl-CoA carboxylase which contains two different subunits 
encoded by PCCA and PCCB and requires the cofactor biotin for proper function. It catalyses the car-
boxylation reaction which produces methylmalonyl-CoA from propionyl-CoA. PA is caused in ~40% 
of the cases by mutations in the PCCA gene and in ~60% by mutations in the PCCB gene (Perez, et 
al., 2003; Yang, et al., 2004). The prevalence of PA varies depending on the cohort tested. It is esti-
mated to be found in 1 of 100,000 live births worldwide; but a higher prevalence is observed, e.g. in 
Saudi Arabia or Greenland (Ravn, et al., 2000). PA is inherited in an autosomal-recessive manner. Pro-
pionyl-CoA carboxylase is involved in the catabolism of amino acids (methionine, isoleucine, valine, 
threonine), odd-chain fatty acids, cholesterol and propionate produced by bacteria in the gut. Its 
deficient activity leads to the accumulation of propionic acid in urine and blood. Also other metab-
olites accumulate such as propionylcarnitine (acylation of propionyl-CoA to carnitine), methylcitrate 
(condensation of propionyl-CoA with oxaloacetate) (Saudubray, et al., 2012) and hydroxypropionate 
(by β- or ω-oxidation of propionyl-CoA) (Ando, et al., 1972). Clinical characteristics are recurrent met-
abolic crises and long-term complications including growth retardation, intellectual disability, sei-
zures, pancreatitis and cardiomyopathy. Treatment options are very similar to MMAuria (see next 
section). 
1.3.2 Methylmalonic aciduria 
Isolated MMAurias are a group of rare inborn errors of metabolism caused by a deficiency of the 
isomerase methylmalonyl-CoA mutase (MUT), which catalyses L-methylmalonyl-CoA to succinyl-
CoA providing anaplerotic substrate to the tricarboxylic acid cycle (TCA cycle). MUT deficiency can 
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be caused by a defect in the apoenzyme itself or in the production of its essential cofactor 5’-deoxy-
adenosylcobalamin (AdoCbl). The disease was first characterized in 1967 as an autosomal recessive 
IEM (Oberholzer, et al., 1967) and named after the name-giving metabolite methylmalonic acid 
(MMA) which is found elevated in urine of MMAuria patients. The estimated frequency in the popu-
lation is estimated at 1:50,000 (Chace, et al., 2001; Shigematsu, et al., 2002; Sniderman, et al., 1999). 
Isolated MMAurias have to be differentiated from combined forms of MMAurias with homocystinuria 
(HC). These disease entities are intertwined because they share a common pathway – the intracellu-
lar cobalamin (Cbl) pathway. In humans Cbl must be converted into two coenzyme forms, methylco-
balamin (MetCbl) and AdoCbl, in order to assure the function of the two target enzymes of Cbl (MUT 
and methionine synthase (MS)), which are responsible for the homeostasis of MMA and homocyste-
ine (Jusufi, et al., 2014). 
MS is located in the cytosol where it utilizes Cbl in the form of MetCbl to convert homocysteine to 
methionine. Deficiencies of MS itself (encoded by the MTR gene, cblG complementation group), me-
thionine synthase reductase (encoded by the MTRR gene, cblE complementation group), and 
methylmalonic aciduria and homocystinuria type D protein (MMADHC, encoded by the MMADHC 
gene, cblD-HC complementation group) all lead to isolated forms of HC, with the latter two proteins 
being involved in the production of MetCbl. 
Since Cbl synthesis and trafficking of MetCbl and AdoCbl have a common pathway after the Cbl mol-
ecule is taken up into the cell via endocytosis, the productions of both cofactors can be defective at 
the same time (Coelho, et al., 2008). Proteins involved at this step are the lysosomal protein LMBRD1 
(encoded by the LMBRD1 gene, cblF complementation group) (Rutsch, et al., 2009) and the trans-
membrane protein with ATPase function ABCD4 (encoded by the ABCD4 gene, cblJ complementa-
tion group) (Coelho, et al., 2012), which probably interact (Deme, et al., 2014) in order to extract Cbl 
from the lysosome and feed it into further processing steps in the cytosol. In the cytosol the proteins 
MMACHC (encoded by the MMACHC gene, cblC complementation group) (Lerner-Ellis, et al., 2006) 
and MMADHC (cblD-MMA/HC complementation group) are further involved. Deficiencies of these 
proteins lead to a combined form of MMAuria and HC. A special case is the MMADHC protein which 
can cause isolated MMAuria, isolated HC or combined forms of both, depending on the location and 
type of the defect in the protein (Stucki, et al., 2012). 
The products of the genes MMADHC, MMAA, MMAB, MCEE, and MUT are involved in production and 
utilization of AdoCbl and are further introduced in the next section. Mutations in these genes can 
lead to isolated MMAuria. 
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1.3.2.1 Molecular basis 
Isolated MMAurias are caused by a defective MUT enzyme or by defects in the pathway exclusive to 
mitochondrial delivery and modification of AdoCbl. Proteins involved in this pathway are MMADHC 
(cblD-MMA complementation group), MMAA (encoded by the MMAA gene, cblA complementation 
group) (Dobson, et al., 2002b) and the cob(I)alamin adenosyltransferase MMAB (encoded by the 
MMAB gene, cblB complementation group) (Dobson, et al., 2002a). Deficiencies of these proteins lead 
to an insufficient supply of the MUT enzyme with its cofactor AdoCbl. The MMAA gene encodes a 
protein which belongs to the G3E family of GTP-binding proteins. The most common mutated allele 
detected is the c.433C>D (p.R145X) point mutation (Saudubray, et al., 2012). In the MMAB gene most 
mutations were detected at the active site of the adenosyltransferase MMAB that it encodes. The 
gene MCEE encodes methylmalonyl-CoA epimerase which converts (R)-methylmalonyl-CoA to (S)-
methylmalonyl-CoA. Mutations in this gene have been found to be associated with mild MMAuria, 
but the clinical relevance is not certain (Bikker, et al., 2006; Dobson, et al., 2006). 
Most commonly isolated MMAuria is caused by a defect in the apoenzyme MUT itself due to muta-
tions in the MUT gene (mut complementation group) (Ledley, et al., 1988a; Ledley, et al., 1988b). De-
pending on the degree of incorporation of radioactively labelled propionate into fibroblast cell pro-
teins of a patient or control cell line (PI assay), mut-type MMAuria can be further subdivided in the 
two classes mut- and mut0. The assay is performed in cell culture, with medium supplemented with 
hydroxocobalamin (OHCbl) or not. A ratio of >1.5 (absolute propionate incorporation under OHCbl-
supplemented conditions over propionate incorporation without supplementation) assigns a pa-
tient cell line to the mut- subclass, whereas a ratio of ≤1.5 allocates the cell line and the correspond-
ing patient into the mut0 subclass. 
1.3.2.2 Clinical presentation 
As with most intoxication-type IEMs, MMAuria patients show normal embryo-foetal development 
with no manifestations of disease during pregnancy. After a non-complicated delivery, no dys-
morphic features are present that might trigger the suspicion of an inherited metabolic disorder. 
MMAuria patients show a typical symptom-free interval after birth. Depending on the severity of the 
defect, patients can start to develop a sepsis-like clinical picture on day 2-4 of life which manifests 
with poor feeding, lethargy and neurological symptoms as first symptoms. Neonates with MMAuria 
present with hypotonia which is correlated with hyperammonemia. Seizures and further deteriora-
tion of the general condition occur, if no treatment is initiated at this point. Other MMAuria patients 
with a less severe defect, may present later in life. Often the disease becomes clinically manifest 
when the throughput of the propionate pathway is unusually high, e.g. due to febrile illness which 
usually induces a catabolic state with increased protein breakdown. The symptoms during these 
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metabolic crises are the same as found in early-onset patients described above. These patients often 
suffer from life-threatening recurrent crises. 
Long-term survivors with isolated MMAuria invariably show chronic kidney damage (tubulo-intersti-
tial nephritis) which subsequently leads to end stage renal failure. Early sings of the development of 
kidney damage can be renal tubular acidosis and hyperuricemia. Over time the glomerular filtration 
rate will be reduced and dialysis and kidney transplantation is often required before the age of 20 
years (Leonard, 1995; Leonard, et al., 2001). 
The second important long-term complication observed in MMAuria patients affects the central 
nervous system (CNS) and is very comparable to the symptoms observed in PA patients. Damage in 
this organ may manifest as progressive extrapyramidal syndrome due to lesions in the basal ganglia, 
especially in the area of the globus pallidus (Baker, et al., 2014). These specific lesions may derive 
from chronic basal ganglia injury or acute crises during which patients may experience the phenom-
enon of a “metabolic stroke” – an acute injury of brain tissue not due to a haemorrhage or a vascular 
occlusion. The pathomechanisms describing how an acute metabolic crisis leads to stroke-like le-
sions in the basal ganglia of MMAuria patients are debated (Kolker, et al., 2008; Kolker, et al., 2006). 
Most patients affected by a metabolic stroke suffer from a disabling movement disorder with paresis 
and choreoathetosis. In addition to these findings, optic atrophy with visual impairment evolves as 
another long-term complication (Traber, et al., 2011; Williams, et al., 2009). Finally, brain MRI of 
MMAuria patients can reveal cerebral atrophy and delayed myelination (Brismar and Ozand, 1994; 
Chemelli, et al., 2000), while patients show variable mild intellectual impairment. 
Prediction of the clinical outcome is very difficult. Based on the assignment of the complementation 
group, the patients show different severity of disease, e.g. patients of the cblB and mut0 complemen-
tation group tend to show an earlier onset of disease and a higher frequency of complications and 
deaths compared to patients belonging to the groups cblA and mut- (Horster, et al., 2007). In vitro 
parameters such as residual enzyme activity and the response to cobalamin (PI assay) may help to 
stratify the patients into more severe and milder prognosis groups (Horster, et al., 2009). Chapter 1 
of this thesis elucidates information on genotype-phenotype correlations in mut-type MMAuria pa-
tients with regard to their clinical outcome. 
1.3.2.3 Diagnosis of methylmalonic aciduria 
Analysis of organic acids in plasma and/or urine by gas-liquid chromatography and mass spectrom-
etry and measurement of acylcarnitines in tandem mass spectrometry may elevated levels of propi-
onylcarnitine, MMA, 2-methylcitrate and hydroxypropionate. These parameters allow a diagnosis of 
unclassified form of MMAuria. Further laboratory investigations, such as PI (Willard, et al., 1976) and 
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MUT enzyme assay (Forny, et al., 2014) together with cobalamin distribution assays, are needed to 
delineate the exact defect in the pathway. Complementation analysis allow the assignment to a 
complementation group (Gravel, et al., 1975). Finally, mutational analysis is performed to confirm 
the defect in the specific gene and to verify the carrier status of the parents of the patient. 
1.3.2.4 Treatment in methylmalonic aciduria 
Treatment in MMAuria aims at detoxification of accumulated metabolites in the acute phase and 
metabolic control in the long-term therapy. The acute exacerbation in MMAuria is usually caused by 
an increased load of the propionate pathway due to a catabolic state (e.g. fasting or febrile illness) or 
increased protein intake. Critical patients in an acute metabolic crisis need stabilization by restora-
tion of volume and promotion of anabolism. Protein intake needs to be reduced or stopped imme-
diately in order to avoid further build-up of toxic metabolites. The application of glucose infusions 
combined with insulin helps to stop further protein catabolism and restore anabolism. During this 
phase careful monitoring of electrolytes, ammonia, pH and blood gases is required. In very severe 
cases hemofiltration has to be performed in order to accelerate the detoxification process. 
Long-term treatment includes diet modification which aims at limiting amino acids that lead to pro-
duction of propionic acid by giving a low protein diet that may be supplemented by a precursor-free 
amino acid mixture. Vitamin B12 responsive patients should be given intramuscular OHCbl injections. 
It is known that most patients of the cblA complementation group respond to this treatment, while 
only some cblB patients display responsiveness (Matsui, et al., 1983a). Also mut- show a higher re-
sponse rate than mut0 patients (Horster, et al., 2007). Responsiveness should be evaluated according 
to proposed protocols (Fowler, et al., 2008). Additional therapy consists of carnitine supplementation 
and metronidazole (or other antibiotics) which reduce the production of gut bacteria-derived propi-
onate. To avoid intermittent crises, infections should be prevented or treated aggressively immedi-
ately after occurrence. 
Liver has the highest amount of propionate conversion, therefore replacement of this organ could 
contribute enzyme activity to the organism’s demand. A liver with normal expression of wild-type 
MUT has a high capacity to turn over most of the propionyl-CoA which is produced by the entire 
body. This concept proved to be partially valid, since transplanted patients are protected against 
metabolic crises, but still display elevated metabolites. Although acute events are prevented, long-
term complications cannot be avoided as shown in several cases of MMAuria patients who were 
transplanted and still suffered from metabolic stroke events (Chakrapani, et al., 2002; Nyhan, et al., 
2002; Vernon, et al., 2014). Possibly very early transplantation may be beneficial to patients as shown 
in recent studies which show improved techniques and outcome of liver transplantation in MMAuria 
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patients (Spada, et al., 2015), but timing remains very difficult to evaluate (Sloan, et al., 2015). Alter-
natively, kidney transplantation can be combined with liver transplantation or performed as a single-
organ transplantation with the same intention of increasing the enzymatic activity of this tissues, 
and also to replace a potentially damaged kidney (Brassier, et al., 2013; Clothier, et al., 2011; Lubrano, 
et al., 2007; Lubrano, et al., 2001; Van Calcar, et al., 1998). 
1.3.2.5 Current mouse models of MMAuria 
Mouse models allow posing of scientific questions regarding the whole organism or organ systems, 
which would otherwise not be feasible to be solved. In MMAuria research the absence of such mod-
els contributed to the persistence of a lack of knowledge on pathomechanisms and therefore the 
development of novel therapies was hindered. This hurdle still needs to be overcome since the avail-
able treatment options for MMAuria patients are not satisfying. Even classical treatment procedures 
cannot be tested in animal models, although this would be especially useful in MMAuria, since the 
small number of patients suffering from this disease only allows very small group sizes in clinical 
studies. Since the 2000’s there have been efforts to fill the gap of a lacking animal model by attempt-
ing to generate a mouse model of MMAuria. 
The first MMAuria mouse model was developed in 2003. A Mut knock-out (ko) model was generated 
by a deletion of exon 3 of the Mut gene which leads to a frameshift and therefore to a null function 
of the Mut enzyme (Peters, et al., 2003). Newborn pups of the homozygous ko/ko genotype only 
survived the first 24 hours of life and perished soon after, most likely due to acute metabolic decom-
pensation. It was clear before that the Mut pathway exists in mice, but its relevance was proved for 
the first time with this model: Similar to the human situation, a null mutation led to very severe met-
abolic decompensation with potentially lethal outcome. Nevertheless, this model was not useful for 
further long-term studies and had to be modified in order to achieve a surviving model. Applying 
the same principle of a deleted exon 3 of the Mut gene (Chandler, et al., 2007), Chandler et al. started 
to modify the background of the mice, aiming at a surviving model. They succeeded in 2009 and 
started to study mitochondrial dysfunction in MMAuria with the help of this model (Chandler, et al., 
2009). In addition, the same group generated an MMAuria mouse model by implementing stable 
transgenic Mut expression in the liver in order to constitute residual enzyme activity. This led to the 
rescue from neonatal lethality in these mice which enabled the first mouse model studies of kidney 
dysfunction in MMAuria (Manoli, et al., 2013). A similar study showed AAV-mediated rescue of the 
Mut-ko mice (Chandler and Venditti, 2008; Chandler and Venditti, 2010), successfully demonstrating 
gene therapy in these models. 
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1.3.2.6 Pitfalls of current models and novel approaches 
Although these mouse models of MMAuria allowed the study of certain aspects of the disease, they 
exhibit some significant pitfalls: 
i. The first model (Peters, et al., 2003) showed neonatal lethality which prevents long-term 
studies on the chronic course of MMAuria. 
ii. Background modification as shown in (Chandler, et al., 2009) is a common method to rescue 
ko mice from neonatal lethality. However, the mechanism or phenomenon underlying a spe-
cific case of rescue remains unclear (Montagutelli, 2000). This uncertainty complicates the 
usage of this model since it remains unknown if the modified background affected relevant 
metabolic pathways which may directly interfere with the Mut pathway of interest. If this 
might be true, any conclusions drawn under these circumstances can be misleading with 
regard to comparing results from the mouse models with the human patient situation. 
iii. Partial rescue models as presented in the previous chapter (Chandler and Venditti, 2010; 
Manoli, et al., 2013) suffer from inaccurate representation of the patient situation where the 
deficient Mut enzyme is constitutively expressed in all cells of the organism. 
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2 PROJECT AIMS 
The PhD project is divided into five main parts. All of them address different aspects of MMAuria and 
try to answer various questions which are relevant for a better understanding of the disease. The 
gathered knowledge should help to enable the development of novel therapeutic approaches in the 
future. 
2.1 MUTATIONAL CHARACTERIZATION OF THE ZURICH/BASEL MMAURIA PATIENT 
COHORT 
The first project deals with MMAuria patients, fibroblasts or DNA of which were referred to the met-
abolic institutions in Basel and Zurich for diagnostic purpose from the years 1977 to 2015. This cohort 
of patients with isolated MMAuria, caused by mutations in the MUT gene, will be analysed in order 
to better understand the landscape of disease-causing mutations in this gene of interest. The study 
aims to stratify the cohort by pursuing the following aims: 
i. Compilation of a list of all patients and corresponding genotypes, biochemical data (propio-
nate incorporation and mutase assay), mut subclass and age of onset. 
ii. Analysis of all detected variants regarding distribution within the MUT gene, frequency, mu-
tation type and structural location. 
iii. Investigation of protein stability by Western blot in crude cell homogenates of a selection of 
patient cell lines (all cell lines homozygous for a missense mutation or compound heterozy-
gous for a missense mutation and a null mutation). 
iv. Analysis of possible correlations between mut subclass assignment and other features such 
as mutation type or age of onset. 
v. Evaluation of in silico prediction tools in the missense mutations of the cohort. 
2.2 MOLECULAR CHARACTERIZATION AND MECHANISMS IN MUT DEFICIENCY 
To better understand the nature of defects which are caused by specific mutations found in the MUT 
gene, 23 missense mutants will be investigated in more detail by pursuing the following aims: 
i. Large scale production, purification and characterization of MUT wild-type and mutants in 
an E. coli expression system. 
ii. Expression of wild-type and mutant MUT in a mammalian expression system. 
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iii. Characterization of mutants regarding protein stability, enzyme activity, cofactor affinity, 
and thermal stability. 
iv. Investigation of the effect of the cobalamin cofactor and other chaperones on protein fold-
ing/stability. 
2.3 PHARMACOLOGICAL CHAPERONES FOR MUT 
Many missense mutations can cause a functional but unstable enzyme. Despite the intact active site, 
the protein is directed to the degradation pathway due to its instability, resulting in a severe reduc-
tion of protein function and therefore leading to disease in patients carrying these mutations. Dis-
eases, which show this phenomenon of instability due to misfolding, have been classified as misfold-
ing disorders (Gersting, et al., 2008; Leandro, et al., 2011b; Muntau and Gersting, 2010), and ideas to 
treat these diseases with stabilizing molecules have evolved (Chaudhuri and Paul, 2006; Santos-
Sierra, et al., 2012). Some of these molecules have already passed the clinical translation phase and 
are currently in use (Parenti, et al., 2015). As previously shown, library screening by differential scan-
ning fluorimetry (DSF) can be a successful approach in the search of protein-stabilizing small mole-
cules (Jorge-Finnigan, et al., 2013; Pey, et al., 2008). In our case, we are interested in pharmacological 
chaperones (PCs) which can stabilize the MUT protein in order to find pilot compounds which can 
be further developed for clinical application. This project is restricted to the initial screening and 
subsequent characterization of hit compounds. The aims are structured as follows: 
i. Establishment of differential scanning fluorimetry for the MUT protein. 
ii. Evaluation of the binding of endogenous ligands (AdoCbl and malonyl-CoA, a substrate an-
alogue) and the stabilization conferred by them. 
iii. High throughput screening of a library of small molecules to search for stabilizing com-
pounds. 
iv. Evaluation of hit compounds regarding their effect on MUT wild-type and mutant stability 
and activity by E. coli and mammalian fibroblast cell culture techniques. 
2.4 INTRODUCTION OF NEW MMAURIA MOUSE MODELS 
As mentioned above currently available mouse models of MMAuria are plagued by important pitfalls 
(see introduction). Hence, we aim to generate mouse models which avoid the disadvantages of pre-
vious models by applying two different approaches. 
First, the neonatal lethality of a full Mut knock-out mouse will be circumvented by deleting the Mut 
gene only in selected organs such as the brain in order to generate a so called conditional knock-out 
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model. This allows us to study the influence of a Mut knock-out specifically in the brain or the kidney 
which is of specific interest in MMAuria. 
Second, we aim to generate a mouse model which survives and mimics the patient situation as close 
as possible. For this approach a missense mutation is selected which is known from MMAuria pa-
tients that show an intermediate phenotype of MMAuria. This should allow us to generate a surviv-
ing model which still shows clear features of MMAuria. 
2.4.1 Mutflox/flox;Nes‐Cre model 
It is known that MMAuria patients may suffer from a severe neurological phenotype, especially as a 
long-term complication (Nicolaides, et al., 1998). The brain is generally affected by white matter loss, 
but also specific lesions in the basal ganglia as a result of metabolic stroke or optic atrophy may be 
found. So far, no studies have investigated the brain phenotype in MMAuria patients at the molecu-
lar and mechanistic level. Studies on the blood-brain barrier have been undertaken in order to inves-
tigate the particular vulnerability of the CNS in other organic acidurias (Sauer, et al., 2006). It has been 
hypothesized that metabolites which are produced by cells within the brain compartment are 
trapped since they cannot cross the blood-brain barrier and are then exerting their toxic effects on 
the CNS (Morath, et al., 2008). 
To answer questions related to the neurological phenotype of MMAuria patients, a novel mouse 
model is generated with a brain-specific knock-out of Mut. This novel model allows the study of the 
CNS phenotype of MMAuria but also the investigation of the “trapping hypothesis”. In this thesis I 
present the initial characterization and evaluate the validity of this novel model with the following 
specific aims: 
i. Validation of downregulation of Mut in the brain tissue at the transcript and protein level. 
ii. Determination of enzymatic activity in brain tissue. 
iii. Consequences of the genetic knock-down in the brain on MMA and 2-MC metabolite levels. 
2.4.2 Mutki/ki and Mutko/ki models 
In order to generate a mouse model which closely mimics the patient situation, a missense mutation 
is selected based on the studies presented in chapters 1 and 2. The mutation of interest has to show 
an intermediate phenotype in patients in order to be found suitable for the generation of a knock-in 
mouse model. We cross the created knock-in allele with a knock-out allele from a mouse model 
which was previously introduced (Peters, et al., 2003). In order to evaluate these new models for signs 
of human MMAuria, the following aims are pursued: 
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i. Selection of a feasible mutation to generate a knock-in mouse model based on a previous 
study (Forny, et al., 2014) and characterization of this mutant by enzymatic in vitro assays. 
ii. Cross-breeding of homozygous Mutki/ki mice with Mutko/wt to generate Mutko/ki mice and mon-
itoring of survival in both new models. 
iii. Basic characterization of the biochemical and clinical phenotype of new mouse models. 
iv. Initial study of the renal and neurological phenotype. 
v. Analysis of the impact of modified diets (high protein, enriched precursor diet) on the new 
mouse models. 
vi. Evaluation of the treatment potential of classical cobalamin therapy. 
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3 CHAPTER I: THE ZURICH/BASEL MUT‐TYPE MMAURIA COHORT FROM 
1977‐2015 
This section represents an article which has been submitted for publication (February 2016). Cita-
tions in this chapter correlate to the bibliography at the end of the thesis. Figure and table number-
ing is only applicable to this section of the thesis. 
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3.1 ABSTRACT 
Isolated methylmalonic aciduria (MMAuria) is an autosomal recessive disorder of propionate metab-
olism in many cases caused by mutations in the methylmalonyl-CoA mutase (MUT) gene (mut-type 
MMAuria). Here, we report a complete list of mutations identified in patients referred for diagnostic 
testing to the Basel and Zurich laboratories from 1977 to 2015. From 151 referred patients, 114 were 
classified as mut0 and 32 as mut- (5 not defined). We identified 110 different mutations of which 41 
were novel. Forty-seven mutations were identified only once, suggesting many patients carry private 
mutations. Investigation of the missense mutations revealed that the mutations p.Asn219Tyr, 
p.Arg369His and p.Arg694Trp recur in >10 alleles. Only one missense mutation was found in the in-
ter-domain linker region, implying this region is tolerant to substitution. Deficient alleles in the mut- 
subclass were mostly caused by missense mutations. On the contrary, only half of the mut0 mutations 
were of the missense type. Western blot analysis revealed reduced MUT protein for all 34 cell lines 
(27 mut0, 7 mut-) tested, suggesting protein instability as a major mechanism of deficiency in mut-
type MMAuria. This large scale evaluation helps to characterize the landscape of MUT mutations and 
dysfunction. 
3.2 KEY WORDS 
methylmalonyl-CoA mutase; MUT; methylmalonic aciduria; missense mutations; genotype-pheno-
type correlation 
3.3 INTRODUCTION 
The mitochondrial enzyme methylmalonyl-CoA mutase (MUT, MIM #609058, EC 5.4.9.22) catalyzes 
the isomerization of L-methylmalonyl-CoA to succinyl-CoA. This chemical reaction represents an im-
portant step in propionate metabolism, funneling metabolites from the breakdown of amino acids 
(valine, isoleucine, methionine, and threonine), odd-chain fatty acids, and the side chain of choles-
terol into the tricarboxylic acid cycle (Fowler, et al., 2008). Deficiency of the MUT apoenzyme is the 
underlying cause of mut-class methylmalonic aciduria (MMAuria, MIM #251000), an autosomal re-
cessive inborn error of propionate metabolism. The disease is biochemically characterized by low 
incorporation of propionate (PI) into cell proteins and low or absent MUT enzyme activity, which 
leads to abnormally high levels of hallmark metabolites such as methylmalonic acid and propio-
nylcarnitine (Fowler, et al., 2008). mut patients show normal intrauterine development, but may de-
velop severe metabolic crisis almost immediately after birth (early-onset) or may present later either 
with intermittent metabolic decompensations or with chronic progression manifesting as failure to 
thrive and developmental delay (late-onset) (Baumgartner, et al., 2014). First signs after a symptom 
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free interval include severe ketoacidosis, feeding difficulties, lethargy and hypotonia. The acute 
symptoms may deteriorate into a comatose state including cerebral edema, apneas, and seizure-like 
episodes. Long-term survivors suffer from chronic renal failure and neurological complications 
(Horster, et al., 2007; Nicolaides, et al., 1998; Zsengeller, et al., 2014). 
The MUT gene, which encodes the MUT enzyme, lies on chromosome 6p12.3 (Ledley, et al., 1988b). 
It consists of 13 exons with the first exon non-coding, resulting in a polypeptide chain of 750 amino 
acids. The folded enzyme is composed of two domains. The N-terminal domain harbors the binding 
site for the substrate methylmalonyl-CoA while the C-terminal domain binds the essential cofactor 
5’-deoxyadenosylcobalamin (AdoCbl) (Froese, et al., 2010b). Both domains are interconnected by a 
linker region spanning amino acid positions 482 to 585. Human MUT assembles as a homodimer and 
has been structurally captured in three different states: the apo form, the holo form with the bound 
cofactor AdoCbl, and a ternary complex with both binding pockets occupied by AdoCbl and the sub-
strate analogue malonyl-CoA (Froese, et al., 2010b). 
Since the MUT enzyme requires AdoCbl as cofactor for proper function, isolated MMAuria can also 
be caused by a deficiency of other proteins involved in the generation of AdoCbl. The malfunction 
of the methylmalonic aciduria type B protein (MMAB, MIM #607568; MMA cblB type, MIM #251110), 
the methylmalonic aciduria type A protein (MMAA, MIM #607481; MMA cblA type, MIM #251100), or 
the methylmalonic aciduria and homocystinuria type D protein (MMADHC, MIM #611935; MMA cblD 
type variant 2, MIM #277410) all lead to isolated MMAuria due to a defect in AdoCbl production. 
Patient cell lines can be assigned to the complementation groups mut, cblA, cblB, or cblD-MMA by 
complementation analysis of fibroblast heterokaryons (Gravel, et al., 1975; Willard, et al., 1978b). In 
this study, we focus only on mut-type MMAuria, which can be further subdivided into the mut- and 
mut0 subclasses. Fibroblasts from mut- patients show a response in the PI assay to supplementation 
with hydroxocobalamin (OHCbl) and display residual MUT activity usually with a KM for AdoCbl ap-
proximately 200 to 5000 times higher than wild-type control, and normal KM for the substrate 
methylmalonyl-CoA (Morrow, et al., 1978; Willard and Rosenberg, 1977). Enzyme from this subclass 
often shows increased thermolability relative to wild-type enzyme (Forny, et al., 2014; Willard and 
Rosenberg, 1980). In addition, mut- patients usually present with a milder phenotype compared to 
mut0, with lower occurrence of mortality, morbidity and long-term complications (Horster, et al., 
2007). By contrast, patients are assigned to the mut0 subclass if their cells are not responsive to OHCbl 
supplementation in the PI assay and no residual mutase activity is detectable even when assayed in 
the presence of highly saturating AdoCbl concentrations (Morrow, et al., 1975; Willard and 
Rosenberg, 1977; Willard and Rosenberg, 1980). 
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255 mutations have been described thus far in the MUT gene (“The Human Gene Mutation Database” 
(HGMD) version 2015.3 as of November 2015, www.hgmd.org). While almost half of all mutations are 
private, some are recurrently found (Fowler, et al., 2008). For example, c.655A>T (p.Asn219Tyr) 
(Acquaviva, et al., 2001) and c.1106G>A (p.Arg369His) (Worgan, et al., 2006) have been repeatedly 
found in mut0 patients, c.2080C>T (p.Arg694Trp) (Lempp, et al., 2007) in mut- patients, c.322C>T 
(p.Arg108Cys) in patients of Mexican/Hispanic origin (Worgan, et al., 2006) and c.2150G>T 
(p.Gly717Val) in patients of African origin (Worgan, et al., 2006). With the work presented here we 
significantly expand the mutational spectrum of MUT based on our entire patient cohort from the 
years 1977 to 2015, representing a large European cohort. 
3.4 VARIANTS 
Analysis of 151 patients (145 families) in our cohort revealed 110 different mutations in the MUT gene 
(Fig. 1, Table 1) almost all of which were confirmed enzymatically or were previously identified (ex-
cept for c.415G>A, c.467A>T, c.1853T>C and c.1975C>T). The missense type was detected in the ma-
jority of cases and was represented by 62 different single amino acid exchanges in our cohort (Fig. 
2A). Other mutations detected were insertions/deletions (23), nonsense (16), those that primarily af-
fected splicing (8) and one start codon mutation (Fig. 2A). Forty-one of the 110 mutations (37%) are 
presented here for the first time. 
The p.Asn219Tyr (c.655A>T) mutation was the most frequently found mutation in our cohort and 
was detected in 24 alleles (17 patients, 17 families) (Table 1, Fig. 2B). N-terminal to p.Asn219, the 
residue p.Gln218 changed to histidine (p.Gln218His, c.654A>C) was found 7 times, suggesting an 
important role for this protein region, which is found within the substrate binding channel (Forny, et 
al., 2014). p.Arg369His (c.1106G>A) was the second most commonly detected disease allele (23 al-
leles, 16 patients, 15 families). Thus, the two most frequent mutations found in our cohort corre-
spond to previous studies which show a high frequency of these two disease alleles (Acquaviva, et 
al., 2001; Worgan, et al., 2006). The third most frequently identified mutation was p.Arg694Trp 
(c.2080C>T) (11 alleles, 7 patients, 7 families) (Fig. 2B), a residue which was alternatively found to be 
mutated to leucine in three cases (p.Arg694Leu, c.2081G>T). Other common missense mutations 
were p.Leu328Phe (c.982C>T) and p.Pro615Thr (c.1843C>A), which were both detected in 9 alleles 
(both in 5 patients, 5 families) with the latter residue also found to be mutated to leucine in 4 alleles 
(p.Pro615Leu, c.1844C>T), while p.Ala191Glu (c.572C>A) and p.Gly203Arg (c.607G>A) (both in 6 al-
leles) were also more frequently identified (Table 1, Fig. 2B). 
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Figure 1. Schematic representation (not to scale) of the MUT gene and location of the presented sequence variants associated with mut-type MMAuria. A. Exons (boxes) and introns 
(lines) represent the structure of the human MUT gene. Greyed areas (exon 1, start of exon 2 and end of exon 13) depict untranslated (non-coding) regions. Exon sizes are proportional to 
each other, except for exon 13 which is longer than represented (indicated by white double-strike). The numbering of exons is according to NG_007100.1. The size of introns is not to scale 
and not proportional. cDNA numbering below exons is according to NM_000255.3, amino acid numbering above exons is according to NP_000246.2. Mutations are written above the exon 
or below the intron, where they occurred. Mutation types are color coded: blue, missense; orange, insertion/deletion; green, nonsense; purple, splicing; red, start codon. The mut subclass 
associated with each mutation is indicated by a circle “°” for mut0 and a minus “-” for mut-. B. Protein schematic of MUT. Below the boxes which represent the exons, the three domains are 
colored similar to (Forny, et al., 2014; Froese, et al., 2010b): light blue, N-terminal substrate binding domain; yellow, linker region; magenta, C-terminal cofactor binding domain. Amino acid 
numbers are indicated above exons
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The two most frequently identified nonsense mutations were p.Arg403* (c.1207C>T, 10 alleles in 8 
patients, 7 families) and p.Arg727* (c.2179C>T, 10 alleles in 7 patients, 6 families), both the result of 
C to T mutations causing a stop codon (Fig. 2B). Slightly less frequent, p.Tyr231* was 6 times (in 3 
patients, 3 families) caused by the duplication mutation c.692dup and twice by the nonsense muta-
tion c.693C>G. Finally, three nonsense mutations (p.Arg31*, c.91C>T; p.Trp43*, c.129G>A; p.Arg511*, 
c.1531C>T) were detected 5 times (Table 1, Fig. 2B). All other mutations were detected less than 5 
times and almost half of all mutations (43%) were identified only once, indicating that many muta-
tions are private. Splicing mutations were rare, accounting for only 7.3% of all mutations found (Fig. 
2A). 
Although mutations were found in every exon – except for the non-coding exon 1 – the distribution 
is not equal (Fig. 1A and 2C). While the DNA sequences encoding the substrate binding N-terminal 
domain and the cofactor binding C-terminal domain show comparable mutation rates, the region in 
between, corresponding to exons 8 to 10, is less often affected by mutations (Fig. 2C). This region 
only carries 5.5% of all mutations but covers 16% of the coding sequence. The amino acids encoded 
by this region correspond almost fully to the protein linker region, represented by amino acids 482 
to 585 (Fig. 1B), which does not contribute residues to either the catalytic center or the ligand bind-
ing pockets (Froese, et al., 2010b). When amino acid conservation is examined, the linker region 
shows a mean conservation score of 0.70, whereas the adjacent N-terminal and C-terminal domains 
(amino acids 1 to 481 and 586 to 750) show conservation scores of 0.79 and 0.75, respectively (Fig. 
2D). Further, we found only one missense mutation (p.Ala552Val, c.1655C>T) in the linker region, 
which lies on an unusually conserved and buried residue (Supp. Fig. S1). The significantly lower con-
servation and the structural property of this region can help explain the lower frequency of deleteri-
ous mutations found, and suggest that this region is more tolerant to sequence alterations. 
Exon 3 shows the highest relative rate of mutations per base pair (Fig. 2C), and its corresponding 
amino acid sequence (residues 129 to 251) has the highest mean conservation score of all encoded 
exons (data not shown). Moreover, in our cohort 4 out of the 8 most common missense mutations 
map to exon 3, further underlining the importance of this genomic segment. The residues encoded 
by exon 3 provide important contributions to the architecture of the substrate binding channel 
(Supp. Fig. S2), a fact which may supply a structural rationalization for the over-proportional repre-
sentation of mutations encoded by this exon. 
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Figure 2. Frequency of variant types and alleles and their distribution. Coloring as in Fig. 1. A. Pie chart summarizing 
the types of MUT mutations found. Insertions, deletions, duplications and indels are condensed in the category “in/del” 
(orange). B. Frequency of the alleles which occurred at least 5 times in the presented cohort. See also Table 1. C. The relative 
mutation frequency for each individual exon (no exon 1, since it is non-coding; only the coding region of exons 2 and 13 
were calculated). D. Conservation score of the three MUT protein domains. Bars represent mean values of all scores of the 
residues in the respective region, error bars are SEM, *: p < 0.05 (as determined by a Student’s t-test). A multiple sequence 
alignment (MSA) file was created with the ConSurf server (Ashkenazy, et al., 2010): PDB code, 2XIQ; 150 homologues. The 
MSA was used to score each individual residue with the Scorecons server (Valdar, 2002). Amino acids at the N- and C-termini 
(1-30, 739-750) were excluded from the analysis since they represent particularly un-conserved residues (see Supp. Fig. S1). 
 
We found eight mutations whose primary defect was suspected to be via altered splicing (Table 1). 
Following analysis by the “Human Splice Finder” (HSF 3.0; http://www.umd.be/HSF3/) (Desmet, et al., 
2009), seven of these mutations were predicted to alter splicing; c.-39-1G>A could not be analyzed. 
RT-PCR analysis of the intronic mutation c.1084-10A>G demonstrated activation of a cryptic splice 
site in intron 5, leading to the insertion (between exon 5 and 6) of the 9 last nucleotides of intron 5 
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in the transcript, resulting in the mRNA r.1084-1_1084ins1084-9_1084-1 and predicted protein se-
quence p.Gln361_Asn362insIlePhe*. We also analyzed the intronic deletion mutation c.1333-
24_1333-13del by RT-PCR, which showed the generation of an alternative splice site in intron 6. As a 
consequence, the last 12 nucleotides of intron six are inserted between exon 6 and 7, resulting in 
r.1333-1_1333ins1333-12_1333-1 and the predicted protein change p.Lys444_Leu445insPheSer-
Phe*. An interesting case was found in the mutation c.1808G>A which lies on the last nucleotide of 
exon 10. RT-PCR analysis confirmed that the major defect detected on the cDNA level was actually 
splicing as shown previously (Martinez, et al., 2005). The activation of an alternative splice site in the 
middle of exon 10 leads to the deletion of the last 62 nucleotides of exon 10, resulting in 
r.1747_1808del and the predicted protein change p.Val583Glyfs*3. 
Sixteen out of the 110 mutations (14.5%) identified occurred on 13 different arginine residues, alt-
hough arginine residues account for only 5.6% of all amino acids in the MUT protein sequence. This 
disproportion may be explained by the fact that 14 out of 16 mutated arginines were found to exist 
on CpG dinucleotides (except c.977G>A and c.1962_1963del), which are known to be highly mutable 
(Cooper and Youssoufian, 1988). By contrast, alanine, the most common amino acid in MUT (9.2% of 
all amino acids), was only found to be mutated six times (5.5% of all mutations). 
3.5 DATABASE 
All unpublished variants in Table 1 were submitted to the freely accessible NCBI ClinVar database 
http://www.ncbi.nlm.nih.gov/clinvar/ using the standard HGVS nomenclature. 
3.6 BIOLOGICAL SIGNIFICANCE 
Mutations may exert their harmful effect on protein function via different mechanisms, one of which 
is impaired structural integrity leading to an unstable protein, which is then degraded by the pro-
teasomal degradation system. Misfolding mutations (usually missense mutations), which result in 
these “unstable” mutants, represent a significant proportion of mutations in MUT (Forny, et al., 2014). 
In the present study, we selected 34 patient cell lines to investigate if the mutant MUT proteins ex-
pressed therein displayed altered protein levels, which can be used as a surrogate marker of protein 
destabilization. Cell lines were selected based on their availability and genotypic configuration: mis-
sense alleles in a homozygous state or compound heterozygous missense alleles in conjunction with 
a CRIM-negative mutation allowed a conclusion about the respective mutant allele. As controls ho-
mozygous truncation mutations were used. 
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Compared to MUT from wild-type fibroblasts, MUT protein levels from patient fibroblasts containing 
at least one missense mutation were mostly low or absent (Fig. 3). However, some missense muta-
tions resulted in residual protein levels above 25% of wild-type. Of these, the most striking pattern 
of high residual protein level was induced by six mutations near the C-terminus (Fig. 3): four homo-
zygous (p.Gln624Arg, p.Asp625Val, p.Asp625Gly, p.Leu674Phe) and two heterozygous mutations 
(p.Gly630Glu together with the truncation mutation p.Arg403*, p.Val633Gly with the mut0 mutant 
p.Asn219Tyr). These results suggest the primary biochemical defect caused by these mutations is 
something other than protein misfolding, e.g. thermolability, impaired catalytic activity or KM defect 
for AdoCbl (Forny, et al., 2014). Structural investigation of all five strictly conserved residues (Supp. 
Fig. S1) revealed that they are located in the C-terminal domain poised next to the active site (Supp. 
Fig. S3). Due to the crucial location and potential for disturbance to the substrate-cofactor interac-
tion, these mutations are likely to cause impaired catalytic activity. Four of the six cell lines (not no. 
18 and 87) are classified as mut0, suggesting a complete abrogation of catalytic activity. However, 
both cell lines from patients no. 18 and 87 showed a clear response to OHCbl supplementation in 
the PI assay (Table 2) and were therefore classified as mut-. Additionally, cell line no. 18 harbors a 
known mut0 mutation (p.Asn219Tyr, c.655A>T) in conjunction with p.Val633Gly (c.1898T>G), which 
has been repeatedly reported as mut- (Acquaviva, et al., 2005; Adjalla, et al., 1998; Lempp, et al., 2007; 
Worgan, et al., 2006). Thus, although located at the active site, this latter mutation likely induces a KM 
defect for AdoCbl, as previously described in vitro (Forny, et al., 2014). 
Cell lines carrying homozygous mutations which caused a premature stop codon showed almost 
completely absent MUT protein (Fig. 3, truncations). As expected, these truncating mutations are all 
classified as mut0 mutations. 
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Figure 3. Western blot analysis and quantification of MUT expression from patient cell lines. The wild-type (wt) con-
trol bar is colored in black. Left: Blue bars represent the quantification of Western blot of cell lines carrying at least one 
missense mutation. Right: Quantification of Western blot of cell lines with homozygous truncating mutations; orange, in-
sertion/deletion mutations; green, nonsense mutations. Relative MUT levels were determined by normalization to internal 
beta-actin controls. Representative MUT bands of a minimum of n = 2 experiments (error bars depict SEM) below the bar 
chart. Missense mutations are from different protein regions, indicated by the light blue (N-terminal domain) and magenta 
(C-terminal domain) coloring. Patient cell lines are designated with the patient number (Table 2), mut class (empty for 
mut0), and mutations on protein level. Western blot was performed according to (Forny, et al., 2014). 
 
3.7 CLINICAL SIGNIFICANCE 
The presented cohort consists of 151 patients from 145 families, all of whom were confirmed to suf-
fer from mut-type MMAuria either by enzymatic testing (PI or mutase assay) or by mutation analysis 
(Table 2). Patients 1 to 35 (Table 2) have been published in (Lempp, et al., 2007). In all, 84 (55.6%) 
patients carried homozygous mutations, 66 (43.7%) patients were found to have compound heter-
ozygous variants, while for 1 patient (0.3%) only one mutation could be identified (Table 2, patient 
no. 11). For the latter patient deficiency of MUT was confirmed by PI and mutase assay. Patients were 
assigned to the mut subclass based on their known mutations or on the ratio in the PI assay. If the 
ratio was >1.5 (ratio of activity with OHCbl versus that without OHCbl supplemented in the culture 
medium) the patients were classified as mut-; the criterion for the mut0 class was no response in the 
PI assay (ratio ≤1.5), as described in (Lempp, et al., 2007). As the basis for evaluating the nature of the 
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clinical course in the mut0 and mut- patients of our cohort, we compared mutation type, residual 
enzyme activity and age of onset in the two subclasses. 
 
 
Figure 4. mut0 versus mut-. A. Number of patients that were classified as mut0, mut- or not defined (ND). B. Number of 
alleles for each subclass shown as a proportion of mutation type. For explanation of allele subclass classification see foot-
note in Table 1. C. Conservation score of residues, which carried a missense mutation, for each mut subclass. Bars represent 
mean values of scores, error bars depict SEM, *: p = 0.001 (by Student’s t-test). For generation of scores see Fig. 2. D. PI ratios 
of each subclass (Table 2) shown as box plot, horizontal line in the box indicates median, whiskers represent minimum and 
maximum, *: p < 0.0001 (by Student’s t-test). E. Bar chart of mean MUT activities with and without AdoCbl supplementation 
for bot mut subclasses, *: p < 0.002 (by two-way ANOVA, Sidak’s multiple comparisons test). F. Age of onset of all patients 
with available data is shown. The vertical line depicts the median value. For clarity, the highest value in the mut- class is not 
shown (5475 days). 
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114 patients (83 alleles) belonged to the mut0 subclass, 32 (18 alleles) to mut- and for 5 patients (9 
alleles) enzymatic data was lacking and therefore designated “not defined” (ND) (Fig. 4A and B). Thus, 
mut0 patients account for more than three quarters of all patients in our cohort (Fig. 4A). Nearly all 
nonsense and insertion/deletion mutations were associated with mut0 alleles (c.1975C>T, p.Gln659* 
and c.2194_2197delinsTGGAA, p.Ala732Trpfs*6 were classified as “not defined” due to a lack of bio-
chemical data), suggesting that these mutation types usually lead to a completely dysfunctional en-
zyme. Within the mut- class, 17 of the 18 mutations were of the missense type (Fig. 4B). Comparison 
of these 17 mut- missense mutations with the 38 missense mutations that produced a mut0 allele 
reveals that the mut0 amino acid exchanges took place at residues with a higher overall conservation 
score (Fig. 4C), providing a possible rationalization for their more severe impact. 
As expected, fibroblasts taken from mut0 patients in our cohort had a lower PI ratio than those from 
mut- (by definition, Fig. 4D). Interestingly, this is in line with enzymatic activity which more than dou-
bled in mut- cells upon AdoCbl supplementation, while activity in mut0 cells stayed the same (Fig. 
4E). This is further evidence that mut- mutations specifically interfere with utilization of the cofactor 
and, in vitro at least, benefit from bolstered AdoCbl levels. 
For more than half of the patients in our cohort the age of onset was well documented (Table 2). 
These patients showed a very broad onset range, from day 1 to 15 years of life; while some patients 
detected in newborn screening were asymptomatic at the time of diagnosis (Table 2). Overall, the 
mut- subclass patients showed a later age of onset (mean age of onset: 273 days; median: 109 days) 
than mut0 patients (mean age of onset: 86 days; median: 6 days) (Fig. 4F), which is consistent with 
previous findings (Matsui, et al., 1983b). 
To further investigate the stratification of the missense mutations into the mut0 and mut- subclasses, 
we mapped them onto the MUT protein structure (Fig. 5). Missense mutations of the mut0 class were 
clearly more present in the N-terminal domain, as 84% of all mut0 missense mutations were found 
there. Therefore, 68% of all missense mutations in this region were of the mut0 subclass. Since the N-
terminal domain harbors the substrate binding site, we hypothesize that the missense mutations 
found in this region caused mainly severe mut0 alleles either via specific interference with the con-
figuration required for substrate binding, or by general loss of protein stability (Fig. 3). The propor-
tion of mut- subclass causing missense mutations was higher in the C-terminal domain (50% of all 
missense mutations) than in in the N-terminal domain (21%). This is consistent with the AdoCbl bind-
ing function of this domain, disturbance of which can lead to inhibited AdoCbl binding, as reflected 
in the higher PI ratio and response to AdoCbl supplementation in the MUT activity assay in mut- fi-
broblasts (Fig. 4D and E). 
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Figure 5. Structural mapping of missense mutations on the MUT protein. The MUT structure according to PDB code 
2XIQ, colored as in Fig. 1B: light blue, N-terminal domain; yellow, inter-domain linker; magenta, C-terminal domain. Mis-
sense mutations (Table 1) are shown as circles in red (mut0), blue (mut-) or grey (ND: not defined). Between the two mono-
mers a schematic protein representation shows the relative distribution of missense mutations in the 2D polypeptide chain. 
 
3.8 DIAGNOSTIC RELEVANCE 
In a clinical setting, general symptoms such as lethargy or even coma combined with vomiting and 
severe ketoacidosis can be the first signs which trigger the suspicion of MMAuria. The initial meta-
bolic differential diagnosis at this step involves – among other diseases – organic acidurias which 
can closely imitate MMAuria, such as maple syrup urine disease, isovaleric aciduria, and propionic 
aciduria. Identification of characteristic changes in the organic acid and acylcarnitine profile, espe-
cially elevated urine and/or blood methylmalonic acid and elevated propionylcarnitine level 
(Baumgartner, et al., 2014) allows the diagnosis of unclassified MMAuria and initiation of acute phase 
treatment. However, optimized long-term treatment and prognosis depend on knowledge of the 
exact defect. A reliable and well-established systematic approach to achieve this involves perfor-
mance of PI assay followed by direct assay of mutase activity and complementary mutation analysis. 
First-line mutation analysis may be appropriate in cases of prenatal diagnosis, known siblings with 
the disorder, or in special populations. However, this study highlights pitfalls in using this approach 
in other situations. The high number of private mutations (here we present 18 novel missense mu-
tations, in total 186 missense mutations are known according to HGMD version 2015.3), together 
with the large number of known SNPs (414 according to dbSNP, NCBI as of November 2015), makes 
it difficult to differentiate whether a novel variant indeed causes disease. This is particularly relevant 
for non-synonymous point mutations resulting in missense changes. 
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We tested all of our missense mutations in silico with three different variant severity prediction pro-
grams (see footnote Table 1). From these, a total of four mutations were designated as “benign” or 
“neutral”. One mutation (p.Arg603Lys) was predicted to be non-detrimental by all three algorithms, 
implying that the predicted protein change might not be the main/only defect conferred by this 
mutation. This hypothesis is supported by the detection of an alternative transcript detected by RT-
PCR (Table 1, c.1747_1808del), indicating that this mutation causes altered splicing. Further, 3 muta-
tions (p.Gly203Arg, p.Ser288Pro, p.Met700Lys) were predicted to be non-damaging by PROVEAN 
and PolyPhen-2 even though there is clear evidence that they are disease-causing. The mutations 
p.Gly203Arg (in patient no. 12 and 95) and p.Ser288Pro (in patients no. 20) were both detected in a 
homozygous state and analysis of the patient cells showed clear enzymatic evidence of MMAuria 
(Table 2). In addition, p.Met700Lys was independently expressed and displayed a catalytic defect in 
a previous study (Forny, et al., 2014). This data demonstrates that these in silico programs can be 
applied as a guide in diagnostic practice, but should not be used as confirmation of a defect. Hence, 
biochemical testing by PI or mutase assay remains crucial for the diagnosis of mut-type MMAuria. 
3.9 FUTURE PROSPECTS 
This study underpins our understanding of a number of mechanistic questions and points to further 
studies regarding the link between mutations and disease in this important disorder. 
First, knowledge of the mut class is important for prognosis of the future development of the disease, 
where mut0 patients show a more severe course of the disorder (Horster, et al., 2007). Supporting 
this, in our cohort mut0 patients presented earlier than mut-. Future studies should evaluate detailed 
follow-up data on clinical course in relation to mut class. In some cases, these investigations will need 
to be combined with expression of particular mutations. However, it needs to be born in mind that 
the prognosis of the clinical course of MMAuria in a single patient, solely based on the biochemical 
mut class assignment, is uncertain. 
Second, establishment of the patient’s response to cobalamin supplementation therapy is crucial for 
a proper treatment regimen and should be tested using a standardized protocol (Baumgartner, et 
al., 2014; Fowler, et al., 2008). Most cblA patients improve upon this therapy and about one third of 
cblB patients respond to cobalamin treatment (Matsui, et al., 1983b; Rosenberg, et al., 1968). How-
ever, mut patients have only been assessed under non-standardized protocols (Horster, et al., 2007; 
Matsui, et al., 1983b) and results can sometimes be confusing, since methylmalonic acid urine levels 
are influenced by factors (e.g. undetected infection) which are difficult to control. As indicated by our 
data, in vitro studies can provide valuable help in assessing the likelihood of an in vivo response. A 
high PI ratio and increase of mutase activity in the assay upon AdoCbl supplementation can indicate 
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a response to cobalamin. We also show that missense mutations, which are localized in the C-termi-
nal domain, are more likely to belong to the mut- class and therefore be responsive to cobalamin in 
vitro. Nevertheless, further study of the biochemical mechanisms behind cobalamin responsiveness 
is needed in order to better understand the molecular behaviour of cofactor binding and its disrup-
tion. 
Third, this study shows that out of all the missense mutations only about one third are associated 
with response to cobalamin in vitro, indicating a cofactor binding defect. As exemplified by our West-
ern blot analysis (Fig. 3), a large proportion of the other missense mutations appear to cause protein 
destabilization. This feature may render these mutations candidates for protein stabilization therapy, 
e.g. by pharmacological chaperones or by inhibition of the proteasomal protein degradation ma-
chinery (Cohen and Kelly, 2003; Muntau, et al., 2014), facilitating an individualized, mutation-tailored 
treatment approach in the future. 
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Table 1. Summary of mutant alleles found in MUT and their consequences 
 
Nucleotide change a Predicted protein change b 
Exon/ 
Intron 
mut 
class c 
No. of 
alleles 
No. of  
patients 
No. of 
families 
PROVEAN 
score d 
SIFT 
score e 
Poly-
Phen-2 
score f 
Literature Reference 
c.-39-1G>A splice site g Intron 1 mut0 1 1 1    This study 
c.2T>C p.(Met1?) Exon 2 mut0 1 1 1    This study 
c.30dup p.(Leu11Thrfs*38) Exon 2 mut0 1 1 1    This study 
c.55dup p.(Val19Glyfs*30) Exon 2 mut0 2 1 1    This study 
c.88C>T p.(Gln30*) Exon 2 mut0 3 2 2    This study 
c.91C>T p.(Arg31*) Exon 2 mut0 5 4 4    (Worgan, et al., 2006) 
c.129G>A p.(Trp43*) Exon 2 mut0 5 3 2    This study 
c.160A>T p.(Lys54*) Exon 2 mut0 2 1 1    (Fuchshuber, et al., 2000) 
c.278G>A p.(Arg93His) Exon 2 mut0 2 1 1 -4.94 0 1 (Raff, et al., 1991) 
c.299A>G p.(Tyr100Cys) Exon 2 mut- 2 1 1 -8.89 0 1 (Lempp, et al., 2007) 
c.322C>T p.(Arg108Cys) Exon 2 mut0 1 1 1 -7.91 0 1 (Worgan, et al., 2006) 
c.323G>A p.(Arg108His) Exon 2 mut- 1 1 1 -7.91 0 1 (Acquaviva, et al., 2005) 
c.330T>G p.(Tyr110*) Exon 2 mut0 1 1 1    This study 
c.360dup p.(Lys121*) Exon 2 mut0 1 1 1    (Acquaviva, et al., 2005) 
c.378C>A p.(Asn126Lys) Exon 2 ND 2 2 1 -4.63 0.003 0.998 This study 
c.394C>T p.(Gln132*) Exon 3 mut0 1 1 1    (Dundar, et al., 2012) 
c.397G>A p.(Gly133Arg) Exon 3 mut0 2 1 1 -7.97 0 1 This study 
c.410C>T p.(Ala137Val) Exon 3 mut0 1 1 1 -3.99 0 1 (Lempp, et al., 2007) 
c.415G>A p.(Asp139Asn) Exon 3 ND 1 1 1 -4.98 0 1 This study 
c.421del p.(Ala141Argfs*39) Exon 3 mut0 2 1 1    (Peters, et al., 2002) 
c.427C>T p.(His143Tyr) Exon 3 mut0 1 1 1 -5.98 0 1 (Lempp, et al., 2007) 
c.443C>T p.(Ser148Leu) Exon 3 mut0 1 1 1 -5.97 0 1 (Acquaviva, et al., 2005) 
c.467A>T p.(Asp156Val) Exon 3 ND 2 1 1 -8.98 0 1 This study 
c.481G>A p.(Gly161Arg) Exon 3 mut0 2 1 1 -7.99 0 1 (Filippi, et al., 2009) 
c.521T>C p.(Phe174Ser) Exon 3 mut0 1 1 1 -7.99 0 1 (Fuchshuber, et al., 2000) 
c.544dup p.(Met182Asnfs*29) Exon 3 mut0 2 1 1    (Fuchshuber, et al., 2000) 
c.560C>G p.(Thr187Ser) Exon 3 mut0 1 1 1 -3.99 0 1 This study 
c.566A>T p.(Asn189Ile) Exon 3 mut- 2 1 1 -8.98 0 1 This study 
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c.572C>A p.(Ala191Glu) Exon 3 mut0 6 5 5 -4.99 0 1 (Acquaviva, et al., 2005) 
c.607G>A p.(Gly203Arg) Exon 3 mut0 6 4 4 -2.43 0 0.999 (Fuchshuber, et al., 2000) 
c.613_615del p.(Glu205del) Exon 3 mut0 1 1 1    This study 
c.622del p.(Val208Tyrfs*15) Exon 3 mut0 1 1 1    (Peters, et al., 2002) 
c.623_624del p.(Val208Alafs*2) Exon 3 mut0 1 1 1    (Ostergaard, et al., 2005) 
c.630del p.(Glu211Argfs*12) Exon 3 mut0 1 1 1    This study 
c.643G>A p.(Gly215Ser) Exon 3 mut0 2 2 2 -5.98 0 1 (Acquaviva, et al., 2005) 
c.654A>C p.(Gln218His) Exon 3 mut0 6 5 5 -4.99 0 1 (Fuchshuber, et al., 2000) 
c.655A>T p.(Asn219Tyr) Exon 3 mut0 24 17 17 -7.98 0 1 (Acquaviva, et al., 2005) 
c.682C>T p.(Arg228*) Exon 3 mut0 1 1 1    (Acquaviva, et al., 2005) 
c.683G>A p.(Arg228Gln) Exon 3 mut0 1 1 1 -3.99 0 1 (Adjalla, et al., 1998) 
c.689C>G p.(Thr230Arg) Exon 3 mut0 4 2 2 -5.99 0 1 This study 
c.691T>A p.(Tyr231Asn) Exon 3 mut- 1 1 1 -8.48 0 1 (Janata, et al., 1997) 
c.692dup p.(Tyr231*) Exon 3 mut0 6 3 3    This study 
c.693C>G p.(Tyr231*) Exon 3 mut0 2 2 2    This study 
c.729_730insTT p.(Asp244Leufs*39) Exon 3 mut0 4 2 2    (Worgan, et al., 2006) 
c.753+2T>A splice site g Intron 3 mut0 2 2 2    (Worgan, et al., 2006) 
c.786T>G p.(Ser262Arg) Exon 4 mut0 1 1 1 -4.99 0 1 (Yi, et al., 2011) 
c.828G>C p.(Glu276Asp) Exon 4 mut- 1 1 1 -2.99 0.001 1 This study 
c.850G>A p.(Gly284Arg) Exon 4 mut0 1 1 1 -7.99 0 1 This study 
c.851G>A p.(Gly284Glu) Exon 4 mut0 1 1 1 -7.99 0 1 This study 
c.862T>C p.(Ser288Pro) Exon 4 mut0 3 2 2 -1.1 0.003 0.012 (Lempp, et al., 2007) 
c.914T>C p.(Leu305Ser) Exon 5 mut0 2 1 1 -5.75 0 1 (Worgan, et al., 2006) 
c.927G>A p.(Trp309*) Exon 5 mut0 1 1 1    This study 
c.974G>A p.(Gly325Asp) Exon 5 ND 2 2 1 -2.65 0 0.998 This study 
c.977G>A p.(Arg326Lys) Exon 5 ND 1 1 1 -3 0 1 This study 
c.982C>T p.(Leu328Phe) Exon 5 mut0 9 5 5 -3.89 0.001 1 (Acquaviva, et al., 2005) 
c.983T>C p.(Leu328Pro) Exon 5 mut0 1 1 1 -6.87 0 1 (Martinez, et al., 2005) 
c.1022dup p.(Asn341Lysfs*20) Exon 5 mut0 1 1 1    (Worgan, et al., 2006) 
c.1031C>T p.(Ser344Phe) Exon 5 mut- 1 1 1 -5.96 0 1 (Lempp, et al., 2007) 
c.1040T>G p.(Leu347Arg) Exon 5 mut0 1 1 1 -5.99 0 1 (Worgan, et al., 2006) 
c.1073T>C p.(Leu358Pro) Exon 5 mut0 1 1 1 -6.53 0 1 (Merinero, et al., 2008) 
c.1084-10A>G h p.(Gln361_Asp362insIlePhe*) Intron 5 mut- 2 1 1    (Liu, et al., 2012) 
c.1084-1G>A splice site g Intron 5 mut0 2 1 1    This study 
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c.1084-2A>G splice site g Intron 5 mut0 1 1 1    This study 
c.1097A>G p.(Asn366Ser) Exon 6 mut- 2 2 1 -4.95 0 1 (Lempp, et al., 2007) 
c.1105C>T p.(Arg369Cys) Exon 6 mut0 2 2 2 -7.92 0 1 (Jung, et al., 2005) 
c.1106G>A p.(Arg369His) Exon 6 mut0 23 16 15 -4.95 0 1 (Janata, et al., 1997) 
c.1130C>A p.(Ala377Glu) j Exon 6 mut0 2 1 1 -4.53 0 1 (Jansen and Ledley, 
1990) 
c.1157A>G p.(His386Arg) Exon 6 mut0 1 1 1 -7.92 0 1 (Worgan, et al., 2006) 
c.1160C>T p.(Thr387Ile) Exon 6 mut- 4 2 1 -5.94 0 1 (Dundar, et al., 2012) 
c.1164T>A p.(Asn388Lys) Exon 6 mut0 2 1 1 -5.94 0 1 This study 
c.1181dup p.(Leu394Phefs*30) Exon 6 mut0 1 1 1    This study 
c.1207C>T p.(Arg403*) Exon 6 mut0 10 8 7    (Peters, et al., 2002) 
c.1271C>T p.(Pro424Leu) Exon 6 mut0 2 1 1 -9.9 0.005 1 This study 
c.1276G>A p.(Gly426Arg) Exon 6 mut- 1 1 1 -5.68 0 1 (Worgan, et al., 2006) 
c.1277G>A p.(Gly426Glu) Exon 6 mut- 2 1 1 -5.68 0 1 This study 
c.1333-24_1333-13del h p.(Lys444_Leu445insPheSerPhe*) Intron 6 mut0 2 1 1    This study 
c.1361G>A p.(Gly454Glu) Exon 7 mut0 1 1 1 -7.93 0 1 (Lempp, et al., 2007) 
c.1420C>T k p.(Arg474*) Exon 7 mut0 4 3 3    (Acquaviva, et al., 2005) 
c.1489G>T p.(Glu497*) Exon 7 mut0 1 1 1    This study 
c.1531C>T p.(Arg511*) Exon 8 mut0 5 3 3    (Acquaviva, et al., 2005) 
c.1541del p.(Gln514Argfs*24) Exon 8 mut0 1 1 1    (Worgan, et al., 2006) 
c.1655C>T p.(Ala552Val) Exon 9 ND 1 1 1 -3.61 0.003 0.98 This study 
c.1658del p.(Val553Glyfs*17) Exon 9 mut0 2 1 1    (Acquaviva, et al., 2005) 
c.1677-1G>C splice site g Intron 9 mut0 4 4 4    (Acquaviva, et al., 2005) 
c.1677_1747dup m p.(Val583Aspfs*11) Exon 10 mut0 1 1 1    This study 
c.1747_1808del n 
(c.1808G>A) 
p.(Val583Glyfs*3) 
(p.(Arg603Lys)) Exon 10 mut
0 2 1 1 
 
(-0.25) 
 
(0.915) 
 
(0.002) 
(Martinez, et al., 2005) 
c.1843C>A p.(Pro615Thr) Exon 11 mut0 9 5 5 -7.82 0 0.998 (Peters, et al., 2002) 
c.1844C>T p.(Pro615Leu) Exon 11 mut0 4 3 3 -9.78 0.013 0.981 (Dundar, et al., 2012) 
c.1853T>C p.(Leu618Pro) Exon 11 ND 1 1 1 -6.32 0 1 This study 
c.1871A>G p.(Gln624Arg) Exon 11 mut0 2 1 1 -3.85 0.001 0.999 (Acquaviva, et al., 2005) 
c.1874A>T p.(Asp625Val) Exon 11 mut0 2 1 1 -8.82 0 1 (Dundar, et al., 2012) 
c.1874A>G p.(Asp625Gly) Exon 11 mut0 2 1 1 -6.86 0 1 This study 
c.1889G>A p.(Gly630Glu) Exon 11 mut0 4 4 4 -7.84 0 1 (Crane and Ledley, 1994) 
c.1898T>G p.(Val633Gly) Exon 11 mut- 1 1 1 -6.8 0 1 (Adjalla, et al., 1998) 
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c.1962_1963del p.(Arg655*) Exon 12 mut0 4 2 2    (Dundar, et al., 2012) 
c.1975C>T p.(Gln659*) Exon 12 ND 2 1 1    This study 
c.2009del p.(Gly670Alafs*2) Exon 12 mut0 1 1 1    (Fuchshuber, et al., 2000) 
c.2020C>T p.(Leu674Phe) Exon 12 mut- 2 1 1 -2.98 0.003 1 (Dundar, et al., 2012) 
c.2053_2055dup p.(Leu685dup) Exon 12 mut0 2 2 2    (Adjalla, et al., 1998) 
c.2078del p.(Gly693Aspfs*12) Exon 12 mut0 2 1 1    This study 
c.2080C>T p.(Arg694Trp) Exon 12 mut- 11 7 7 -5.15 0.001 1 (Crane and Ledley, 1994) 
c.2081G>T p.(Arg694L) Exon 12 mut- 3 2 2 -4.09 0.007 0.938 (Lempp, et al., 2007) 
c.2099T>A p.(Met700Lys) Exon 12 mut- 3 3 3 -3.36 0 0.146 (Acquaviva, et al., 2005) 
c.2150G>T p.(Gly717Val) Exon 13 mut- 2 2 2 -8.82 0 1 (Crane, et al., 1992) 
c.2159_2160del p.(Asn720Serfs*17) l Exon 13 mut0 2 1 1    (Worgan, et al., 2006) 
c.2179C>T p.(Arg727*) Exon 13 mut0 10 7 6    (Worgan, et al., 2006) 
c.2193_2196dup p.(Val733Cysfs*6) Exon 13 mut0 1 1 1    This study 
c.2194_2197delinsTGGAA p.(Ala732Trpfs*6) Exon 13 ND 2 2 2    This study 
c.2200C>T p.(Gln734*) Exon 13 mut0 1 1 1    This study 
c.2206C>T p.(Leu736Phe) Exon 13 mut- 1 1 1 -2.82 0.001 0.786 (Forny, et al., 2014) 
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Table Footnotes: 
a According to cDNA sequence NM_000255.3. Sequencing of mutations was performed according to 
(Lempp, et al., 2007). 
b According to amino acid sequence NP_000246.2. 
c Since in patient cells the two present alleles cannot be tested individually but only in combination, 
we assigned in our study the mut subclass to the alleles as follows: 1) In homozygous cell lines both 
alleles were assigned the same subtype as the tested patient cell line; 2) in a heterozygous mut0 cell 
line, both alleles were assigned mut0; 3) in a heterozygous mut- cell line, the first allele was assigned 
mut-, if the second one was a known mut0 allele; 4) previously determined alleles were assigned the 
same mut class in all patient cell lines. ND, not defined. 
d Protein Variation Effect Analyzer (PROVEAN) scores of missense mutations were calculated on 
http://provean.jcvi.org/. If the PROVEAN score is equal to or below a threshold of -2.5, the protein variant 
is predicted to have a “deleterious” effect. If the PROVEAN score is above the threshold, the variant 
is predicted to have a “neutral” effect (in bold) (Choi and Chan, 2015). 
e SIFT scores (0-0.05 corresponds to amino acid changes that likely affect protein function, “benign” 
changes have a score of >0.05 and are in bold) of missense changes were calculated on the server 
http://sift.jcvi.org/ (Kumar, et al., 2009). 
f PolyPhen-2 scores of missense changes were calculated on http://genetics.bwh.harvard.edu/pph2/. 
Scores above 0.432 are categorized as “probably damaging”, scores below predict the variant as “be-
nign” (in bold) (Adzhubei, et al., 2010). 
g RT-PCR investigations did not reveal the effect of the mutation on transcript level. 
h For splicing effect see text. 
j Reported as p.(Ala378Glu) in reference. 
k Reported as c.1423C>T in reference. 
l Reported as p.(Asn720Serfs*14) in reference. 
m This mutation in patient no. 141 was identified at the cDNA level, but was not confirmed at the 
genomic level. 
n The major defect conferred by this variant was found to be splicing as detected on cDNA level 
(c.1747_1808del). The genomic mutation and its predicted protein change are given in brackets. For 
details see text.
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Table 2. Summary of the patient cohort reports age of onset, biochemical data, mut class and genotype 
 
Patient ID a 
Age of onset 
(days) b 
Propionate incorporation c 
(nmol/mg protein/10 or 16 h) 
MUT activity d 
(pmol/min/mg protein) 
Mutations 
  
Medium  
-OHCbl 
Medium  
+OHCbl 
PI ratio 
(+OHCbl/ 
-OHCbl) 
Assay  
-AdoCbl 
Assay  
+AdoCbl 
Nucleotide change e Predicted protein change f 
Patients classified as mut- in this study a 
18 5475 0.23 2.01 8.62 22* 182* c.655A>T c.1898T>G 
p.(Asn219Tyr) 
p.(Val633Gly) 
128 n.r. 0.73 6.01 8.21 0 71 c.1207C>T c.2099T>A 
p.(Arg403*) 
p.(Met700Lys) 
125 NBS 0.79 5.71 7.22 15 352 c.655A>T c.828G>C 
p.(Asn219Tyr) 
p.(Glu276Asp) 
13 90 0.88 5.22 5.97 98* 142* c.299A>G (hom) p.(Tyr100Cys) 
22 14 1.45 6.66 4.59 55* 88* c.2099T>A c.623_624del 
p.(Met700Lys) 
p.(Val208Alafs*2) 
31 180 0.47 1.77 3.75 15* 36* c.572C>A c.2099T>A 
p.(Ala191Glu) 
p.(Met700Lys) 
74 n.r. 1.46 5.43 3.72 32 105 c.1276G>A c.1655C>T 
p.(Gly426Arg) 
p.(Ala552Val) 
144 n.r. 0.73 2.65 3.64 9 35 c.1277G>A (hom) p.(Gly426Glu) 
121.1 5 0.70 2.51 3.61 16 18 c.1160C>T (hom) p.(Thr387Ile) 
16 630 1.49 5.22 3.51 84* 163* 
c.2081G>T 
c.1207C>T 
p.(Arg694L) 
p.(Arg403*) 
67 n.r. 2.54 8.23 3.24 50 199 
c.753+2T>A 
c.2206C>T 
splice site 
p.(Leu736Phe) 
41 1095 2.03 6.28 3.09 20 63 c.566A>T (hom) p.(Asn189Ile) 
87 2 0.30 0.85 2.81 5 0 c.2020C>T (hom) p.(Leu674Phe) 
15.2 60 0.37 1.05 2.80 3* 2* c.1097A>G c.1106G>A 
p.(Asn366Ser) 
p.(Arg369His) 
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17 90 0.29 0.76 2.63 4* 8* c.91C>T c.323G>A 
p.(Arg31*) 
p.(Arg108His) 
15.1 150 0.36 0.89 2.49 37* 87* c.1097A>G c.1106G>A 
p.(Asn366Ser) 
p.(Arg369His) 
137 n.r. 4.62 10.59 2.29 205 159 c.977G>A c.2194_2197delinsTGGAA 
p.(Arg326Lys) 
p.(Ala732Trpfs*6) 
143 n.r. 0.50 1.13 2.27 33 832 c.1207C>T c.2150G>T 
p.(Arg403*) 
p.(Gly717Val) 
54.1 NBS 0.88 1.98 2.25 0 3 c.378C>A c.974G>A 
p.(Asn126Lys) 
p.(Gly325Asp) 
49 98 1.35 2.78 2.05 107 140 c.1084-10A>G (hom) p.(Gln361_Asp362insIlePhe*) 
36 NBS 2.74 5.53 2.02 24 37 c.572C>A (hom) p.(Ala191Glu) 
1 540 0.84 1.52 1.85 44* 80* c.2080C>T (hom) p.(Arg694Trp) 
2 28 0.48 0.83 1.75 3* 34* c.654A>C c.1106G>A 
p.(Gln218His) 
p.(Arg369His) 
37 n.r. 1.17 1.97 1.68 49 75 c.2080C>T (hom) p.(Arg694Trp) 
131 120 0.71 1.20 1.68   c.1022dup c.2150G>T 
p.(Asn341Lysfs*20) 
p.(Gly717Val) 
4 n.r. 0.83 1.43 1.67 26* 49* c.2080C>T (hom) p.(Arg694Trp) 
9 210 1.59 2.61 1.66 11* 62* c.1106G>A 
c.691T>A 
p.(Arg369His) 
p.(Tyr231Asn) 
21 90 0.75 1.25 1.63 30* 28* c.2080C>T (hom) p.(Arg694Trp) 
11 1095 0.58 0.88 1.55 19* 29* c.1031C>T g p.(Ser344Phe) 
54.2 n.r.      c.378C>A c.974G>A 
p.(Asn126Lys) 
p.(Gly325Asp) 
121.2 n.r.      c.1160C>T (hom) p.(Thr387Ile) 
140 420      c.2081G>T (hom) p.(Arg694Leu) 
Patients classified as mut0 in this study a 
130 h 270 1.06 1.67 1.57 5* 11* c.1531C>T (hom) p.(Arg511*) 
76 510 0.13 0.20 1.50 5* 10* c.927G>A c.983T>C 
p.(Trp309*) 
p.(Leu328Pro) 
101 n.r. 0.77 1.12 1.45 0* 17* c.654A>C c.1106G>A 
p.(Gln218His) 
p.(Arg369His) 
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154 n.r. 0.71 0.95 1.34 86 69 c.2T>C c.850G>A 
p.(Met1?) 
p.(Gly284Arg) 
73 n.r. 0.91 1.22 1.34 29 45 c.1871A>G (hom) p.(Gln624Arg) 
142 4 1.06 1.40 1.33 49 24 c.1658del (hom) p.(Val553Glyfs*17) 
145 n.r. 0.61 0.81 1.33 5 0 c.1271C>T (hom) p.(Pro424Leu) 
89 n.r. 0.83 1.09 1.32 35 1 c.1874A>G (hom) p.(Asp625Gly) 
45 300 0.25 0.32 1.27 0 4 c.654A>C (hom) p.(Gln218His) 
80 NBS 0.54 0.68 1.26 1* 20* c.1106G>A (hom) p.(Arg369His) 
152 n.r. 0.51 0.64 1.26 0 0 c.654A>C c.655A>T 
p.(Gln218His) 
p.(Asn219Tyr) 
149 n.r. 0.61 0.76 1.25 7 6 c.91C>T c.2080C>T 
p.(Arg31*) 
p.(Arg694Trp) 
63 n.r. 0.76 0.94 1.24 0 0 c.982C>T (hom) p.(Leu328Phe) 
153 n.r. 0.33 0.40 1.23 0 6 c.862T>C c.1157A>G 
p.(Ser288Pro) 
p.(His386Arg) 
141 n.r. 0.82 0.99 1.21 59 52 c.129G>A c.1677_1747dup 
p.(Trp43*) 
p.(Val583Aspfs*11) 
48 n.r. 0.58 0.70 1.21 251 219 c.397G>A (hom) p.(Gly133Arg) 
47 210 0.36 0.43 1.19 125 96 c.689C>G (hom) p.(Thr230Arg) 
34 2 0.34 0.40 1.16 40* 37* c.1106G>A c.2009del 
p.(Arg369His) 
p.(Gly670Alafs*2) 
102 21 0.57 0.66 1.16 12* 11* c.394C>T c.655A>T 
p.(Gln132*) 
p.(Asn219Tyr) 
39 n.r. 1.41 1.62 1.15 65* 37* c.655A>T (hom) p.(Asn219Lys) 
50 n.r. 0.58 0.67 1.14 172 177 c.786T>G c.1889G>A 
p.(Ser262Arg) 
p.(Gly630Glu) 
65 540 0.94 1.07 1.14 0 0 c.91C>T c.2053_2055dup 
p.(Arg31*) 
p.(Leu685dup) 
14 42 0.89 1.01 1.14 14* 5* c.1361G>A c.427C>T 
p.(Gly454Glu) 
p.(His143Tyr) 
139 3 0.49 0.56 1.13   c.729_730insTT (hom) p.(Asp244Leufs*39) 
126 n.r. 1.94 2.16 1.11   c.91C>T (hom) p.(Arg31*) 
129 n.r. 0.61 0.67 1.10 113 42 c.160A>T (hom) p.(Lys54*) 
60 n.r. 0.72 0.80 1.10 120 116 c.421del (hom) p.(Ala141Argfs*39) 
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122 n.r. 0.58 0.63 1.09 0 2 c.692dup (hom) p.(Tyr231*) 
66 5 1.17 1.26 1.08 0 0 c.1106G>A (hom) p.(Arg369His) 
136 n.r. 0.74 0.80 1.08   c.544dup (hom) p.(Met182Asnfs*29) 
68 n.r. 0.73 0.79 1.08   c.692dup (hom) p.(Tyr231*) 
8 1 1.83 1.97 1.08 0* 21* c.982C>T (hom) p.(Leu328Phe) 
38 5 0.44 0.48 1.07 22* 27* c.2159_2160del (hom) p.(Asn720Serfs*17) 
88 n.r. 0.24 0.25 1.07 2* 12* c.1843C>A (hom) p.(Pro615Thr) 
5 42 0.49 0.52 1.06 118* 139* c.2080C>T 
c.1677-1G>C 
p.(Arg694Trp) 
splice site 
32 150 0.76 0.81 1.06 38* 26* c.655A>T (hom) p.(Asn219Tyr) 
150 n.r. 0.72 0.76 1.06 41 23 c.682C>T c.1181dup 
p.(Arg228*) 
p.(Leu394Phefs*30) 
83 n.r. 0.62 0.65 1.06 126 90 c.1130C>A (hom) p.(A377Glu) 
84 n.r. 0.72 0.76 1.05 24 14 c.88C>T c.521T>C 
p.(Gln30*) 
p.(Phe174Ser) 
116 3 2.45 2.58 1.05 0 18 c.560C>G (hom) p.(Thr187Ser) 
113 n.r. 0.91 0.95 1.05 85 84 c.1843C>A (hom) p.(Pro615Thr) 
71 n.r. 0.65 0.67 1.04 263 264 
c.1489G>T 
c.2193_2196dup 
p.(Glu497*) 
p.(Val733Cysfs*6) 
99 3 0.49 0.51 1.04 3 3 
c.30dup 
c.1040T>G 
p.(Leu11Thrfs*38) 
p.(Leu347Arg) 
91 n.r. 0.99 1.02 1.03 75 71 c.1106G>A (hom) p.(Arg369His) 
25 3 2.08 2.11 1.03 28* 0* c.655A>T c.1420C>T 
p.(Asn219Tyr) 
p.(Arg474*) 
96 7 0.41 0.42 1.02 11 32 c.278G>A (hom) p.(Arg93His) 
75 21 1.30 1.33 1.02 22 29 c.322C>T c.1531C>T 
p.(Arg108Cys) 
p.(Arg511*) 
92 n.r. 0.29 0.29 1.02 6* 11* c.982C>T (hom) p.(Leu328Phe) 
155 n.r. 0.92 0.94 1.02 91 86 c.360dup 
c.2179C>T 
p.(Lys121*) 
p.(Arg727*) 
19 3 1.06 1.08 1.02 39* 62* c.2080C>T c.1677-1G>C 
p.(Arg694Trp) 
splice site 
61 n.r. 0.57 0.57 1.01 10 5 c.1843C>A c.2179C>T 
p.(Pro615Thr) 
p.(Arg727*) 
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133 n.r. 0.41 0.42 1.01 20 24 c.655A>T c.1889G>A 
p.(Asn219Tyr) 
p.(Gly630Glu) 
7 3 0.22 0.22 1.00 64* 69* c.607G>A c.1106G>A 
p.(Gly203Arg) 
p.(Arg369His) 
108 n.r. 0.49 0.49 0.99   c.330T>G c.630del 
p.(Tyr110*) 
p.(Glu211Argfs*12) 
138 2 0.57 0.57 0.99 139 134 c.683G>A c.2200C>T 
p.(Arg228Gln) 
p.(Gln734*) 
51 n.r. 0.53 0.53 0.99 190 159 c.-39-1G>A (hom) splice site 
64 n.r. 0.85 0.84 0.99 0 2 c.982C>T (hom) p.(Leu328Phe) 
132 n.r. 0.74 0.73 0.99 7* 7* c.1962_1963del (hom) p.(Arg655*) 
117 10 0.90 0.89 0.98 89 89 c.1084-1G>A (hom) splice site 
35 2 0.64 0.62 0.98 17* 15* c.654A>C c.1677-1G>C 
p.(Gln218His) 
splice site 
90 n.r. 0.92 0.90 0.98 138 91 c.481G>A (hom) p.(Gly161Arg) 
26 3 0.39 0.39 0.98 34* 10* c.443C>T c.1677-1G>C 
p.(Ser148Leu) 
splice site 
86 n.r. 1.18 1.15 0.98 6* 13* c.693C>G c.1106G>A 
p.(Tyr231*) 
p.(Arg369His) 
10 390 1.05 1.03 0.98 30* 0* c.1106G>A (hom) p.(Arg369His) 
46 2 0.30 0.29 0.97 160 145 c.1962_1963del (hom) p.(Arg655*) 
12 42 2.19 2.12 0.97 0* 0* c.607G>A (hom) p.(Gly203Arg) 
58 7 0.51 0.49 0.96 2 0 c.572C>A c.1541del 
p.(Ala191Glu) 
p.(Gln514Argfs*24) 
123 5 0.88 0.84 0.96   c.655A>T (hom) p.(Asn219Tyr) 
27 3 1.60 1.54 0.96 4* 19* c.655A>T (hom) p.(Asn219Tyr) 
52 150 0.35 0.34 0.96 135 130 c.914T>C (hom) p.(Leu305Ser) 
56 7 0.81 0.78 0.96 22 30 c.55dup (hom) p.(Val19Glyfs*30) 
3 1 1.61 1.54 0.96 12* 0* c.1106G>A (hom) p.(Arg369His) 
55 n.r. 0.77 0.74 0.96 145 156 c.2179C>T (hom) p.(Arg727*) 
115 120 3.39 3.23 0.95 34 23 c.729_730insTT (hom) p.(Asp244Leufs*39) 
97 330 0.66 0.63 0.95 6 1 c.1207C>T c.1889G>A 
p.(Arg403*) 
p.(Gly630Glu) 
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6 3 0.32 0.29 0.95 77* 4* c.410C>T c.655A>T 
p.(Ala137Val) 
p.(Asn219Tyr) 
72 n.r. 0.91 0.85 0.94 6* 12* c.1420C>T (hom) p.(Arg474*) 
40 1 0.24 0.22 0.92 34 24 c.1747_1808del (hom) 
(c.1808G>A) 
p.(Val583Glyfs*3) (p.(Arg603Lys)) 
44 3 0.16 0.15 0.92 0 0 c.88C>T (hom) p.(Gln30*) 
148.1 n.r. 0.66 0.61 0.92 16 102 c.1207C>T (hom) p.(Arg403*) 
82 n.r. 1.00 0.91 0.92 7* 14* c.622del c.2053_2055dup 
p.(Val208Tyrfs*15) 
p.(Leu685dup) 
28 5 0.66 0.60 0.91 8* 0* c.1843C>A (hom) p.(Pro615Thr) 
85 4 0.60 0.55 0.91 16 9 c.689C>G (hom) p.(Thr230Arg) 
53 n.r. 0.76 0.69 0.91 94 64 c.1164T>A (hom) p.(Asn388Lys) 
81.1 n.r. 1.61 1.45 0.90 1* 65* c.2179C>T (hom) p.(Arg727*) 
57 30 0.58 0.50 0.87 39 61 c.851G>A c.982C>T 
p.(Gly284Glu) 
p.(Leu328Phe) 
98 n.r. 0.40 0.33 0.83 42 29 c.1531C>T (hom) p.(Arg511*) 
59 4 0.71 0.59 0.83 124 117 c.1874A>T (hom) p.(Asp625Val) 
119 3 0.41 0.34 0.83 87 83 c.613_615del c.1420C>T 
p.(Glu205del) 
p.(Arg474*) 
95 8 0.76 0.62 0.81 30* 25* c.607G>A (hom) p.(Gly203Arg) 
93 570 1.82 1.46 0.81 12* 23* c.1084-10A>G c.1333-24_1333-13del 
p.(Gln361_Asn362insIlePhe*) 
p.(Lys444_Leu445insPheSer-
Phe*) 
151 n.r. 1.23 0.98 0.80   c.753+2T>A 
c.1084-2A>G 
splice site 
splice site 
147 2 0.67 0.52 0.78   c.1106G>A (hom) p.(Arg369His) 
33 120 1.13 0.86 0.76 85* 25* c.655A>T c.1889G>A 
p.(Asn219Tyr) 
p.(Gly630Glu) 
94 90 0.33 0.24 0.72 16* 12* 
c.607G>A 
c.1105C>T 
p.(Gly203Arg) 
p.(Arg369Cys) 
24 180 0.13 0.09 0.68 16* 13* c.655A>T (hom) p.(Asn219Tyr) 
20 n.r. 0.25 0.12 0.50 37* 67* c.862T>C (hom) p.(Ser288Pro) 
104 14 0.31 0.12 0.40 27* 18* c.2078del (hom) p.(Gly693Aspfs*12) 
62 n.r.    48 63 c.692dup (hom) p.(Tyr231*) 
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78 n.r.      c.1843C>A (hom) p.(Pro615Thr) 
79 n.r.      c.1105C>T 
c.1207C>T 
p.(Arg369Cys) 
p.(Arg403*) 
81.2 n.r.      c.2179C>T (hom) p.(Arg727*) 
105 n.r.      c.643G>A c.2179C>T 
p.(Gly215Ser) 
p.(Arg727*) 
106 n.r.      c.655A>T c.1106G>A 
p.(Asn219Tyr) 
p.(Arg369His) 
107 n.r.      
c.1073T>C 
c.1844C>T 
p.(Leu358Pro) 
p.(Pro615Leu) 
110 n.r.      c.1844C>T (hom) p.(Pro615Leu) 
111 n.r.      c.572C>A c.1207C>T 
p.Ala191Glu) 
p.(Arg403*) 
114 n.r.      c.655A>T (hom) p.(Asn219Tyr) 
120.1 3      c.129G>A (hom) p.(Trp43*) 
120.2 n.r.      c.129G>A (hom) p.(Trp43*) 
127 360      c.655A>T (hom) p.(Asn219Tyr) 
134 n.r.      c.643G>A c.2179C>T 
p.(Gly215Ser) 
p.(Arg727*) 
148.2 n.r.      c.1207C>T (hom) p.(Arg403*) 
156 n.r.      c.1106G>A (hom) p.(Arg369His) 
Patients with undefined mut subclass in this study a 
109 n.r.      c.655A>T c.2194_2197delinsTGGAA 
p.(Asn219Tyr) 
p.(Ala732Trpfs*6) 
112 n.r.      c.1844C>T c.1853T>C 
p.(Pro615Leu) 
p.(Leu618Pro) 
118 n.r.      c.415G>A c.572C>A 
p.(Asp139Asn) 
p.(Ala191Glu) 
124 2      c.467A>T (hom) p.(Asp156Val) 
135 n.r.      c.1975C>T (hom) p.(Gln659*) 
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Table Footnotes: 
a Patients are listed according to decreasing PI ratio, separated into the mut subclasses as follows: 
Patients were assigned to the mut- class when the PI assay showed a ratio of >1.5 and to the mut0 
class when the ratio was ≤1.5. Five patients had an undefined mut subclass. Patient ID numbers are 
not incremental. If there are siblings, the index patient is indicated by the suffix .1. Patients 1-35 cor-
respond to (Lempp, et al., 2007), where patient 15.1. is 15 and 15.2 is 15.1. 
b Some patients were detected during newborn screening (NBS) without being symptomatic. “n. r.” 
means the age of onset was not reported. 
c Results from PI assay are given as absolute values and ratio of incorporation of 14C-propionate in 
patient fibroblasts cultured in supplemented (1 or 10 mg OHCbl (+OHCbl)) and un-supplemented 
medium (-OHCbl). Numbers represent means of duplicate values from 1-4 replicate experiments. 
Control values (mean ±SD from n = 110 experiments) in wild-type fibroblasts from healthy controls 
are: -OHCbl, 9.25 ±3.43; +OHCbl, 10.90 ±4.19; ratio, 1.19 ±0.17. For patients 5, 7, 19, 20, 31, 34 and 35 
at least one experiment has the control values (mean ±SD from n = 32 experiments): -OHCbl, 3.54 
±1.71; +OHCbl, 3.64 ±1.80; ratio, 1.03 ±0.09. 
d Methylmalonyl-CoA mutase activity was assayed with (+AdoCbl) and without AdoCbl (-AdoCbl) in 
crude homogenates of patient fibroblasts, which were grown for one passage in medium supple-
mented with 1 mg of OHCbl (except for patients no. 62 and 86, where no OHCbl was added to the 
medium). Numbers represent means of duplicate values from one or two experiments. Empty fields 
mean no data available. Most values were generated by the method described in (Forny, et al., 2014) 
and correspond to the following control values (mean ±SD from n = 49 experiments): -AdoCbl, 1058 
±381; +AdoCbl, 2569 ±782. Values which were generated by the method described in (Baumgartner, 
1983) are indicated by asterisks (*) and have the following controls (mean ±SD from n = 48 experi-
ments): -AdoCbl, 454 ±229; +AdoCbl, 1085 ±516. 
e According to cDNA sequence NM_000255.3. For heterozygous patients both mutations are given. 
Homozygous patients are indicated by “hom”. 
f According to amino acid sequence NP_000246.2. 
g Only one mutation identified. 
h This patient carries a known mut0 mutation in a homozygous state and was therefore classified as 
mut0. 
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3.12 SUPPLEMENTARY FIGURES 
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Supp. Figure S1. Sequence alignment of MUT from human to E. coli. Protein sequences of Homo sapiens (Homo_sapi-
ens, NP_000246.2), Pan troglodytes (Pan_troglodytes, XP_001146876.1), Bos taurus (Bos_taurus, NP_776364.2), Mus muscu-
lus (Mus_musculus, NP_032676.2), Gallus gallus (Gallus_gallus, XP_420055.1), Danio rerio (Danio_rerio, NP_001092696.1), 
Xenopus tropicalis (Xenopus_tropicalis, XP_002933609.2), Caenorhabditis elegans (C._elegans, NP_497786.2), Escherichia 
coli (E._coli, WP_000073223.1) were used to create a multiple sequence alignment created by multalin (Corpet, 1988) and 
visualized by usage of the ESPript 3.0 server (Robert and Gouet, 2014). Strictly conserved residues are marked in red shad-
ing, well conserved residues in red font. Missense mutations are marked by black asterisks. Secondary structure elements 
from the human MUT structure (PDB ID: 2XIQ) are indicated at the top of the alignment: α- and 310-helices (represented by 
the η symbol) are displayed as squiggles, β-strands are rendered as arrows, strict β-turns as TT letters. The relative surface 
accessibility of each residue is indicated by the color in the row “acc”: blue, accessible; cyan, intermediate; white, buried; 
red, accessibility is not predicted. Schematic protein domains are colored according to Fig. 1B: light blue, N-terminal do-
main; yellow, inter-domain linker; magenta, C-terminal domain.  
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Supp. Figure S2. MUT structure with highlighted region which corresponds to exon 3. A. Human MUT structure with 
coloring according to domains: light blue, N-terminal domain; yellow, inter-domain linker; magenta, C-terminal domain. 
Ligands are in sticks: dark blue, malonyl-CoA (substrate analogue); red, cobalamin; orange, adenosyl moiety. The green 
space fill region represents the segment of the polypeptide chain which corresponds to the area of exon 3. B. and C. A 
magnified view onto the malonyl-CoA ligand reveals that one side of the binding channel for the substrate is built by amino 
acids encoded by exon 3. 
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Supp. Figure S3. Structural mapping of mut- missense mutations which show high MUT protein levels in Western 
blot quantification. A. MUT structure in complex with malonyl-CoA (dark blue) in the N-terminal domain (light blue) and 
cobalamin (red) with adenosyl moiety (orange) in the C-terminal domain (magenta). Linker domain in yellow. Black balls 
represent residues of missense mutations, which were found to have high residual MUT levels in Fig. 3 and are discussed 
in the section “Biological Significance”. From left to right (on residue p.Asp625 two mutations were found): p.Val633, 
p.Gly630, p.Leu674, p.Asp625, p.Gln624. B. Magnified region of the five residues. The parts of the protein structure, which 
block the view onto the area of interest, are clipped off. 
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4 CHAPTER II: MOLECULAR CHARACTERIZATION OF MISSENSE 
MUTATIONS IN MUT 
This section represents an article which was published in 2014 during the PhD project (Forny, et al., 
2014). Citations in this chapter correlate to the bibliography section at the end of the thesis. Figure 
and table numbering is only applicable to this section of the thesis. 
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4.1 ABSTRACT 
Methylmalonyl-CoA mutase (MUT) is an essential enzyme in propionate catabolism that requires 
adenosylcobalamin as cofactor. Almost 250 inherited mutations in the MUT gene are known to cause 
the devastating disorder methylmalonic aciduria; however, the mechanism of dysfunction of these 
mutations, more than half of which are missense changes, has not been thoroughly investigated. 
Here, we examined 23 patient missense mutations covering a spectrum of exonic/structural regions, 
clinical phenotypes and ethnic populations in order to determine their influence on protein stability, 
using two recombinant expression systems and a thermostability assay; and enzymatic function, by 
measuring MUT activity and affinity for its cofactor and substrate. Our data stratify MUT missense 
mutations into categories of biochemical defects, including: (i) reduced protein level due to misfold-
ing, (ii) increased thermolability, (iii) impaired enzyme activity, and (iv) reduced cofactor response in 
substrate turnover. We further demonstrate the stabilization of wild-type and thermolabile mutants 
by chemical chaperones in vitro and in bacterial cells. This in-depth mutation study illustrates the 
tools available for MUT enzyme characterization, guides future categorization of further missense 
mutations and supports the development of alternative, chaperone-based therapy for patients not 
responding to current treatment. 
4.2 KEY WORDS 
inborn errors of metabolism, methylmalonic aciduria, methylmalonyl-CoA mutase (MUT), cobalamin, 
missense mutations, thermolability 
4.3 INTRODUCTION 
Mitochondrial methylmalonyl-CoA mutase (MUT, EC 5.4.99.2) catalyzes the reversible isomerisation 
of L-methylmalonyl-CoA to succinyl-CoA, requiring vitamin B12 (cobalamin) in the form of adeno-
sylcobalamin (AdoCbl) as cofactor. In humans, this reaction represents an important step in propio-
nate catabolism, funnelling metabolites from the breakdown of amino acids (valine, isoleucine, me-
thionine and threonine), odd-chain fatty acids, and the side chain of cholesterol into the tricarboxylic 
acid cycle (TCA cycle). The MUT enzyme is highly conserved from bacteria to human, and is well 
studied at the enzymatic (Banerjee and Ragsdale, 2003; Fenton, et al., 1982) and structural (Froese, 
et al., 2010b; Mancia, et al., 1996) level. The importance of the MUT-catalyzed reaction is further un-
derlined by the metabolic disorder methylmalonic aciduria (MMAuria) which is caused by a genetic 
defect in the MUT enzyme itself (MIM# 251000, MMA mut type), or in one of several proteins (MMAA, 
MMAB, MMADHC,) involved in the uptake, modification and delivery of AdoCbl to the MUT enzyme 
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for its activity (MMA cblA type, MIM# 251100; MMA cblB type, MIM# 251110; MMA cblD-variant 2 
MIM# 277410) (Fowler, et al., 2008). 
The human MUT gene (OMIM: 609058; chromosome location 6p12-21.2) (Ledley, et al., 1988a; Ledley, 
et al., 1988b) is the site of almost 250 deleterious mutations reported to cause MMAuria (Froese and 
Gravel, 2010) (human gene mutation database, HMGD Professional version as of December 2013, 
hgmd.org). Patient cell lines can be assigned to the mut type MMAuria by complementation analysis 
of fibroblast heterokaryons (Gravel, et al., 1975; Willard, et al., 1978a). Further biochemical character-
ization, applying MUT activity assay and propionate fixation, allows mut classification into two sub-
types. Mutants with residual mutase activity in cell homogenates under saturating concentrations of 
AdoCbl, and whose ability to incorporate [1-14C]propionate into acid precipitable material in intact 
skin fibroblasts is responsive to supplementation of the culture medium with hydroxocobalamin, are 
designated mut-; mutants with no residual MUT activity and no response of propionate incorporation 
to hydroxocobalamin, are designated mut0 (Willard and Rosenberg, 1980). mut0 patients often pre-
sent in the newborn period with ketoacidosis, lethargy, repeated vomiting, coma or even death, and 
suffer from severe long-term complications such as renal failure and neurological impairments. On 
the contrary, mut- patients have a lower occurrence of mortality, morbidity and long-term complica-
tions (Horster, et al., 2007). Dietary interventions, carnitine supplementation and symptom manage-
ment are the mainstay of current treatment, although pharmacological doses of hydroxocobalamin 
are given to some MUT deficient patients (Horster, et al., 2007). While some mut- patients seem to 
respond to this treatment, others – including most if not all mut0 patients – do not (Horster, et al., 
2007). Alternative therapeutic approaches should therefore be investigated, evaluating therapeutic 
potential on the basis of a systematic characterization of individual mut0 and mut- alleles. Neverthe-
less, the sheer quantity of mutations in the MUT gene – most of which are private and rare 
(Acquaviva, et al., 2005; Fowler, et al., 2008; Lempp, et al., 2007; Worgan, et al., 2006) – means that 
such a large-scale analysis has not been forthcoming, with previous reports of in vitro MUT charac-
terization on only a handful of mutations, e.g. (Crane and Ledley, 1994; Janata, et al., 1997). 
Common to many other metabolic disorders (e.g. phenylketonuria, PKU (Mitchell, et al., 2011); orni-
thine transcarbamylase deficiency (Shchelochkov, et al., 2009)), the largest proportion of MUT muta-
tions are missense changes (131 out of 243, 54%; hgmd.org) whose effects on the protein are difficult 
to predict a priori (Froese and Gravel, 2010; Yue, et al., 2014). MUT is therefore an attractive target to 
interrogate the genotype-specific biochemical penalties for missense mutations at the protein level, 
an approach adopted for other metabolic enzymes (Pekkala, et al., 2010; Pey, et al., 2007; Shi, et al., 
2012). With this in mind, we have chosen 7 mut0 and 16 mut- missense mutations for an in-depth 
analysis. Based on recombinant expression (E. coli and human fibroblasts), thermal denaturation and 
enzyme assays, we catalogue each mutation as defective in stability, activity or both, and further 
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define subcategories in each. To the best of our knowledge, this work represents the first large scale 
biochemical categorization of MUT mutations and sets the stage for exploring the potential of small 
molecule therapeutics, an approach that is gaining wide interest to augment mutant enzyme activity 
(Gomes, 2012). 
4.4 MATERIALS & METHODS 
4.4.1 Cloning 
For expression in E. coli we used a previously described construct of MUT (called hMUT in (Froese, et 
al., 2010b)). For expression in fibroblasts, the MUT cDNA sequence was purchased from Gene-
Copoeia (Construct ID: E0205; RefSeq NM_000255.3) and subsequently subcloned into pTracer-
CMV2 (Invitrogen) via EcoRV and NotI restriction sites by PCR, using the following primers: ACATA-
GATATCCACGCTGTTTTGA (EcoRV site underlined) and AGTGGTTGATCGCGTGCATG (NotI site is part 
of the original GeneCopoeia plasmid), respectively. All single-site missense mutations were gener-
ated using the QuikChange site-directed mutagenesis kit (Stratagene) following manufacturer’s in-
structions, using forward and reverse primers (Microsynth) described in Supp. Table S2, and con-
firmed by Sanger sequencing. 
4.4.2 Bacterial expression and purification 
MUT was expressed in E. coli, and purified as previously described (Froese, et al., 2010b) with minor 
modifications. For small scale purification, cells were grown in a total of 50 ml, induced with 0.1 mM 
IPTG at 18°C overnight, harvested by centrifugation at 4000 xg, lysed by sonication and purified by 
affinity (Ni-NTA; Qiagen) chromatography. Where applicable, chemical chaperones were added con-
currently with the IPTG. Samples from total cell lysate (1 μl of 2 ml total) (‘L’), including all cellular 
proteins both soluble and insoluble, and affinity eluants (15 μl of 250 μl total) (‘E’), including those 
soluble proteins eluted from the nickel affinity column, were analyzed by SDS-PAGE and stained with 
Coomassie blue (Expedion). For large scale purification, cells were grown in a total of 6 l, harvested 
by centrifugation at 5000 xg, lysed with an Emulsiflex C3 homogenizer, and purified by affinity (Ni-
NTA, Qiagen), size-exclusion (Superdex 200; GE Healthcare), cleavage with His-tagged TEV protease 
and reverse-affinity chromatography (Ni-NTA). Purification buffers are detailed in the webpage 
http://www.thesgc.org/structures/details?pdbid=2XIQ. 
4.4.3 Transfection and expression in fibroblasts 
Fibroblasts of a mut0 patient homozygous for the mutation p.Q30* were immortalized by transfec-
tion with pRNS1 (Litzkas, et al., 1984) using electroporation (Baumgartner, et al., 2001) and grown in 
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Dulbecco's Modified Eagle Medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 
antibiotics (PAA), as previously described (Suormala, et al., 2004). pTracer-MUT wt and mutant con-
structs were transiently transfected into the immortalized fibroblasts by electroporation with a trans-
fection efficiency of 6-24%, as determined by FACS measuring the proportion of cells co-expressing 
the green fluorescent protein from the pTracer construct. This is comparable to previous observa-
tions (Coelho, et al., 2008). Cells were harvested 48 hours after electroporation by trypsinization, 
washed twice with phosphate buffered saline and stored frozen at -80°C until assayed for MUT ac-
tivity or used for Western blotting. 
4.4.4 Western blot 
Fibroblast lysates were obtained by sonication (details under MUT activity assay). Crude cell lysates 
(25 μg of protein per sample) were mixed with 2x Laemmli Sample Buffer (Bio-Rad) and heated to 
96°C for 6 minutes. Proteins were separated by 10% SDS-PAGE, transferred to a Protran BA85 nitro-
cellulose membrane (Whatman), blocked at room temperature for 1 h with Buffer A (5% skimmed 
milk, 1.2% w/v Tris-Base, 9% w/v NaCl, 0.2% Tween 20, pH 7.6), incubated with polyclonal mouse 
anti-human MUT (Abcam) (1:1000 in Buffer A), or â-actin (Sigma-Aldrich) (1:4000 in Buffer A) over-
night, detected by incubation with goat anti-mouse antibody coupled to horseradish peroxidase 
(Santa Cruz) (1:5000 in Buffer A) for one hour, and visualized with ECL Western Blotting Detection 
Reagents (GE Healthcare Life Sciences) on a Gel Logic 6000 Pro (Carestream). 
4.4.5 MUT activity assay 
MUT activity was assayed in crude cell lysates by measuring the production of [14C]succinate from 
[14C]methylmalonyl-CoA by a modification of earlier described methods (Baumgartner, 1983; Causey 
and Bartlett, 1984). All operations were performed in a dark room illuminated with a 15W red Safe-
light bulb (Dr. Fischer). Cell lysates were prepared by pipetting 5 mM potassium phosphate buffer 
(pH 7.4) on frozen cells and disrupting the pellet by sonicating twice for 15 seconds using the micro-
probe of an XL-2000 sonicator (Microson) at amplitude 1.5. Specific activities were measured in 50 μl 
reaction mixture containing 0.1 M potassium phosphate buffer (pH 7.4), 1 mM DL-2-[methyl-
14C]methylmalonyl-CoA (ARC; specific activity 7.03 MBq/mmol in assay) and 50 – 100 μg cell proteins 
without (holo-MUT activity) and with (total MUT activity) 50 μM AdoCbl. To estimate KM for AdoCbl, 
its concentration was varied between 0.0025 μM and 50 μM. To estimate KM for methylmalonyl-CoA, 
its concentration was varied between 0.01 and 1.0 mM in the presence of 50 μM AdoCbl. Reactions 
were initiated by addition of cell lysate, allowed to proceed for 30 min at 37°C and terminated by 
addition of 6 μl 5N KOH (Merck). Samples were re-incubated for 15 min at 37°C to hydrolyze CoA 
derivatives, neutralized by adding 5 μl 5N perchloric acid (Merck) and spiked with 5 μl of 1% solution 
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(w/v) of succinic acid (Merck) in order to visualize succinate during high performance liquid chroma-
tography (HPLC) separation. Samples were centrifuged to remove precipitate, 50 μl of the superna-
tant were injected into an Amimex HPX-87H Ion Exclusion column (300 mm x 7.8 mm. H-form, 9 μm, 
Biorad) and [14C]succinate was separated from [14C]methylmalonate by elution with 0.5 mM H2SO4 at 
30°C using a flow rate of 0.4 ml/min. Succinate (retention time 17 min) and methylmalonate (11 min) 
peaks were visualized at 210 nm using an UV detector, 0.2 ml fractions covering the succinate peak 
were collected and [14C]succinate was quantitated in a Tri-Carb C1 900TR scintillation spectrometer 
(Packard) with Optiphase Higsafe 2 counting cocktail (PerkinElmer). Protein in cell lysates was deter-
mined by the Lowry method. MUT activity was expressed as nmol succinate formed per min and mg 
protein. KM values for AdoCbl were determined using Eadie-Hofstee plot. 
4.4.6 Differential scanning fluorimetry 
Purified homodimeric MUT was assayed for shifts in melting temperature (Tm), which is the midpoint 
transition from a folded to an unfolded state, as previously described (Froese, et al., 2010a; Niesen, 
et al., 2007). Each mutant and wt protein was assayed in the apo state, or with pre-incubation of 50 
μM AdoCbl (Sigma-Aldrich), or a combination of 50 μM AdoCbl and 500 μM malonyl-CoA (MCoA) 
(Sigma-Aldrich). MCoA was used as a substrate analogue because it has been confirmed to bind to 
the substrate pocket (PDB: 2XIQ) (Froese, et al., 2010b). For chemical osmolyte screening, various 
concentrations of betaine and TMAO (up to 1200 mM) and glyercol (up to 40%) were pre-incubated 
with protein before analysis. 
4.5 RESULTS 
4.5.1 Rationale for mutation selection 
From the repertoire of known MUT missense mutations, we selected 23 for this study (Table 1) with 
the rationale that they (i) cover both phenotypically severe mut0 (n=7) and milder mut- (n=16) sub-
types, (ii) are widely distributed across the gene (exons 2-13), and (iii) include representative muta-
tions prevalent in different ethnic populations, e.g. African Americans (p.G717V, c.2150G>T) 
(Worgan, et al., 2006), Caucasians (p.N219Y, c.655A>T; p.R369H, c. 1106G>A; p.R694W, c.2080C>T) 
(Acquaviva, et al., 2005; Lempp, et al., 2007), and Turkish Asians (p.P615T, c.1843C>A) (Dundar, et al., 
2012). These 23 mutations, reported in both homozygous and heterozygous states, are found in 
highly-conserved residues, and their amino acid substitutions are predicted to be largely untolerated 
according to SIFT prediction (Table 1B). All selected mutations have been reported (Table 1A, refer-
ences therein) with the exception of p.L736F, c.2206C>T, a novel mutation that exists in a compound 
heterozygous state with the splice site mutation c.753+2T>A (Worgan, et al., 2006) in an MMAuria 
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patient diagnosed in our lab. Propionate fixation and MUT activity assays on cells from this patient 
are consistent with the mut- subtype. 
We mapped the missense mutations onto the human MUT crystal structure (Froese, et al., 2010b) to 
understand their local structural environments (Supp. Figure S1; an interactive version is available at 
www.thesgc.org/MUT). These mutations are located across the entire polypeptide, including the N-
terminal substrate binding domain (n=13), C-terminal cofactor binding domain (n=9), and inter-do-
main linker (n=1) (Figure 1A). A number of them contribute to the binding regions of the substrate 
(e.g. p.Y100C) and cofactor (e.g. p.M700K) (Figure 1B), while four residues are buried at, or located 
near, the MUT dimer interface (p.P86L, p.Y316C, p.R369H, p.G426R) (Table 1B, Figure 1B). Compatible 
with the large proportion of private mutations, no hot spot regions are found for the above, or other 
known MUT mutations. 
 
 
Figure 1. Structural mapping of MUT missense mutations. A. The human MUT structure in complex with MCoA and AdoCbl 
(PDB code 2XIQ) is coloured according to domains, i.e. N-terminal substrate binding domain cyan, C-terminal cofactor bind-
ing domain magenta, inter-domain linker yellow. Mutations in this study are shown as red circles (mut0) or blue circles (mut-
). Ligands are in stick representation, coloured white for MCoA and black for AdoCbl. B. Domain organization of MUT high-
lighting locations of the studied mutations, dimerization interface, and binding regions for MCoA and AdoCbl in the poly-
peptide. An interactive version of this structural representation is available online at www.thesgc.org/MUT. 
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4.5.2 Effects on protein integrity in two expression systems 
The diverse structural locations of the 23 missense mutations, many of which are distant from the 
catalytic centre, suggest some mutations may impact on non-catalytic properties such as the stabil-
ity of translated polypeptides. To investigate this, we reconstructed these alleles in two recombinant 
expression systems, E. coli and human fibroblasts (Figure 2A, B), both of which have been used to 
produce MUT previously (Froese, et al., 2010b; Janata, et al., 1997; Wilkemeyer, et al., 1991). For E. coli 
expression, the mutant proteins (n=21, excluding p.N219Y and p.Y316C which we were unable to 
clone) were assessed on their (i) expression level relative to wild-type (wt) protein, as judged by pro-
tein amount in total cell lysate, and (ii) solubility, as judged by protein amount after affinity purifica-
tion. We first tested several post-induction growth temperatures (37/26/18/12oC) for wt MUT, and 
observed the highest solubility level with 18oC overnight growth (data not shown). While all 21 mu-
tants are expressed in E. coli at this temperature (Figure 2A, lanes ‘L’), a number of them have poor 
solubility compared to wt, resulting in no (p.A191E and p.L328F) or reduced (p.S344F, p.F573S, 
p.P615T/L) protein recovery from the affinity eluant (lanes ‘E’). This observation, unchanged by a 
lower post-induction temperature (12oC; data not shown), indicates insoluble mutant protein ex-
pression likely due to a global folding defect. In addition to E. coli, we expressed MUT mutants using 
an immortalized MUT-deficient patient fibroblast cell-line. Western blot (Figure 2B) of the expressed 
mutants detected very low protein levels for p.P615T/L, which agrees with bacterial expression. 
However, the p.A191E and p.L328F proteins, insoluble in E. coli, have near-wt expression levels in 
human fibroblasts, suggesting that additional factors exclusive to eukaryotes may assist in the 
proper folding for certain mutant proteins. 
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Figure 2. MUT missense mutations confer different effects on stability and activity. A. Coomassie staining of SDS-PAGE 
following small-scale bacterial expression and affinity purification. For each mutation lanes for total cell lysate (‘L’, left) and 
eluant after purification (‘E’, right) are shown. B. Western blot following expression of each mutation in a MUT deficient 
patient cell line. Vector, empty vector. C. Total MUT activity (assay with 50 μM AdoCbl) of each mutation expressed as 
percent of mean wt activity. D. KM for AdoCbl, expressed as times the mean wt value. E. ΔTm of apo mutant compared to 
apo-wt protein (see Figure 3). ‘–‘, not applicable. 
 
4.5.3 Effects on enzymatic function 
MUT catalyzes the isomerization of methylmalonyl-CoA to succinyl-CoA via reactive radical interme-
diates generated from a homolytic bond cleavage of AdoCbl (Banerjee and Ragsdale, 2003). To in-
vestigate if and how each mutation affects MUT enzymatic function, we determined catalytic activity 
PhD thesis  Patrick Forny 
64 
and ligand affinity for wt and mutant MUT expressed in MUT-deficient human fibroblasts. Under sat-
urating AdoCbl levels (50 μM), wt MUT exhibited a mean substrate turnover of 20.2 nmol/min/mg 
protein (Supp. Table S1). All 23 mutants showed decreased enzyme activity, ranging from 0.2-85 % 
of wt values (Figure 2C; Supp. Table S1). They can be broadly described as having high (> 50% of wt, 
n=5), intermediate (5-50% of wt, n=6) and low (< 5% of wt, n=12) levels of residual enzyme activity 
(Supp. Figure S2). All mut0 mutants studied were near the assay detection limit (< 2% of wt), con-
sistent with their reported clinical severity, while the mut- mutants (2.7-85% of wt) are distributed 
into all three levels of activity. The more substantial residual activity of mut- mutations allowed us to 
further determine their KM values for AdoCbl and methylmalonyl-CoA. wt MUT had a mean KM for 
AdoCbl of 4.7 nM (Supp. Table S1), similar to published values (Morrow, et al., 1978). All characterized 
mutants exhibited higher KM values than wt, to varying degrees (Figure 2D). Seven proteins had a KM 
of > 200-times wt levels, of which four (p.Y231N, p.G426R, p.G648D and p.G717V) are at least three 
orders of magnitude higher, indicating a strong KM defect. On the contrary, five proteins had near-
wt KM (e.g. Y316C and p.F573S, < 5-times wt), suggesting their catalytic impairment is not primarily 
due to reduced cofactor affinity. No mutants showed large increases in KM for methylmalonyl-CoA 
(data not shown), suggesting substrate binding was not defective in these mutants, as has been 
shown previously (Willard and Rosenberg, 1980). 
4.5.4 Effects on protein thermolability  
To test whether the catalytic impairment of certain MUT mutants relates to changes in their struc-
tural integrity, we expressed and purified in large-scale those mutants that were sufficiently soluble 
in E. coli (Figure 2A, n=15). They had similar retention volumes in size exclusion chromatography as 
wt MUT (Froese, et al., 2010b), with no detection of higher-order aggregates (data not shown), indi-
cating a native-like homodimer devoid of global folding defects. To identify any subtle stability 
changes, we applied a differential scanning fluorimetry (DSF) assay (Vedadi, et al., 2006) to follow 
temperature induced protein unfolding in order to measure the melting temperature (Tm) of each 
purified protein. As proof of principle, we first interrogated the stability effect of physiological lig-
ands (cofactor AdoCbl, substrate analogue malonyl-CoA (MCoA)) on the Tm of wt MUT, with the ra-
tionale that binding of the cognate ligands should stabilize MUT thereby increasing its Tm. Consistent 
with this, wt MUT (at 1 μM) exhibits a Tm of 58.2°C in the apo form, which increases in a dose-depend-
ent manner upon addition of the native-like ligands (Supp. Figure S3A, B), reaching Tm values of 
60.8°C (ΔTm = 2.6°C) with AdoCbl (50 μM), and 73.7°C (ΔTm = 15.5°C) with both AdoCbl (50 μM) and 
MCoA (500 μM) (Figure 3 inset). The extent of these ‘Tm shifts’ corroborates previous structural ob-
servations (Froese, et al., 2010b), in that the smaller ΔTm by binding AdoCbl alone is consistent with 
a modest rearrangement in the MUT C-terminal domain (Supp. Figure S4A), while the larger ΔTm with 
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AdoCbl+MCoA is associated with a substantial conformational change in the N-terminal domain 
(Supp. Figure S4B). Notably, MCoA alone (500 μM) did not increase the Tm of MUT beyond apo levels 
(data not shown), suggesting an ordered binding mechanism of AdoCbl cofactor first, followed by 
substrate, in the ternary complex. 
 
 
Figure 3. Thermolability of MUT mutations. The change in Tm values (ΔTm, compared to apo wt) for each mutant MUT in 
the apo state, or following addition of AdoCbl alone or with AdoCbl and MCoA, are shown. Black, apo protein; red, with 50 
μM AdoCbl; blue, with 50 μM AdoCbl and 500 μM MCoA. Error bars depict SEM from at least 3 measurements. Inset. Rep-
resentative DSF melting curves of wt MUT in the apo form (black), with 50 μM AdoCbl (red) and with 50 μM AdoCbl and 
500 μM MCoA (blue). 
 
We subsequently measured the Tm values of purified mutant proteins in the apo, AdoCbl bound, and 
AdoCbl+MCoA bound states (Figure 3), to determine if they had a lower Tm than wt, an indicator of 
protein destabilization (Leandro, et al., 2011a). For clarity, the ΔTm of apo-mutants compared to apo-
wt is given in Figure 2E. Six out of 15 proteins exhibited near-wt Tm in their apo forms, indicating 
intact protein integrity. Of these, two (p.F573S, p.V633G) responded to AdoCbl+MCoA stabilization 
with similar Tm shifts as wt, while four (p.Y100C, p.N366S, p.R369H, p.T387I) did not, suggesting that 
the latter mutants lost the capacity for native ligand stabilization. In particular, p.T387I showed a 
concentration-dependent decrease of Tm when adding AdoCbl alone (Supp. Figure S3C). The other 
nine proteins, however, were more thermolabile than wt in their apo forms. While five (p.Q218H, 
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p.Y231N, p.G648D, p.R694W, p.M700K) had slightly lower Tm than wt (ΔTm range -2.7 to -1.3) and re-
sponded to AdoCbl+MCoA stabilization, four (p.P86L, p.G426R, p.R694L, p.G717V) were substantially 
more thermolabile than wt (maximum destabilization: p.P86L, ΔTm -8.7°C) and did not respond to 
ligand supplementation. 
4.5.5 Stabilization of MUT mutants by osmolytes 
The insolubility and thermolability of a number of MUT mutants, compared to wt, implicate protein 
destabilization as a biochemical defect and prompted us to investigate the potential for post-trans-
lational stabilization of mutant proteins by six different osmolytes using DSF and bacterial expres-
sion (Figure 4; Supp. Figure S5, S6). When applied in high-mM concentrations, these uncharged, low 
molecular weight compounds function as ‘chemical chaperones’ and have been shown to stabilize 
a number of disease-associated proteins prone to misfolding, an effect likely mediated by osmotic 
changes in the milieu (Majtan, et al., 2010; Nascimento, et al., 2008). The two most thermolabile MUT 
mutants in our study, p.P86L and p.G426R, showed Tm increases at high osmolyte concentrations 
(10% glycerol, 600 mM others), with the efficacy of stabilization dependent on the osmolyte used 
(Figure 4A, B). These osmolytes confer a non-saturating dose response, and the effect appears non-
selective, as wt and all mutant proteins tested demonstrate stabilization in their apo forms to similar 
degrees (Supp. Figure S5). To determine if osmolytes could also stabilize proteins co-translationally, 
we expressed several mutants with varying levels of solubility in E coli, and supplemented their 
growth (Supp. Figure S6). Compared to no supplement control, soluble protein yield was improved 
with glycerol (at 1% concentration: p.A191E and p.G426R; 5%: p.R694W), TMAO (100 mM: p.P615T 
and p.R694W), and to a lesser extent betaine (100mM: p.R694W). No improvement for p.L328F was 
seen, while wt protein was very soluble under all conditions, suggesting the rescue could be mutant 
specific. Together, our data demonstrate the amenability of small exogenous molecules to modulate 
MUT stability, and support the notion to develop target-specific ‘pharmacological chaperones’. 
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Figure 4. Stabilization of mutant MUT by osmolytes. Representative DSF melting curves for p.P86L (A) and p.G426R (B) 
mutants in the apo form (grey) and in the presence of osmolytes (colours) are shown along with MUT-wt (black). 
 
4.6 DISCUSSION 
Our study aimed to establish a genotype-phenotype correlation by characterizing the biochemistry 
associated with a set of MUT missense mutations. Earlier small scale studies have tested the activity 
and expression of MUT missense mutants, for example using the lower eukaryote S. cerevisiae (5 mu-
tations) (Crane and Ledley, 1994) and E. coli (4 mutations) (Janata, et al., 1997) as recombinant hosts. 
Our selected set of 23 mutants, five of which overlap with those previous studies (p.Y231N, p.R369H, 
p.G648D, p.R694W, p.G717V), constitutes to our knowledge the largest biochemical analysis of MUT 
mutations to date.  
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4.6.1 A catalogue of biochemical defects in MUT mutants 
Traditionally, MMAuria phenotypes are broadly classified into mut0 and mut- subtypes based on the 
response of a patient cell line to hydroxocobalamin in propionate incorporation (Lempp, et al., 2007). 
In order to understand the molecular mechanism(s) governing the mut0/mut- subtypes and cata-
logue the associated biochemical defects, we have further assessed MUT mutations based on stabil-
ity and catalytic properties as summarized in Table 1B. 
We evaluated mutants on two stability criteria, ‘folding’ and ‘thermolability’. ‘Folding’ defects refer to 
the aggregation or degradation of translated polypeptides, thereby reducing the steady state pro-
tein. These mutants displayed drastically reduced soluble protein yield, as exemplified by p.P615T/L. 
Four other mutants, two from each mut subtype (mut0: p.A191E, p.L328F; mut-: p.S344F, p.F573S), 
also fit this category, having reduced detectable protein in one of the two expression systems. A few 
mutants displayed only slightly decreased soluble E. coli expression, such as p.G717V and p.R694W, 
consistent with a previous report (Crane and Ledley, 1994), and were not included in the ‘folding’ 
category. ‘Thermolabile’ mutants had near-wt levels of recombinant expression and solubility, reflect-
ing near-native folding, but increased temperature sensitivity. Four mutations in this study fell into 
the ‘thermolabile’ category (p.P86L, p.G426R, p.R694L, p.G717V). 
Inspection of the MUT crystal structure shows that both ‘folding’ and ‘thermolabile’ mutants involve 
amino acid changes that (i) remove a conformationally-restricted proline residue (e.g. p.P86L, 
p.P615L/T); (ii) cause steric clashes with a bulky side-chain (e.g. p.L328F, p.S344F); or (iii) disrupt the 
natively charged/polar (e.g. p.R694L) or non-polar (e.g. p.A191E) environment. Furthermore, stability 
mutations are distributed across the entire polypeptide, indicating that all domains of the protein 
contribute to its intrinsic stability. 
In addition to stability mutants, we also identified direct kinetic impairment, which we termed ‘cat-
alytic’ and ‘KM’ mutants. ‘Catalytic’ mutants had low residual activity (< 5% of wt) despite detectable 
eukaryotic expression, and constituted the largest category of mutants (10 in this study, Table 1B). 
Of particular note, two ‘catalytic’ mutants, p.Q218H and p.A219E, involve structurally adjacent resi-
dues lining the substrate binding channel (Figure 1A; Supp. Figure S1d, e), where p.Q218 has been 
implicated in transition state stabilization (Loferer, et al., 2003). ‘KM’ mutants exhibited > 200-fold 
increased KM for AdoCbl compared to wt. Among the seven ‘KM’ mutants identified (Table 1B), only 
three (p.V633G, p.G648D and p.G717V) are buried within the C-terminal cobalamin binding domain 
(Figure 1A; Supp. Figure S1p, q, t). The other four are towards the N-terminal end: p.Y231N is situated 
at the inter-domain interface, within a loop that contacts the cobalamin corrin ring (Supp. Figure 
S1f); p.G426R is situated at the dimeric interface; and p.P86L and p.Y100C are located near the N-
terminal substrate binding channel, distant from any obvious involvement in cobalamin binding. 
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Further investigation is therefore warranted to understand how the KM effect of these mutations is 
mediated. 
It is of note that our classification scheme is not aimed at ‘pigeonholing’ mutant alleles into disparate, 
mutually exclusive categories; on the contrary, there is a high degree of interdependence between 
various stability and catalytic properties that together contribute to proper enzyme function. This is 
clearly exemplified with seven mutants fitting multiple criteria. Three of them had a significantly in-
creased KM but were also thermolabile (p.P86L, p.G426R, p.G717V), one was ‘thermolabile’ with a ‘cat-
alytic’ dysfunction (p.R694L), and three met the criteria of ‘folding’ and ‘catalytic’ defects (p.A191E, 
p.L328F, p.S344F). In addition, three mutations were termed ‘unclear’ (p.Y316C, p.T387I and p.L736F), 
since in our assays they lack definitive aberration in stability and enzyme kinetics, showed detectable 
protein by Western blot, intermediate enzyme activity and only moderate KM change. 
Future studies should aim to address the lesser characterized biochemical aspects of MUT and pos-
sible mutational effects, which are beyond the scope of this study. These include: (i) possible allostery 
between substrate and cofactor binding, which could potentially explain the Tm shift from 
MCoA+AdoCbl but not MCoA alone; (ii) potential formation of a supramolecular complex with the 
GTPase MMAA and adenosyltransferase MMAB (Froese and Gravel, 2010), required for the proper 
assembly of AdoCbl onto the MUT enzyme; and (iii) inter-allelic rescue of certain MUT disease alleles 
(e.g. p.R93H and p.G717V), (Worgan, et al., 2006). 
4.6.2 Clinical utility and implications of in vitro characterization 
A clinical application for our biochemical categorization of MUT genotypes is to help prognosticate 
the course of the disease. As expected the characterized mut0 mutants harbour ‘folding’ or ‘catalytic’ 
defects, resulting in very low or undetectable residual enzyme activities consistent with their pre-
dominance in neonatal onset patients with severe long-term complications. On the contrary, the 
characterized mut- mutants can present in any one, or combinations, of the four biochemical defects 
defined here. We postulate that mutations that do not interfere with protein stability and have less 
of a catalytic penalty would result in milder disease (e.g. p.P86L or p.G426R). Similar to other meta-
bolic diseases where an activity threshold of ~5-10% of wt is sufficient to ameliorate disease 
(Leinekugel, et al., 1992; Suzuki, 2013), mut- patients often show a later onset and less long-term 
complications, presumably due to the intermediate level of residual MUT activity. 
Whether any MUT deficient patient, including those of the mut- subtype, benefit from treatment with 
high doses of hydroxocobalamin is controversial. Early publications documented no response 
(Matsui, et al., 1983a; Wilcken, et al., 1977) and recent documentation of a possible response has 
relied on retrospective reviews (Horster, et al., 2007), while up to now, no controlled studies clearly 
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demonstrating response to hydroxocobalamin have been published. This picture is very different 
from PKU, where > 40% patients respond clinically to the cognate cofactor tetrahydropterin (BH4) of 
PAH (Zurfluh, et al., 2008). For mut type MMAuria, a clinical response to treatment is usually defined 
as reduced plasma or urinary concentration of methylmalonic acid. While difficult to measure be-
cause of its broad variation in body fluids (Fowler, et al., 2008; Horster, et al., 2007; Thompson and 
Chalmers, 1990), and clinical improvement even more difficult to determine reliably, lower 
methylmalonic acid levels are thought to reflect a higher residual enzyme activity protecting pa-
tients from severe long-term complications (e.g. chronic renal failure and neurological complica-
tions) (Cosson, et al., 2009; Horster, et al., 2007; Thompson and Chalmers, 1990). Therefore, careful 
evaluation of potential responsiveness to hydroxocobalamin treatment in all MMAuria patients is 
warranted, and a protocol has been proposed (Fowler, et al., 2008). Our thermal denaturation data 
offer a molecular explanation to a possible mechanism of cobalamin treatment by revealing AdoCbl-
induced stability improvement in certain mutants, in a ligand-specific manner similar to that of BH4 
on mutant PAH. Our results also predict that patients harbouring a ‘KM‘ defect (e.g. p.G648D) are more 
likely to benefit from cobalamin treatment, on the assumption that increased hydroxocobalamin 
plasma levels result in increased cellular AdoCbl production, since in our enzyme assay these mu-
tants exhibited high activity levels in the presence of high AdoCbl concentration. Nevertheless, hy-
droxocobalamin treatment may only benefit a small subset of patients with intermediate to high 
residual activity, if any, outlining an imperative to search for alternative therapies.  
4.6.3 Small molecule chaperones as alternative therapy? 
Our stability data add MUT to the growing list of metabolic enzymes in which mutation-induced 
protein destabilization is widely believed to play a causative role in disease pathogenesis (Gregersen, 
2006). In this model, mutant polypeptides tend to misfold, aggregate and be degraded by protein 
quality control in the cell. Chemical or pharmacologic approaches to partially correct misfolding, di-
vert the mutant polypeptide from degradation/aggregation pathways, and deliver it to the native 
subcellular destination may therefore allow a sufficient recovery of physiological function. This small 
molecule ‘chaperoning’ approach has been proposed as a viable treatment for a number of protein 
misfolding diseases (Gomes, 2012; Pey, et al., 2008). We provide proof of principle for MUT chaperone 
therapy by showing in vitro and in cell stabilization of several mutant proteins using chemical osmo-
lytes. These small organic solutes enhance protein stability via a non-selective, non-target-specific 
mode of preferential exclusion from the protein’s surface (Arakawa and Timasheff, 1985), although 
necessitating high effective concentrations (in mM range) that may be toxic to the cell - restricting 
their therapeutic utility.  
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Alternatively, target-specific pharmacological chaperones (PCs) could be developed for MUT which, 
unlike chemical chaperones, exert a direct stabilization effect by binding to the affected protein, po-
tentially allowing lower, clinically tolerable dosage concentrations. PCs have shown promise in sev-
eral lysosomal storage diseases, entering early-stage clinical trials for Gaucher, Tay-Sachs and Fabry 
diseases (Boyd, et al., 2013). In the case of MUT, we anticipate that an effective PC molecule need 
only stabilize the mutant protein ‘long enough’ to be delivered to mitochondria, where it can be 
further stabilized by its native ligands and protein interaction partners (MMAA, MMAB). Such a PC 
molecule may increase the residual enzyme activity of the mutant protein to a sufficient level that 
copes with the cellular demands of propionate catabolism. Therefore PC therapy is likely to rescue 
mild stability defects (i.e. alleles that give rise to destabilized protein and partial loss-of-function; e.g. 
p.G426R, p.M700K, p.G717V), either to be administered alone, or as a complement to the existing 
diet/hydroxocobalamin treatment. Other ‘catalytic’, ‘KM’ mutations, without stability defects, may 
also benefit from PCs that potentially increase residual activity, acting as ‘enzymatic activators’. Al-
together, the stage is set for a systematic, non-biased screening regime in the search for PC mole-
cules targeting MUT, and our established DSF assay may provide a good starting point for this 
screening. 
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4.8 TABLE 
To improve readability, the table is presented in landscape mode. 
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Table 1. Selection of mutations in the MUT gene and study results. 
A. pre-study data B. study results 
amino acid 
change 
nucleotide 
change& 
genomic 
location 
mut sub-
type 
references 
category of biochemical 
defect 
conservation 
score* 
buried surface 
at dimer# 
SIFT 
tolerance¶ 
p.P86L c.257C>T exon 2 mut- (Worgan, et al., 2006) thermolabile, KM 0.705 100% 0.00 
p.Y100C c.299A>G exon 2 mut- (Lempp, et al., 2007) KM 0.953 0% 0.00 
p.A191E c.572C>A exon 3 mut0 (Acquaviva, et al., 2005; Worgan, et al., 2006) folding, catalytic 0.936 0% 0.00 
p.Q218H c.654A>C exon 3 mut0 (Worgan, et al., 2006) catalytic 1.000 0% 0.00 
p.N219Y c.655A>T exon 3 mut0 (Acquaviva, et al., 2005; Lempp, et al., 
2007; Worgan, et al., 2006) 
catalytic 1.000 0% 0.00 
p.Y231N c.691T>A exon 3 mut- (Lempp, et al., 2007; Worgan, et al., 
2006) 
KM 0.951 0% 0.00 
p.Y316C c.947A>G exon 5 mut- (Worgan, et al., 2006) unclear 0.817 97% 0.00 
p.L328F c.982C>T exon 5 mut0 (Acquaviva, et al., 2005; Lempp, et al., 2007) folding, catalytic 0.901 0% 0.01 
p.S344F c.1031C>T exon 5 mut- (Lempp, et al., 2007) folding, catalytic 0.944 0% 0.00 
p.N366S c.1097A>G exon 6 mut- (Lempp, et al., 2007) catalytic 1.000 0% 0.00 
p.R369H c.1106G>A exon 6 mut0 (Lempp, et al., 2007; Worgan, et al., 2006) catalytic 1.000 99% 0.00 
p.T387I c.1160C>T exon 6 mut- (Dundar, et al., 2012) unclear 1.000 0% 0.00 
p.G426R c.1276G>A exon 6 mut- (Worgan, et al., 2006) thermolabile, KM 0.702 98% 0.00 
p.F573S c.1718T>C exon 10 mut- (Worgan, et al., 2006) folding 0.586 0% 0.03 
p.P615T c.1843C>A exon 11 mut0 (Acquaviva, et al., 2005; Lempp, et al., 2007) folding 0.862 0% 0.00 
p.P615L c.1844C>T exon 11 mut0 (Dundar, et al., 2012) folding 0.862 0% 0.00 
p.V633G c.1898T>G exon 11 mut- (Lempp, et al., 2007; Worgan, et al., 
2006) 
KM 0.794 0% 0.00 
p.G648D c.1943G>A exon 11 mut- (Ledley and Rosenblatt, 1997) KM 0.729 0% 0.00 
p.R694W c.2080C>T exon 12 mut- (Acquaviva, et al., 2005; Lempp, et al., 2007) catalytic 0.549 0% 0.00 
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p.R694L c.2081G>T exon 12 mut- (Lempp, et al., 2007) thermolabile, catalytic 0.549 0% 0.08 
p.M700K c.2099T>A exon 12 mut- (Acquaviva, et al., 2005; Lempp, et al., 
2007; Worgan, et al., 2006) 
catalytic 0.570 0% 0.00 
p.G717V c.2150G>T exon 13 mut- (Worgan, et al., 2006) thermolabile, KM 0.840 0% 0.00 
p.L736F c.2206C>T exon 13 mut- this studyç unclear 0.625 0% 0.02 
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Table Footnotes: 
& Nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference 
sequence (NM_000255.3), with the initiation codon as codon 1. 
* The conservation score (0 = unconserved; 1 = strictly conserved) was calculated using Scorecons 
server (http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/valdar/scorecons_server.pl, as of June 
2014) (Valdar, 2002), based on a multiple sequence alignment of 146 MUT homologues from differ-
ent phyla, generated from the CONSURF server (http://consurf.tau.ac.il/, as of June 2014) (Ashkenazy, 
et al., 2010). 
# Percentage of the amino acid total surface that is buried in the human MUT dimer, calculated from 
the PISA server v1.48 (http://www.ebi.ac.uk/pdbe/pisa/) (Krissinel and Henrick, 2007). 
¶ SIFT tolerance score (0-0.05 correspond to amino acid changes that likely affect protein function) 
was calculated using the SIFT server (http://sift.jcvi.org/, as of June 2014) (Kumar, et al., 2009). 
ç The new variant has been submitted to dbSNP (http://www.ncbi.nlm.nih.gov/SNP/). 
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4.9 SUPPLEMENTARY MATERIAL 
 
   
    
   
(f) Tyr231 (e) Asn219 
(d) Gln218 
(b) Tyr100 (a) Pro86 
(c) Ala191 
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(g) Tyr316 (h) Leu328 
(i) Ser344 (j) Asn366 
(k) Arg369 (l) Thr387 
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(m) Gly426 (n) Phe573 
(o) Pro615 (p) Val633 
(q) Gly648 (r) Arg694 
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Figure S1. Structural view of the amino acid environment for each mutation in this study. For each panel, the amino acid 
of interest is coloured cyan. Secondary structure elements are coloured cyan for the N-terminal substrate binding domain, 
yellow for inter-domain linker, and magenta for C-terminal cobalamin binding domain. For panels a, b, d, e, i and l, malo-
nyl-CoA is shown as sticks (yellow carbon atoms). For panels d, k, p, q, s and t, adenosylcobalamin is shown as sticks (black 
carbon atoms). For panels a, g, k and m, the neighboring subunit in the MUT dimer is shown as black cartoon. For panels 
c, h, m, o and q, amino acids surrounding the site of interest are also shown in spheres, to highlight the tight steric packing. 
Where applicable, hydrogen bonds are shown as dashed lines (distance in angstrom). An interactive version of this struc-
tural representation is available at www.thesgc.org/MUT.  
(s) Met700 (t) Gly717 
(u) Leu736 
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Figure S2. Enzyme activities of MUT wt and mutants in decreasing order. Each bar represents the mean of at least two 
replicate experiments (error bars depict SEM). Black bars indicate high (50-100% of wt, n=5), dotted bars intermediate (6-
49% of wt, n=5) and white bars low (0-5% of wt, n=13) levels of activity. 
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Figure S3. Ligand-dependent thermal denaturation of MUT. wt MUT is stabilized with increasing concentrations of AdoCbl 
(A) and malonyl-CoA (B). Mutant p.T387I is destabilized with increasing AdoCbl concentrations (C). 
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Figure S4. Substrate/cofactor-induced conformational changes in MUT. A. Superposition of MUT structures in the apo and 
AdoCbl-bound (holo) states shows modest rearrangement in the C-terminal domain (boxed) by the binding of AdoCbl 
alone. B. Superposition of MUT structures in the holo and ternary (AdoCbl and MCoA bound) states reveals substantial 
conformational changes in the N-terminal domain (boxed) by the additional binding of MCoA. Ligands are shown in sticks 
(AdoCbl, yellow carbon; MCoA, green carbon. (PDB codes: apo, 2XIQ; holo, 2XIJ; ternary, 2XIQ). 
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Figure S5. Concentrations-dependent thermal stabilization in wild-type and mutant MUT upon addition of chemical chap-
erones: A. proline, B. glycerol, C. betaine, D. sorbitol, E. TMAO, F. sucrose.  
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Figure S6. SDS-PAGE of test purification for wild-type, p.A191E, p.L328F, p.G426R, p.P615T and p.R694W after co-transla-
tional expression in the presence of chemical osmolytes. Glycerol (at 1% and 5%), TMAO and betaine at 100 mM were 
tested. For clarity, only the relevant gel section is shown. CC: chemical chaperone; TLC: total cell lysate; E: eluant after affin-
ity purification; marker on left: sizes in kDa.  
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Table S1. Methylmalonyl-CoA mutase (MUT) activities and KM values for the cofactor, adenosylcobalamin (AdoCbl). Trans-
fection with mut0 mutations resulted in severely deficient activities of both holo- and total MUT whereas mut- mutations 
showed a clear response to AdoCbl with increase of MUT activity to variable levels associated with mild to highly elevated 
KM for AdoCbl. 
  MUT activity, nmol/min/mg protein¶  
  holo-MUT (–AdoCbl) total MUT (+AdoCbl) KM for AdoCbl, nM 
amino 
acid 
change 
mut  
class single values mean single values mean % of wt single values mean times wt 
p.P86L mut- 0.03, 0.20 0.12 17.1, 14.8 16.0 79 3014 3014 636 
p.Y100C mut- 0.02, 0.05, 0.07 0.05 8.49, 11.9, 15.8 12.1 60 3648 3648 770 
p.A191E mut0 0.21 0.21 0.17 0.17 0.8 n.a.   
p.Q218H mut0 0.04, 0.07 0.06 0.07, 0.11 0.09 0.4 n.a.   
p.N219Y mut0 0.21 0.21 0.24 0.24 1.2 n.a.   
p.Y231N mut- 0.03, 0.24, 0.46 0.25 9.35, 12.6, 14.5 12.2 60 4759, 7280 6020 1270 
p.Y316C mut- 
0, 0.03, 0.05,  
0.17 
0.06 
3.38, 3.48, 3.70,  
3.99 
3.64 18 15.5, 24.1 19.8 4 
p.L328F mut0 0.03, 0.06 0.05 0.04, 0.06 0.05 0.2 n.a.   
p.S344F mut- 0, 0.01, 0.05,  
0.06 
0.03 
0.41, 0.54, 0.74,  
0.79 
0.62 3.1 27.9, 44.9 36.4 8 
p.N366S mut- 0, 0.01, 0.07 0.03 0.49, 0.56, 0.71 0.59 2.9 219 219 46 
p.R369H mut0 0.05, 0.16, 0.16 0.12 0.04, 0.28, 0.49 0.27 1.3 n.a.   
p.T387I mut- 0.01, 0.05, 0.37 0.14 1.06, 2.06, 2.39 1.84 9.1 66.6 66.6 14 
p.G426R mut- 0, 0.22 0.11 2.39, 2.79 2.59 13 9261 9261 1954 
p.F573S mut- 0, 0.01, 0.05,  
0.07 
0.03 
0.93, 1.02, 1.05,  
1.89 
1.22 6.0 6.21, 36.5 21.4 5 
p.P615T mut0 0.06, 0.24 0.15 0.10, 0.34 0.22 1.1 n.a.   
p.P615L mut0 0.07 0.07 0.09 0.09 0.4 n.a.   
p.V633G mut- 0, 0.02, 0.04 0.02 8.73, 9.99, 11.9 10.2 51 1016 1016 214 
p.G648D mut- 0, 0.14 0.07 15.0, 19.4 17.2 85 6503, 6720 6612 1395 
p.R694W mut- 0.01, 0.07, 0.19 0.09 0.40, 0.80, 0.99 0.73 3.6 45.9 45.9 10 
p.R694L mut- 0.01, 0.02, 0.06 0.03 0.26, 0.67, 0.70 0.54 2.7 84.1 84.1 18 
p.M700K mut- 0, 0.05, 0.05 0.03 0.60, 0.66, 0.75  0.67 3.3 543, 208 376 79 
p.G717V mut- 0.01, 0.03, 0.06 0.03 2.78, 4.69, 8.88 5.45 27 8484 8484 1790 
p.L736F mut- 0, 0.06, 0.20 0.08 1.54, 2.96, 3.47 2.66 13 221 221 47 
wt 
mean 
range 
n 
0.46 
0.01 - 2.94 
10 
 
 
20.2 
12.4 - 34.1 
10 
 
100 
 
 
4.74 
1.65-12.3 
7 
 
1 
 
 
vector 
only# 
mean 
range 
n 
0.04 
0 – 0.17 
7 
 
0.06 
0 – 0.25 
7 
     
 
‘n.a.’, not applicable. 
¶ Values are single values or the mean of duplicates from replicate experiments. 
# Negative control: MUT activities measured after transfection with empty pTracer vector. 
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Table S2. Primers used for site-directed mutagenesis of pTracer-MUT wt and pNIC-MUT wt constructs. 
amino acid change F/R primer sequence 5'-3' 
p.P86L Forward GACTTACCTGAAGAACTTCTAGGAGTGAAGCCA 
p.P86L Reverse TGTGAATGGCTTCACTCCTAGAAGTTCTTCAGG 
p.Y100C Forward GGACCATATCCTACCATGTGTACCTTTAGGCC 
p.Y100C Reverse GGTCCAGGGCCTAAAGGTACACATGGTAGGATA 
p.A191E Forward TCCATGACTATGAATGGAGAAGTTATTCCAGTT 
p.A191E Reverse TGCAAGAACTGGAATAACTTCTCCATTCATAGT 
p.Q218H Forward AAACTTACTGGTACCATCCACAATGATATACTA 
p.Q218H Reverse TTCCTTTAGTATATCATTGTGGATGGTACCAGT 
p.N219Y Forward CTTACTGGTACCATCCAATATGATATACTAAAG 
p.N219Y Reverse AAATTCCTTTAGTATATCATATTGGATGGTACC 
p.Y231N Forward TTTATGGTTCGAAATACAAACATTTTTCCTCCA 
p.Y231N Reverse TGGTTCTGGAGGAAAAATGTTTGTATTTCGAAC 
p.Y316C Forward GGAATTGGAATGAATTTCTGTATGGAAATAGCA 
p.Y316C Reverse CATCTTTGCTATTTCCATACAGAAATTCATTCC 
p.L328F Forward ATGAGAGCTGGTAGAAGATTCTGGGCTCACTTA 
p.L328F Reverse CTCTATTAAGTGAGCCCAGAATCTTCTACCAGC 
p.S344F Forward CAGCCTAAAAACTCAAAATTTCTTCTTCTAAGA 
p.S344F Reverse GTGTGCTCTTAGAAGAAGAAATTTTGAGTTTTT 
p.N366S Forward GAGCAGGATCCCTACAATAGTATTGTCCGTACT 
p.N366S Reverse TATTGCAGTACGGACAATACTATTGTAGGGATC 
p.R369H Forward CCCTACAATAATATTGTCCATACTGCAATAGAA 
p.R369H Reverse CATTGCTTCTATTGCAGTATGGACAATATTATT 
p.T387I Forward GGGACTCAGTCTTTGCACATAAATTCTTTTGAT 
p.T387I Reverse AGCTTCATCAAAAGAATTTATGTGCAAAGACTG 
p.G426R Forward AAAGTGGCTGATCCTTGGAGAGGTTCTTAC 
p.G426R Reverse CATCATGTAAGAACCTCTCCAAGGATCAGC 
p.F573S Forward GATGCCCTGAAAAAGGTATCTGGTGAACATAAA 
p.F573S Reverse ATTCGCTTTATGTTCACCAGATACCTTTTTCAG 
p.P615T Forward GAACGTGAAGGTCGCAGAACTCGTCTTCTTGTA 
p.P615T Reverse TTTTGCTACAAGAAGACGAGTTCTGCGACCTTC 
p.P615L Forward GAACGTGAAGGTCGCAGACTTCGTCTTCTTGTA 
p.P615L Reverse TTTTGCTACAAGAAGACGAAGTCTGCGACCTTC 
p.V633G Forward CATGACAGAGGAGCAAAAGGTATTGCTACAGGA 
p.V633G Reverse AGCAAATCCTGTAGCAATACCTTTTGCTCCTCT 
p.G648D Forward GGTTTTGATGTGGACATAGACCCTCTTTTCCAG 
p.G648D Reverse AGGAGTCTGGAAAAGAGGGTCTATGTCCACATC 
p.R694W Forward GAACTTAACTCCCTTGGATGGCCAGATATT 
p.R694W Reverse GACAAGAATATCTGGCCATCCAAGGGAGTT 
p.R694L Forward GAACTTAACTCCCTTGGACTGCCAGATATT 
p.R694L Reverse GACAAGAATATCTGGCAGTCCAAGGGAGTT 
p.M700K Forward CGGCCAGATATTCTTGTCAAGTGTGGAGGGGTG 
p.M700K Reverse TGGTATCACCCCTCCACACTTGACAAGAATATC 
p.G717V Forward ATTTCTGTTTGAAGTTGTTGTTTCCAATGT 
p.G717V Reverse CAAATACATTGGAAACAACAACTTCAAACA 
p.L736F Forward AAGGCTGCCGTTCAGGTGTTTGATGATATTGAG 
p.L736F Reverse ACACTTCTCAATATCATCAAACACCTGAACGGC 
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5 CHAPTER III: SCREENING AND VALIDATION OF PCS FOR MUT 
This section presents the results from a screening experiment which aimed at identifying stabilizing 
compounds for MUT, including subsequent validation experiments. The figure and table numbering 
is only applicable to this section of the thesis. 
5.1 BACKGROUND 
In a previous publication, also presented in this thesis (Forny, et al., 2014), we have described several 
‘folding’ mutants of MUT. These mutants were found to show very low or absent amounts of residual 
MUT protein on Western blotting. Therefore, they were assigned to the biochemical class of unstable 
mutant proteins. Since the active site is often unaffected in these mutants, resulting in a normal or 
sub-normal enzyme activity, they are candidates for a small molecule “chaperoning” approach in 
order to stabilize their native confirmation or to help the folding of a mutant polypeptide into a 
functional enzyme. The use of pharmacological chaperones (PCs) has been proposed as a treatment 
option for various protein misfolding diseases such as phenylketonuria (Nascimento, et al., 2008; Pey, 
et al., 2004; Pey, et al., 2008; Torreblanca, et al., 2012) or LSDs (Fan, 2008; Guce, et al., 2011; Lieberman, 
et al., 2007; Maegawa, et al., 2007; Suzuki, 2013). 
A relatively simple and widespread method for the screening of small molecule protein stabilizers is 
differential scanning fluorimetry (DSF), which originated from the field of protein crystallization. The 
big need of such molecules required for protein stabilization in order to increase the likelihood of 
the formation of ordered crystals, led to the development of this method (Niesen, et al., 2007). DSF 
utilizes a hydrophobic fluorescent dye which binds to non-polar residues of proteins. These residues 
are usually buried within the core of a soluble protein and are only exposed after induced degrada-
tion, e.g. by heat exposure. The increasing temperature leads to the binding of the dye to the hydro-
phobic residues of the protein and thus the dye becomes unquenched and starts emitting a fluores-
cent signal. The earlier a signal can be detected, the earlier the protein degrades upon heat exposure. 
During a screening for stabilizers employing the DSF method, a small molecule library is randomly 
tested for compounds which are able to increase the melting point of the tested protein. In the pre-
sented study, MUT-wt protein was used to perform this screening experiment. As a proof of concept, 
this protein was shown to be stabilized by the natural ligands AdoCbl and malonyl-CoA (substrate 
analogue) (Forny, et al., 2014). After the initial screening, these compounds were validated in cell 
culture experiments and also tested for their effect on mutant MUT proteins. With this study, we 
evaluate MUT for its amenability to PC screening. 
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5.2 INITIAL LIBRARY SCREENING 
The screening was performed in collaboration with the Department of Biomedicine at the University 
of Bergen in September 2012 at the lab of Prof. Aurora Martinez which has great expertise with the 
screening of small molecule stabilizers (Calvo, et al., 2010; Jorge-Finnigan, et al., 2013; Pey, et al., 
2008; Stevens, et al., 2010; Thony, et al., 2008). For this screening, MUT-wt protein was purified as 
previously described (Forny, et al., 2014). The screened library (MyriaScreen Diversity Library) con-
sisted of 10,000 compounds, which were all dissolved in dimethyl sulfoxide (DMSO). High-through-
put screening was performed by the DSF method and each compound was evaluated for its ability 
to enhance thermal stability of the tested MUT-wt protein in comparison to the baseline condition 
with DMSO only. 
Initially, 27 hit compounds were found to cause a positive shift of the thermal melting curve (3 ex-
amples in Fig. 1). First, false-positive compounds were excluded, e.g. by the pan assay interference 
compounds (PAINS) method (Dahlin, et al., 2015). Compounds can form aggregates or directly inter-
fere with the signalling molecule of the assay (Baell and Holloway, 2010). Medicinal chemistry anal-
ysis allowed further reduction of the compounds to finally 14 hits which had to undergo validation 
experiments by biophysical methods and cell culture assays. 
 
 
Figure 1. Three examples of compounds (F, D, C (see table 1) )which were able to induce a thermal stabilization of MUT-wt 
in DSF. Upper graphs in each panel: The blue curve represents the melting curve with added compound, the black curve is 
the control condition with DMSO only. Lower graphs in each panel: The curves represent the slope of the curves in the 
upper panels. 
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5.3 VERIFICATION OF HIT COMPOUNDS 
After the results from the high-throughput screening revealed positive hits, they were partly con-
firmed by surface plasmon resonance (SPR) as shown by the two examples in Fig. 2 and by repeated 
DSF experiments. Based on SPR and DSF results, the hits were further reduced to six compounds. For 
further verification of these compounds we performed experiments in cell culture in order to trans-
late the observed stabilizing effect in DSF to a biological environment. We over-expressed MUT-wt 
and MUT mutants in an E. coli and a human fibroblast cell expression system to investigate the effects 
of the selected compounds on cell viability, residual protein levels and enzyme activity. 
 
 
Figure 2. SPR results depict the binding curve of two exemplary compounds (A, D (see table 2)) which showed a clear 
binding behaviour at both concentrations tested. 
 
5.3.1 Selection of hit compounds 
Based on the first validation data, we compiled a list of compounds which were promising according 
to DSF and SPR. Because of a lack of overlapping results, we had to select the compounds mostly 
according to their individual behaviour in either DSF or SPR experiments (Table 1). 
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Compound number Screening by DSF Validation by SPR 
A  X 
B X  
C X  
D X X 
E  X 
F X  
Table 1. The list depicts the compounds which were selected for evaluation in cell culture experiments. “X” indicates con-
firmation of hit compound in either the DSF or SPR experiments. 
 
5.3.2 Evaluation of compounds in the E. coli expression system 
To investigate the influence of compounds on the stability of MUT-wt and mutant MUT proteins of 
human and mouse, we reconstructed these alleles in a recombinant E. coli expression system. The 
proteins were assessed on their: 
i. expression level relative to wt protein, as judged by protein amount in total cell lysate,  
ii. and solubility, as judged by protein amount after affinity purification (eluant fraction). An 
increase in protein amount in the eluant fraction was considered a stabilization effect of the 
compound. 
Final concentration of compounds was at 0.1 mM, final DMSO concentration was 0.5%. The respec-
tive compounds were added when protein expression was induced with IPTG before overnight cell 
growth as previously described (Forny, et al., 2014). 
While the expression levels varied to some degree between human and mouse wt, and mouse mu-
tant p.M698K respectively, the expression of each was stable (Fig. 3, left lanes) and unaffected by the 
growth condition (control, DMSO or compound supplemented). For human MUT-wt protein, no ob-
servable differences in protein stability could be identified regardless of the compound supple-
mented. This same protein had been used in a purified form for the library screening in the first place, 
where its thermostability was increased by all the tested compounds. The stabilization effect ob-
served in the DSF experiment therefore could not be replicated with this complementary method. 
Although some compounds seemed to have changed the stability of mouse Mut-wt and mouse Mut-
p.M698K, these effects might be unspecific, since DMSO increases the amount of mouse Mut-wt (Fig. 
3, right lanes). 
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Figure 3. The influence of compounds on the stability of mutase protein after overexpression in E. coli system. Bac-
terial overnight cell growth was performed under standard conditions (two first lanes, ‘no’) or supplemented with either 
DMSO or one of the compounds A-F (lanes adjacent to the control (‘no’) lane). For each condition, lanes for total cell lysate 
(left) and eluant after one-step nickel purification (right) are shown. Calculated molecular weight of mutase: 84 kDa; hs, 
homo sapiens; mm, mus musculus. 
 
Since unstable mutant proteins might be more sensitive to stability corrections mediated by a com-
pound, we hypothesized that an increase in protein level may be better seen in an experiment with 
mutated translated polypeptides. Based on previous results (Forny, et al., 2014) we have selected five 
low-solubility MUT mutants to evaluate the effects of the compounds on their stability. 
Other than compound A, which may have upregulated the soluble fraction of the human MUT mu-
tant p.R694W, none of the compounds showed a change in the level of soluble mutant protein (Fig. 
4). Compound E was not tested in this second experiment since it had shown cellular toxicity in fi-
broblast cell culture as further outlined in the next section (Table 2). 
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Figure 4. Compounds cannot rescue unstable MUT mutants overexpressed in E. coli system. E. coli bacteria, trans-
formed with different hsMUT constructs, were grown under standard conditions and supplemented with either DMSO or 
a compound (lysates, left lanes; eluants, right lanes; details see Fig. 3); hs, homo sapiens; mm, mus musculus; no, no supple-
ment added. 
 
5.3.3 Evaluation of compounds in human wild‐type fibroblasts 
We have used a fibroblast cell culture system (human wt cell line PJP-T) to test the influence of com-
pounds on MUT-wt stability and activity in a Eukaryotic cell environment. After cells were grown to 
80% confluence, the cell culture medium was supplemented with compounds to a final concentra-
tion of 0.1 mM (0.5% DMSO). As control conditions, the culture medium was supplemented with 
DMSO only and non-supplemented cell culture medium was used. Cells were incubated and moni-
tored by microscopy for 48 hours and then harvested. The cell pellet was re-suspended in 0.005 M K-
phosphate lysis buffer with subsequent sonication to obtain a cell lysate which was stored at -20°C 
and later exposed to heat for several hours or used for MUT activity assay. To find the ideal temper-
ature for heat exposure preliminary experiments were carried out. As a proof of principle, cells were 
incubated with Cbl to show the stabilization effect conferred by the endogenous ligand as previously 
shown in DSF. 
5.3.3.1 Heat treatment of cell lysates 
From DSF studies it is known that the Tm (temperature at the transition point of the melting curve) 
of MUT-wt is about 58°C (Forny, et al., 2014). Therefore, a range of temperatures from 42 to 56°C was 
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applied for up to six hours and MUT degradation was followed by Western blot analysis. At all tem-
peratures tested the MUT protein was degraded over time, although at different speeds. A temper-
ature just above 46°C resulted in useful degradation curve (Fig. 5). 
 
 
Figure 5. MUT protein degrades over time when exposed to heat. The degradation at 46°C corresponds to a non-lin-
ear fitting curve as shown on the right. ACTB = β-Actin; MUT = methylmalonyl-CoA mutase. 
 
5.3.3.2 Proof of concept: MUT can be stabilized by the cofactor ligand 
Previously we have demonstrated by the DSF assay that the cofactor AdoCbl can increase thermo-
stability of purified MUT-wt protein by approximately 2.5°C in vitro (Forny, et al., 2014). To replicate 
this finding in cell culture, we supplemented the cell culture medium of fibroblasts with hydroxoco-
balamin (OHCbl) for two days and investigated its effect on MUT stability when the cell lysate was 
exposed to heat afterwards. Since OHCbl is taken up by fibroblasts and converted to the two cofactor 
forms MetCbl and AdoCbl, we expected OHCbl supplementation to result in the production of 
AdoCbl, which would then stabilize MUT. 
Aliquots of cell lysates were taken during incubation at 47°C at 0 to 5 hours and Western blot analysis 
was performed. Degradation of MUT was slowed down when the cells had been previously incu-
bated with OHCbl (Fig. 6). 
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Figure 6. Mutase can be stabilized when supplemented with OHCbl for 48 hours during cell growth in human wt 
fibroblasts. Western blot images on the left show decreasing amount of MUT protein when incubated at 47°C for up to 5 
hours. Quantification of the Western blot bands reveals a higher heat resistance of MUT derived from OHCbl treated cells 
compared to MUT from cells which were grown in non-supplemented cell culture medium. MUT band intensities were first 
normalized to β-Actin and then to the condition at 0 hours. ACTB = β-Actin. 
 
5.3.3.3 Effect of compounds on cell growth 
Fibroblast cell growth was monitored by microscopy during the full 48 hours following compound 
addition to evaluate toxicity effects. Compound E showed clear toxicity, killing all cells within 24 
hours of incubation, and was therefore excluded from all further experiments. Compounds A, B and 
F slowed down cell proliferation, and compound F also changed the morphological appearance of 
the fibroblasts (Table 2). 
 
Compound Before incubation After 24 hours After 48 hours 
no 80 95 >100 
DMSO 80 95 >100 
A 80 70 80 
B 80 95 100 
C 80 95 >100 
D 80 95 >100 
E 80 0 0 
F 80 90 90 
Table 2. Confluency of fibroblasts following addition of compounds. Cell viability was influenced by compounds as 
judged by confluence of the cell layer. Numbers indicate representative levels of confluence in percent (no cells: 0%; flask 
bottom is fully covered with cells: 100 %; over-confluent: >100%); no, no compound added. 
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5.3.3.4 MUT stability and activity after incubation with compounds 
MUT protein level was determined by Western blot analysis after the cells had been incubated for 48 
hours with the respective compound. None of the compounds increased MUT protein level. By con-
trast, some resulted in clearly reduced protein amounts (compounds A, B, F; Fig. 7i), possibly due to 
unspecific cell toxicity effects since these three compounds resulted in decreased cell proliferation 
(Table 2). 
Although activity measurements are corrected for protein amount, the compounds which caused 
the MUT amount to decrease by Western blot analysis also showed low enzyme activity (Fig. 7ii). 
While DMSO has an effect on MUT protein level, it does not change the level of enzymatic activity. 
 
 
Figure 7. MUT amount and activity are influenced by the addition of compounds. (i.) Western blot analysis reveals 
different levels of detected MUT protein, suggesting an unspecific effect of the compounds on protein expression. (ii.) 
None of the compounds increased enzyme activity in lysates of incubated fibroblasts. ACTB = β-Actin. Significance levels 
are derived from the respective value for the compound compared to wt control values and were determined by ANOVA 
multi comparison test; *: p < 0.05; **: p < 0.0001. 
 
5.3.3.5 Effect of heat exposure on MUT stability in incubated cells 
To check the stabilization potential of compounds when they were added to cell culture medium for 
two days, the lysates were exposed to 48°C for 0 to 5 hours and Western blot analysis was performed. 
Similar to OHCbl (Fig. 6), some compounds (C, D, and F) might potentially stabilize MUT by slowing 
down the degradation of the protein, although this effect might be unspecific since DMSO shows a 
similar phenomenon (Fig. 8). 
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Figure 8. None of the compounds mediate a clear improvement of MUT stability. After wt fibroblast cells have been 
grown under standard conditions (‘no’) or incubated with DMSO or one of the compounds, its lysates were exposed to 
48°C for 0 to 5 hours. Quantification of Western blot bands was normalized first to beta-actin and then to the band intensity 
at 0 hours for each individual condition. ACTB = β-Actin. 
 
5.3.3.6 Compound effect on wt fibroblast lysates 
To circumvent the effect that compounds might have during cell growth, the compounds were 
added at a later stage directly to lysates of wt fibroblasts, which were grown under normal conditions 
without any compound supplements. Ten minutes after the compounds were added to the lysates, 
one aliquot was frozen, and the second aliquot was exposed to 50°C for three hours and then frozen. 
Investigation of both samples after incubation to this slightly higher temperature showed two bands 
for MUT in Western blot with the lower one likely being derived from degraded MUT protein. This 
experiment aimed at checking whether the addition of compounds can (i) stabilize MUT, and (ii) de-
celerate the formation of degraded MUT protein. 
The addition of the compounds in a later phase of the experiment did not change the outcome re-
garding MUT stabilization. The compounds were not capable of stabilizing the MUT protein at this 
higher temperature (Fig. 9). The formation of degraded MUT protein was not decelerated when the 
compounds were added to the cell lysate, as it was observed in the DMSO control. 
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Figure 9. Compounds cannot avoid the formation of degraded MUT. Western blot on top shows two lanes for each 
condition: the sample on the right was exposed to 50°C for three hours after the respective compound was added while 
the other sample was only supplemented with compound. The heat treated sample shows two bands for MUT, with (*) the 
top band representing MUT protein with undisturbed integrity and (#) the lower band showing degraded MUT protein. 
The left graph depicts the quantification of the MUT bands (without considering the lower band) normalized to beta actin 
and relative to the sample which was not heat exposed. The right graph delineates the degradation of MUT protein nor-
malized to the first sample where no compound was added (‘no’). ACTB = β-Actin. 
 
5.4 CONCLUSION 
From the results generated in this study a clear indication, that any of the compounds increase the 
protein level or stability of wt or mutant MUT in either of the two test systems (E. coli or fibroblasts) 
applied, is not apparent. In the MUT activity assay, only unspecific (detrimental) effects were de-
tected which may also be biased by the effects these compounds have on cell proliferation and via-
bility. The effects which were promising (e.g. compound A in Fig. 4 or compound F in Fig. 9), can 
mostly be explained either by (i) unspecific effects which are also present in DMSO or (ii) an ambig-
uous impact on cell proliferation and viability. 
The absence of a clear-cut MUT-specific compound effect does not directly imply an inefficacy of the 
selected molecules, as it remains unclear whether a change in the experimental conditions would 
lead to different results with different implications. Although none of these compounds have thus 
far shown a consistent positive effect in our validation experiments, we believe they might be worth 
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further time and experimental investigation (e.g. further verification by modified cell culture experi-
ments or subsequent testing in mouse models).  
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6 CHAPTER IV: GENERATION OF A CONDITIONAL MUT‐KO MOUSE 
MODEL 
This chapter represents the results from a subproject which aimed at introducing a novel mouse 
model to study the CNS phenotype in MMAuria. The data presented will serve as a basis of future 
projects. The figure numbering is restricted to this section of the thesis. 
6.1 BACKGROUND 
One of the major long-term complications in MMAuria affects the central nervous system (CNS). Neu-
rological disorder manifests mainly with extrapyramidal movement disorder with ataxia, diplegia 
and tetraparesis (Nicolaides, et al., 1998). The reason why the brain is specifically vulnerable in 
MMAuria remains unclear. Nevertheless, studies on glutaryl CoA dehydrogenase deficiency have in-
vestigated the role of the blood-brain barrier and how limited flux across this barrier can contribute 
to the CNS phenotype in this other organic aciduria (Sauer, et al., 2006). The “trapping hypothesis” 
conveys that the accumulating metabolites produced by cells within the blood-brain barrier cannot 
sufficiently be exported into the blood circulation (Morath, et al., 2008). This hypothesis is further 
supported by the finding of acute lesions in the brains of patients who have undergone solid organ 
transplantation (Chakrapani, et al., 2002; Kaplan, et al., 2006; Vernon, et al., 2014), suggesting that 
these patients remain at risk due to exposure of the brain to high levels of accumulating metabolites. 
A similar situation in line with this hypothesis can be studied in the mouse using a conditional knock-
out model. 
The rationale to study MMAuria neurology in rodents is given by the fact that the catabolic pathway 
of propionate metabolism is expressed in the rat CNS (Ballhausen, et al., 2009). To circumvent the 
neonatal lethality shown in homozygous ko pups (Peters, et al., 2003), we have developed a tissue-
specific knock-out mouse model using the well-established Cre-Lox site-specific recombination 
technology (Friedel, et al., 2011). We generated a mouse model with a floxed exon 3 of the Mut gene, 
which allows the excision of the floxed DNA segment by a tissue-specifically expressed Cre recom-
binase. This process leads to the knock-out of the target gene (Mut) in this particular tissue, since 
deletion of exon 3 has a deleterious effect on Mut expression as previously shown (Peters, et al., 
2003). To create a CNS-specific knock-out of Mut we have crossed the Mutflox/flox strain with a Nestin-
Cre (Nes-Cre) expressing mouse line to breed Mutflox/flox;Nes-Cre mice. Nestin is an intermediate fila-
ment protein and it is expressed at high levels in neuro-epithelial precursor cells. Hence, Nes-Cre is 
frequently used to induce deletion in precursor cells of the CNS (Tronche, et al., 1999). This chapter 
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recapitulates the basic characterization of these mice, aiming at evaluating this novel model for its 
suitability in the study of the neurological phenotype observed in MMAuria. 
6.2 RESULTS 
To verify the efficient deletion of exon 3 of Mut and the subsequent absence of Mut protein/activity 
in brain tissue, quantitative real-time PCR (RT-qPCR), Western blot analysis and enzymatic measure-
ments were performed. To further investigate the consequence of Mut deletion on tissue metabo-
lites, we determined levels of MMA and 2-methylcitrate (2-MC). For the presented experiments we 
used brain tissue samples harvested at 35 days of age and generated whole brain homogenates as 
described in chapter 7. Mice with three different genotypes were investigated: Mutflox/flox;Nes-Cre, and 
wild-type (wt) and Mutflox/flox as controls. To compare brain data to values from other tissue, we used 
liver tissue from the same mice. 
6.2.1 Downregulated Mut expression leads to absent Mut protein 
To determine Mut expression in whole brain homogenates we used the RT-qPCR TaqMan method 
and compared Cre-positive floxed mice to wt and Cre-negative floxed mice. In Mutflox/flox;Nes-Cre an-
imals the Mut gene is significantly downregulated compared to the control animals (Fig. 1). The al-
most complete absence of Mut mRNA suggest an efficient deletion of exon 3 Mut on the genomic 
level by the Cre recombinase and subsequent nonsense-mediated mRNA decay of this modified 
mRNA molecule. To observe how these results translated to the protein level, Western blotting was 
used to detect the amount of residual Mut protein in the brain tissue homogenates. Consistent with 
RT-qPCR results, Mut is absent in Mutflox/flox;Nes-Cre animals while it shows comparable levels in wt 
and Mutflox/flox mice (Fig. 2). 
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Figure 1. Mut expression is significantly reduced in Mutflox/flox;Nes-Cre mice. Bars represent mean values (n = 5) of the fold 
change in Mut expression compared to mean wt expression level which is set to 1. All results have been normalized to β-
actin levels in the individual samples. Error bars depict SD, *: p < 0.01 determined by ANOVA multiple comparison test. 
 
 
Figure 2. Western blot reveals the absence of the Mut protein in the brains of Mutflox/flox;Nes-Cre mice. Lane 1, ladder (not 
shown); lanes 2-5, wt samples; lanes 6-9, Mutflox/flox samples; lanes 10-13, Mutflox/flox;Nes-Cre samples. Lower band depicts β-
actin (41 kDa), upper band represents the Mut protein (84 kDa). 
 
6.2.2 Decreased Mut activity leads to elevated MMA and 2‐MC levels 
To determine the tissue-specificity of the Cre knock-down, we measured Mut activity in brain and 
liver tissue as described (Forny, et al., 2014). While Mut activity was clearly down-regulated below 
detection limit of the assay in brain tissue of Mutflox/flox;Nes-Cre mice, activity levels in brains of control 
mice (Mutflox/flox and wt mice) was normal (Fig. 3, left panel). In liver the genotype of the mice did not 
affect the activity levels (Fig. 3, right panel), suggesting that Nes-Cre is not active in liver cells. This 
finding points to a tissue specificity of Cre activity in the brain, where it led to the knock-out of Mut. 
As a consequence of the absent Mut activity in brains of Mutflox/flox;Nes-Cre mice, MMA and 2-MC were 
elevated in this tissue but not in the brain of control mice (Fig. 4), while metabolites were low or 
below detection limit of the assay in wt and Mutflox/flox mice. Liver tissue showed constant levels of 
MMA and 2-MC (Fig. 4) which is in line with the normal enzyme activity found in this organ (Fig. 3). 
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Figure 3. The activity assay shows no residual mutase activity in the brain homogenates of Mutflox/flox;Nes-Cre mice. Data 
points represent single animals; horizontal lines represent the mean values of the respective group. 
 
 
Figure 4. MMA (left panel) and 2-MC (right panel) values were determined in brain and liver homogenates by LC-MS. MMA 
levels were only increased in brains of Mutflox/flox;Nes-Cre mice. 2-MC showed the same pattern while in liver this metabolite 
was not detectable. 
 
6.3 DISCUSSION 
Mut activity is down-regulated below detection limit in the brain, but normal in liver of Mutflox/flox;Nes-
Cre mice. This indicates that Cre deletion of exon 3 of Mut is tissue-specific and efficient at the same 
time. Although the enzyme assay has a detection limit, the real activity of Mut in the brain of 
Mutflox/flox;Nes-Cre mice seems to be lowered enough in order to lead to increased metabolites de-
rived from the substrate of the Mut catalysed reaction. Although the application of Nes-Cre trans-
genic mice is regarded as reliable (Dubois, et al., 2006), one has to bear in mind the pitfalls of the Cre-
Lox site-specific recombination system (Harno, et al., 2013). In our experiments we could show that 
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Mutflox/flox did not show any effects of Cre-induced deletion of Mut, indicating a robust system without 
epigenetic Cre transmission during breeding as described previously (Harno, et al., 2013). 
Overall, these preliminary results confirm the conditional-ko model and its tissue-specific nature. 
They encourage further studies in which the neurological phenotype in mice can be investigated. In 
fact, the “trapping hypothesis” as described in (Morath, et al., 2008) could be confirmed with these 
results, since metabolites which are produced in the brain of Mutflox/flox;Nes-Cre mice due to Mut de-
ficiency are only found to be accumulated in brain homogenates but not in the liver. 
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7 CHAPTER V: BASIC CHARACTERIZATION OF NOVEL MMAURIA MOUSE 
MODELS 
This section represents an article which is prepared to be submitted for publication. Citations in this 
chapter correlate to the bibliography at the end of the thesis. Figure and table numbering is only 
applicable to this section of the thesis. 
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7.1 ABSTRACT 
Methylmalonic aciduria (MMAuria), caused by deﬁciency of methylmalonyl-CoA mutase (MUT), usu-
ally presents in the newborn period with failure to thrive and metabolic crisis leading to coma or 
even death. Survivors remain at risk for further metabolic decompensations (e.g. due to infection or 
increased protein load) and often suffer severe long-term complications, most notably renal failure 
and neurological impairment. Mut knock-out (ko) mice display neonatal lethality, limiting their value 
as a disease model. To create surviving mouse models closely mimicking human MMAuria, we have 
generated a constitutive Mut knock-in (ki) based on the p.M700K patient mutation, which can be 
used homozygously (ki/ki) or combined with a ko allele (ko/ki). Transgenic Mutki/ki and Mutko/ki mice 
survive post-weaning, show decreased weight gain, increased methylmalonic acid levels in blood, 
urine and tissues, and increased blood propionylcarnitine, odd-chain fatty acid and sphingoid bases, 
compared to littermate controls. Consistent with a genetic dosage effect, Mutko/ki mice show lower 
residual Mut activity, less weight gain, and higher levels of metabolites than Mutki/ki. Further, Mutko/ki 
mice exhibit manifestations of kidney and brain damage, as illustrated by increased plasma urea, 
impaired diuresis and changes in brain weight. When fed a high protein diet, Mutki/ki and Mutko/ki mice 
have further elevated metabolite levels, including blood ammonia, and show catastrophic weight 
loss, which, in Mutki/ki mice, is rescued by treatment with hydroxocobalamin. Together, these two 
new mouse models provide an accurate clinical and biochemical recapitulation of human MMAuria, 
and contribute a platform from which further pathogenesis and treatments studies can be per-
formed. 
7.2 INTRODUCTION 
Methylmalonyl-CoA mutase (MUT) is a homodimeric enzyme that catalyzes the reversible isomeriza-
tion of L-methylmalonyl-CoA to succinyl-CoA by using vitamin B12 (cobalamin; Cbl) in the cofactor 
form (5’-deoxyadenosylcobalamin; AdoCbl). In this anaplerotic reaction, several metabolic path-
ways, including the breakdown of branched chain amino acids, odd-chain fatty acids, and the side 
chain of cholesterol, converge on the propionate pathway. The vital importance of this enzyme is 
demonstrated by the severe inborn error of metabolism methylmalonic aciduria (MMAuria), which 
is caused by mutations in the MUT gene (mut-type MMAuria, OMIM #251000) or by defects of AdoCbl 
synthesis. Dysfunction of MUT leads to an accumulation of methylmalonic acid (MMA), 2-
methylcitrate (2-MC), propionylcarnitine (C3) and other metabolites in body fluids and tissues. mut-
type MMAuria patients often present in the newborn period with ketoacidosis, lethargy, failure to 
thrive, coma or even death. In surviving patients, the chronic course manifests with organ-specific 
complications, the most common being neurological impairment and renal dysfunction. End stage 
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renal disease, occurring as early as the 2nd decade of life in patients with severe MMAuria, is fre-
quently seen (Baumgartner, et al., 2014; Cosson, et al., 2009; Horster, et al., 2007; Horster, et al., 2009). 
Besides symptomatic care, there are a few rational treatment approaches, including reduction of 
protein intake in order to decrease the flux through the propionate pathway, as well as carnitine and 
Cbl supplementation (Baumgartner, et al., 2014). Although this treatment appears to partly improve 
metabolic control in some cases, most patients still suffer severe long-term complications. 
Since the mouse Mut gene shows a high homology to human MUT, several attempts to generate a 
mouse model of mut-type MMAuria have been undertaken. The first such effort was made in 2003, 
when a Mut knock-out (ko) model resulted in neonatal lethality of all homozygous (ko/ko) pups 
(Peters, et al., 2003). In 2007, Chandler et al. generated their own Mut-ko mouse by the same method 
(Chandler, et al., 2007). Their switch to a different genetic background resulted in a semi-penetrant 
neonatal lethality with some ko/ko mice surviving the neonatal period (Chandler, et al., 2009), alt-
hough nearly all died within 25 days (Chandler and Venditti, 2010). Using their own ko model, the 
same group applied AAV-mediated gene therapy (Chandler and Venditti, 2008; Chandler and 
Venditti, 2010) and stable transgenic Mut expression in the liver (Manoli, et al., 2013) to provide a 
long-term rescue of lethality. However, despite these efforts, no model to date has been able to pro-
vide an accurate depiction of the patient situation. Neonatal or early lethality disallow studies of the 
chronic development of disease, while transgenic rescue of Mut does not represent the natural situ-
ation, where a patient carries the same genetic defect in all cells. 
In order to devise a model of MMAuria reflective of the patient situation and amenable to the study 
of the long-term disease course, we opted to knock-in (ki) a hypomorphic allele based on a patient 
missense mutation. From our previous in depth MUT missense mutation characterization (Forny, et 
al., 2014), we identified p.Met700Lys (c.2099T>A human cDNA; p.Met698Lys in mouse) as an ideal 
candidate for this allele due to the residual enzymatic activity and in vitro response to hydroxocobal-
amin (OHCbl) found in MUT protein carrying this mutation. p.Met700Lys has been detected hetero-
zygously in 4 MMAuria patients in conjunction with severe mutations (Acquaviva, et al., 2005; Forny, 
et al., 2016), but at least 3 of these patients have had an intermediate disease course with a relatively 
late age of onset (between 14 days and 6 months) (Forny, et al., 2016), supporting the potential of 
this mutation to cause moderate MMAuria. To assess the effect of genetic dosage on the phenotype 
and to generate a more severe disease model, the new ki mutation was combined with a ko mutation 
(Peters, et al., 2003). Here we present a thorough characterization of these newly generated Mutki/ki 
and Mutko/ki mouse models, which survive long-term and recapitulate the key biochemical and clini-
cal features of MMAuria. 
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7.3 RESULTS 
7.3.1 In vitro characterization of the p.Met698Lys knock‐in allele 
To characterize the selected ki mutation, we tested the biochemical properties of the human muta-
tion p.Met700Lys (hs-p.Met700Lys) and the equivalent mutation in mouse (mm-p.Met698Lys). Sep-
arate constructs incorporating each allele were overexpressed in human fibroblasts carrying a ho-
mozygous null allele of MUT in order to determine enzyme activity and kinetics. In both, the residual 
activity was reduced to a few percent of wild-type (wt) (Fig. 1A) with an almost 100-fold increased KM 
for AdoCbl (Fig. 1B). These nearly identical biochemical results for the human and mouse equivalent 
mutations led us to conclude that the mm-p.Met698Lys mutation would be expected to produce an 
intermediate phenotype of MMAuria, similar to its hs-p.Met700Lys counterpart. 
 
 
Fig. 1. Human (hs) and mouse (mm) mutant proteins show similar enzyme parameters when expressed in a mut0 patient 
cell line. (A) Bar chart depicts mean enzyme activities measured in fibroblast homogenates after overexpression of the 
respective constructs. Mutant values were calculated in relation to their wt counterparts and normalized to percent residual 
activity of wt. (B) Bars are absolute KM values for AdoCbl determined by measuring MUT activity with increasing concentra-
tions of AdoCbl ranging from 0.0025 to 50 μM. Error bars in both panels depict SD; means were calculated from at least 
two independent experiments; wt, black; mutant, grey. 
 
7.3.2 Generation of ki allele and initial characterization 
To generate the knock-in p.Met698Lys mutation, a targeting vector was designed to replace the thy-
mine with an adenine at position c.2093 of Mut (based on NM_008650.3). The construct contained a 
long arm of homology of 4.5 kilobases (kb) (spanning the sequence of intron 8 to exon 12), a short 
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homology arm of 1.4 kb covering most of intron 12, and an insert comprised of the point mutation 
in exon 12 and a neomycin cassette flanked by flippase recognition target (FRT) sites (Fig. 2A). Upon 
embryonic stem cell (C57BL/6-derived) targeting, the clone 12H5 was confirmed to be positive by 
Southern hybridization (Fig. 2B) and was used for blastocyst injections to generate chimeric mice. 
Pups of chimeras and flippase (Flp)-deleter mice were screened for germ-line transmission of the 
targeted allele by detection of the remaining FRT-site after Flp recombination via PCR genotyping 
(Fig. 2C, upper panel). Additionally, Mutko/ki mice were generated as a second disease model by cross-
ing the previously established Mutko/wt mice (Peters, et al., 2003) with our Mutki/ki mice, and followed 
by PCR genotyping of the ko allele (Fig. 2C, lower panel). 
To determine the direct consequences of the missense change on Mut transcript, stability and func-
tion, we investigated Mut expression and activity in various tissues. In wt mice, we found Mut expres-
sion to be lower in brain than in liver or kidney (Fig. 2D), similar to previously published results 
(Ballhausen, et al., 2009). The ki allele did not result in an appreciable decrease of Mut transcript levels 
in all tissues tested, however, mice with one ko allele had ~50% of Mut transcript levels compared to 
wt (Fig. 2E), likely indicative of nonsense mediated decay. At the protein level, the amount of the 
homozygous Mutki/ki protein was massively reduced compared to controls, suggesting an unstable 
mutant protein, while ko/ki Mut protein showed similar massive reduction (Fig. 2F). Mut activity from 
wt mice significantly varied among tissue types, with highest activities in kidney, liver and heart (Fig. 
2G). Activities from ki/ki and ko/ki mice were greatly decreased in all tissues tested (Fig. 2H), compa-
rable to the in vitro measurements (Fig. 1A). Furthermore, a gene dosage-dependent decrease of 
enzyme activity was identified, with Mutko/ki activity slightly lower than Mutki/ki in most tissues (Fig. 
2H). As expected, ~50% percent of residual activity was maintained in the Mutki/wt and Mutko/wt ani-
mals, reflecting the activity of the remaining wt allele (Fig. 2H). 
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Fig. 2. Generation of ki allele and initial characterization. (A) Based on the wt mouse Mut gene, a targeting construct was 
generated to replace the Mut gene region spanning from intron 8 to intron 12 (shaded in grey), consisting of a long and 
short arm of homology as well as an insert with the missense mutation (p.Met698Lys) and a neomycin cassette (neo, green 
arrow) flanked by FRT sites (vertical green triangles). Homologous recombination and Flp-deletor breeding resulted in the 
final targeted ki allele with the mutation and one remaining FRT site. Exons are represented by red triangles or boxes, 
arrows “fwd” and “rev” indicate forward and reverse genotyping primers, respectively. (B) Southern blotting of targeted 
clone 12H5. (C) Upper panel: genotyping PCR of ear biopsy DNA for the ki allele with fwd and rev primers depicted in panel 
A. Asterisk indicates an additional heterodimer band as confirmed by Sanger sequencing. Lower panel: genotyping PCR of 
ko allele. (D) Mut expression among wt tissues (error bars are SEM; n = 4; *: p < 0.01) and (E) ko allele dependent loss of Mut 
expression (bars are means normalized to wt in each tissue; error bars depict SEM; n ≥ 4; *: p < 0.05). (F) Western blot analysis 
of Mut protein levels using β-actin as loading control. (G) Mut activity varies by tissue and (H) by genotype (bars are mean 
values and in each tissue normalized to the wt value; error bars are SEM; n ≥ 4; *: p < 0.0001). Significance levels are the 
same in all five tissues (not depicted for clarity). 
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7.3.3 Gene dosage‐dependent clinical/biochemical features in Mutki/ki and Mutko/ki mice 
Mice homozygous for the targeted point mutation (Mutki/ki) were viable and, when crossed with het-
erozygous Mutki/wt mice, reproduced at the expected Mendelian ratio of 50% percent per genotype 
(Table 1A). Breeding of Mutko/ki also resulted in viable animals and displayed the expected Mendelian 
distribution of the genotypes (50% Mutko/ki and 50% Mutki/wt; Table 1B). Mice of both genotypes sur-
vived long-term (> 1 year), allowing us to monitor long-term development. At early stages of life, 
Mutki/ki and Mutko/ki mice were largely indistinguishable from their heterozygous littermates (Mutki/wt) 
and wt control mice. However, after the age of about 100 days in females (Fig. 3A) and about 150 
days in males (Supp. Fig. S1A), mice of both genotypes showed signs of significant growth retarda-
tion. The difference between littermate control (Mutki/wt) and Mutko/ki female mice was 30% after ~1 
year (Fig. 3A), while food intake and weight loss (when single-caged overnight) remained constant 
(Supp. Fig. S1B). In this cohort, C3 (normalized to acetylcarnitine, C2) in blood and MMA in urine were 
constantly elevated over the entire time span investigated (Fig. 3B and C). Survival was the same in 
all three groups (all mice still alive after one year except for 1 Mutki/ki and 1 Mutko/ki, both of which died 
during blood collection). 
 
A 
Breeding pair Genotype of animals   
Mut-ki/wt × Mut-ki/ki  Mut-ki/wt Mut-ki/ki total 
litters: 33* 96 94 190 
  51% 49% 100% 
*All animals (except 1 with unclear genotype) survived post-weaning 
B 
Breeding pair Genotype of animals   
Mut-ko/wt × Mut-ki/ki  Mut-ki/wt Mut-ko/ki total 
litters: 36* 100 104 204 
  49% 51% 100% 
*All animals (except 5 with unclear genotype) survived post-weaning 
 
Table 1. Breeding patterns of pairs to generate Mutki/ki and Mutko/ki mice. 
 
To gain further insight into the consequences of massively reduced Mut enzymatic activity, we per-
formed a cross-sectional analysis of hallmark metabolites of MMAuria (Kolker and Okun, 2005) at 35 
days of age. The eponymous compound MMA was found elevated in a genetic dosage-dependent 
manner in tissues, urine and dried blood, with the highest levels found in Mutko/ki mice (Fig. 3D). Alt-
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hough Mutki/ki animals showed considerably lower levels, they were still significantly elevated com-
pared to controls (Fig. 3D). Propionylcarnitine (C3) levels (normalized to C2) showed the same trend 
(Fig. 3E). Mutki/wt and Mutko/wt did not show any elevations, suggesting that one functional wt allele is 
sufficient to cope with the demands of the propionate pathway (Fig. 3D and E). Ammonia levels, 
which are elevated during metabolic crisis in patients, were normal (Fig. 3F), suggesting these ani-
mals did not suffer from acute crises on normal chow. Similar to patients (Kolker, et al., 2015; Matsui, 
et al., 1983b; Perry, et al., 1977), both Mutko/ki and Mutki/ki showed elevated glycine levels (Fig. 3G), 
while other amino acid levels were mostly unchanged (Supp. Fig. 2). 
In addition to classic metabolites, we performed a comprehensive analysis of fatty acids and sphin-
goid bases. We found increased levels of odd-chain fatty acids (Fig. 3H), including the 17-carbon 
chain length fatty acid, which has recently been proposed as a biomarker of MMAuria (Malvagia, et 
al., 2015), with normal levels of even-chain fatty acids (Supp. Fig. S3A; Supp. Table 1). Further, we 
show here for the first time an elevation in odd-chain length sphingoid bases in plasma (Fig. 3I) and 
tissues (Fig. 3J), possibly as a consequence of the increased odd-chain fatty acids, while levels of 
even-chain sphingoids remained normal (Supp. Fig. S3B; Supp. Table 2).
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Fig. 3. Clinical and biochemical phenotype of Mutki/ki and Mutko/ki mice. (A) Monitoring of body weight of female mice over time (male data in Supp. Fig. S1A). Decreased body weight in Mutki/ki 
mice is significant compared to Mutki/wt from day 162, and in Mutko/ki significant compared to Mutki/wt from day 114. For both: p < 0.05. (B) C3 levels in dried blood spots normalized to 
acetylcarnitine (C2). (C) MMA levels measured by LC-MS/MS in urine collected overnight in metabolic cages. In panels A-C points represent mean values, error bars depict SEM and n = 5 per 
group. (D) MMA levels in tissues (left panel), urine (middle) and dried blood (right), determined by tandem mass spectrometry. (E) C3 levels normalized to C2 in dried blood. (F) Ammonia 
levels measured in whole blood. (G) Glycine concentration determined in dried blood by tandem mass spectrometry. (H) Fatty acid levels determined in plasma and expressed as percent of 
total fatty acids. (I) Plasma levels of sphingoid bases (expressed as pmol per μl plasma). (J) 17-carbon chain sphingoid base levels in different tissues expressed as pmol per μg protein. Panels 
D-J: bars represent mean values from 35 days old mice (error bars depict SD; n ≥ 4; *: p < 0.05).
PhD thesis  Patrick Forny 
113 
7.3.4 Initial characterization of the renal and neurological phenotypes 
We investigated whether Mutko/ki mice suffer from similar long-term complications as patients with 
MMAuria, e.g. renal dysfunction. When normalized to body weight, Mutko/ki mice consistently pro-
duced less urine during adulthood than littermate controls (Mutki/wt) (Fig. 4A), although water intake 
was not significantly different between the two groups (Fig. 4B). Consistent with renal dysfunction, 
these mice also had increased plasma urea throughout the time course measured (Fig. 4C), sugges-
tive of a decreased glomerular filtration rate (Schwartz, et al., 2009). Renal tubular dysfunction in 
these animals was further underlined by disturbed excretion of several electrolytes in urine (Fig. 4D). 
These signs of kidney dysfunction were further supported by the finding of increased levels of the 
biomarker Lipocalin-2 (Lcn2) in kidney tissue (Fig. 4E). However, no gross changes in weight (Supp. 
Fig. S1B) in the Mutki/ki and Mutko/ki kidneys were detected, suggesting that the source of these renal 
defects are likely at the (sub)cellular level. 
Neurological dysfunction is the other important long-term complication of MMAuria (Nicolaides, et 
al., 1998), often manifesting as movement disorder due to lesions in the basal ganglia caused by 
metabolic stroke, which may also induce brain edema in the acute phase. In the Mutko/ki mice we 
observed an increase in brain weight at the age of one month as well as one year (Fig. 4F), which 
may be suggestive of brain edema. Although brain histology was normal in the basal ganglia (Supp. 
Fig. S4), we also identified an upregulation in Lcn2 at the mRNA and protein level (Fig. 4G). 
Together, the initial characterization of both the brain and kidney, in combination with the metabo-
lites already identified in these organs, suggest an initial dysfunction in each, which has not yet man-
ifested at the gross level. 
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Fig. 4. Renal and neurological phenotype. (A) Urine production measured in metabolic cages overnight and expressed as 
microliters of urine per hour normalized to body weight. (B) Overnight water intake measured in grams of water normalized 
to body weight. (C) Urea in plasma expressed in mg per deciliter. (D) Electrolytes measured in urine and normalized to 
grams of creatinine. (E) Western blot of Mut and Lcn2 at two different time points. (F) Kidney histology. (G) Brain weight 
normalized to body weight at three different time points. (H) Expression of Lcn2 in brain tissue on mRNA level normalized 
to β-actin and on protein level (β-actin as loading control). In panels A-D and G-H, points and bars represent mean values; 
error bars depict SEM; *: p < 0.05. 
 
7.3.5 Diet‐induced metabolic decompensation 
An increased throughput of the propionate pathway in patients with MMAuria, e.g. due to a cata-
bolic state or an augmented protein intake, often results in metabolic decompensation (crisis). In 
order to replicate this state in our MMAuria mouse models and exacerbate their clinical phenotype, 
we used dietary challenge. Mice were fed a high protein (HP) diet, as used previously (Manoli, et al., 
2013), or a precursor-enriched (PE) diet comprised of increased levels of amino acids directly relevant 
to the propionate pathway (isoleucine, valine, threonine; for formulations see Supp. Table 3). Upon 
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initiation of both diets at the age of 2 months, both Mutko/ki and Mutki/ki mice experienced rapid weight 
loss, which was so severe that the study had to be terminated after 3 days (Fig. 5A; Supp. Fig. S5). The 
effect exerted by the PE diet appeared to be stronger than the HP diet, as shown by the more pro-
nounced weight loss (Fig. 5A), likely reflecting the two-fold higher isoleucine, valine and threonine 
content in the PE diet (Supp. Table 3). Brain weight (normalized to body weight) was increased in 
Mutko/ki mice under both diets, which was not the case on reference chow (RC) at this age (Fig. 5B). 
Investigation of the sacrificed animals revealed, from both diets, elevated levels (2.5-3.5 times) of 
plasma MMA, C3, and for the first time in these mice, ammonia (~4-7 times; Fig. 5C, D and E), con-
sistent with the induction of metabolic crisis. Further investigation of MMA and C3 in brain, kidney 
and liver demonstrated a gene dosage-dependent increase in both metabolites for mice on either 
diet compared to those on the control diet (RC) in all tissues tested (Fig. 5F, G and H; Supp. Fig. S6). 
Indeed, while these metabolites were already elevated in Mutko/ki and Mutki/ki mice on RC (e.g. brain 
levels of MMA in Mutko/ki are 4.4 times higher than Mutki/wt, Fig. 5F), they were further increased up to 
53-times when the diet was changed to HP or PE (Fig. 5F). 
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Fig. 5. Modified diet leads to disease acceleration. A) Start of both modified diets (upper panel: PE, precursor-enriched; 
lower panel: HP, high protein) at 60 days of age is indicated by the black arrows. Monitoring of body weight showed sig-
nificant differences among the three groups on day 63 for both diets. (B) Weight of kidney and brain whole organs normal-
ized to body weight after determination of diet study. (C) MMA in dried blood. (D) C3 (normalized to C2) in dried blood. (E) 
Whole blood ammonia before and after diet modification. (F-H) MMA and 2-MC values in homogenates of (F) brain, (G) 
kidney, and (H) liver tissue on reference chow (RC), high protein (HP) and precursor-enriched (PE) as determined by GC-MS. 
For all panels, from 5 animals for each genotype bars and points represent means; error bars are SEM; *: p < 0.01; n.s., not 
significant. 
 
7.3.6 Cobalamin treatment partly rescues diet induced metabolic crisis 
To attempt to mitigate the effects exerted by the HP diet, we treated the mice with daily intraperito-
neal (i.p.) injections of hydroxocobalamin (OHCbl, 0.3 μg/g) for a week before and continuously dur-
ing the dietary challenge. These injections resulted in nearly doubled levels of plasma Cbl (Fig. 6A), 
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indicating efficient uptake of the vitamin into the blood stream. Mutki/ki mice appeared to be at least 
partially protected by this treatment, as, in contrast to mice on the HP diet alone (Fig. 5A), OHCbl 
treated Mutki/ki mice did not show significant weight loss (Fig. 6B). Further, elevations in C3 and am-
monia were markedly delayed, although they increased considerably, along with MMA, by the 
study’s end (Fig. 6C-E). Mutko/ki mice showed a less obvious, but still slight protective effect. They lost 
less weight compared to their untreated counterparts (compare Fig. 5A HP and Fig. 6B), and did not 
have the significantly increased brain weight (Fig. 6F) seen previously (Fig. 5B). However, they did 
show immediate and striking increases in metabolite levels (Fig. 6C-E) suggesting they remained 
metabolically compromised. 
 
 
Fig. 6. Treatment of HP diet-induced phenotype by OHCbl. (A) Cobalamin levels in plasma of untreated mice and OHCbl 
treated mice; *: p < 0.0001. (B) Time course of body weight. Black arrow indicates start of HP diet on day 60. Differences of 
body weight on day 64 were significant between Mutko/ki and the other two genotypes (Mutki/ki and wt) which did not differ 
significantly. (C) C3 (normalized to C2), (D) MMA levels in dried blood and (E) whole blood ammonia levels were measured 
on the day before diet start and on day 62 and day 64 following diet commencement. (F) Weights of brain whole organs in 
sacrificed animals at the end of the study. In panels B-E duration of HP diet was from day 60 to day 64 and OHCbl treatment 
from day 53 to day 64 as indicated by capped horizontal lines. Points and bars represent mean values; error bars in all 
panels depict SEM. 
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7.4 DISCUSSION 
In this study, we aimed to generate a novel mouse model of MMAuria which survives through adult-
hood but shows clear biochemical and clinical signs of disease. To achieve this model, we knocked 
in a missense mutation to the mouse Mut gene. This constitutive ki allele causes Mut deficiency, 
which is further aggravated by combination with a ko allele. The success of this approach is demon-
strated by the successful production of ki/ki and ko/ki mouse pups, which survive into adulthood, 
but show growth retardation, elevated metabolites in blood and tissues, and signs of renal and neu-
rological dysfunction. Further, these biochemical and clinical signs of disease follow a gene dosage-
dependent increase, where mice with one ko allele are clearly more affected than those homozygous 
for the ki allele. Thus, these novel mouse models recapitulate the biochemical and clinical features 
of MMAuria. 
7.4.1 Novel mouse models recapitulate clinical and biochemical phenotype of 
MMAuria 
The most striking phenotypic sign in our mice was growth retardation, which is likely a correlate of 
failure to thrive described in human patients (Baumgartner, et al., 2014). This lack of weight gain is 
not readily explained by reduced energy intake, as we identified no difference in overnight food 
consumption between the mutant mice and controls, suggesting that other, possibly subcellular, 
processes are affected. Previous studies point towards inhibited tricarboxylic acid cycle enzymes and 
interference with oxidative phosphorylation in MMAuria (de Keyzer, et al., 2009; Morath, et al., 2008). 
It will be important to assess these potential mechanisms in future studies. 
Further clinical signs could be observed when the disease was accelerated by means of a high pro-
tein challenge. The success of this approach was demonstrated by the massive elevation of metab-
olites and immediate loss of weight in both diets (HP and PE) for both mouse genotypes (Mutko/ki and 
Mutki/ki), suggesting that the propionate pathway was unable to process the additional metabolic 
load contributed by the modified diets. As indicated by the significantly elevated ammonia levels, 
this induced situation is consistent with acute metabolic crisis, where aggressive treatment is re-
quired to prevent encephalopathy when ammonia levels rise above a threshold of 200 μmol/l 
(Brismar and Ozand, 1994; Haberle, et al., 2012). 
Along with these general organism-wide symptoms, we were able to identify organ-specific disturb-
ances in the kidney and the brain. Under normal diet conditions, adult Mutko/ki mice showed mani-
festations of kidney dysfunction, as evidenced by increased plasma urea, impaired diuresis and 
changes in the urinary excretion of electrolytes. These changes mirror the dysfunction found in 
MMAuria, in which chronic renal failure is observed in almost half of all cases (Baumgartner, et al., 
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2014; Cosson, et al., 2009; Horster, et al., 2007; Horster, et al., 2009). In our mice, these changes were 
accompanied by increased renal levels of Lcn2, a protein which has been suggested to be an early 
biomarker of chronic kidney damage (Fassett, et al., 2011; Malyszko, et al., 2008), including in MMAu-
ria (Manoli, et al., 2013). Further, we found increased brain weight in the Mutko/ki mice at 1 month and 
1 year of age, potentially indicative of edema as a sign of cytotoxic stress. Interestingly, we also found 
increased Lcn2 mRNA and protein levels in the brain of these mice. In contrast to its potential role as 
a kidney specific marker, upregulation of Lcn2 in the brain has been suggested to be a biomarker in 
multiple sclerosis (Berard, et al., 2012), and was found to be upregulated in animal models of brain-
specific diseases (Ferreira, et al., 2015; Marques, et al., 2012; Naude, et al., 2012). Hence, the specific 
role of Lcn2 as an organ-specific biomarker remains unclear, however, the finding of upregulation in 
affected tissues suggests at least a general role in dysfunctional cells. 
Biochemically, the phenotype of human patients was accurately emulated, as illustrated by the types 
of metabolites which were increased and the extent of their elevation. For example, MMA levels in 
the urine were detected in a range comparable to human mut- patients (Fowler, et al., 2008), while 
glycine, speculated to increase via inhibition of the intra-mitochondrial glycine cleavage enzyme 
due to accumulated organic acids or their CoA esters (Hillman and Otto, 1974), was found at high 
levels in our mice, similar to the description in the first MMAuria patients (Oberholzer, et al., 1967). 
Further, we found elevated levels of odd-chain fatty acids, in line with their proposed role as an ad-
ditional aid to monitoring MMAuria in patients (Baumgartner, et al., 2014; Coker, et al., 1996; 
Merinero, et al., 2008; Wendel, et al., 1991). In addition, we present for the first time elevations of 
odd-numbered chain sphingoid bases in plasma and tissue. Their elevation may be explained by the 
disturbed fatty acid metabolism, i.e. serine palmitoyltransferase, a key enzyme in sphingoid base 
synthesis, may more often utilize 17- or 19-carbon fatty acid-CoAs as substrate, instead of the nor-
mally preferred 14- or 18-chain length fatty acids. The pathophysiological significance of this newly 
discovered phenomenon remains unknown. 
Overall, these novel models of MMAuria recapitulate many of the biochemical and clinical hallmarks 
of MMAuria patients and thus are excellent tools to study the pathogenesis of disease. Application 
of a long-term dietary challenge with less potent diets will potentially allow monitoring of chronic 
disease progression, leading to more pronounced impacts on brain and kidney tissue. 
7.4.2 Gene dose‐dependence allows titration of disease severity 
Patients carrying the p.Met700Lys mutation show an intermediate phenotype with relatively late 
onset and residual enzyme and pathway activity in fibroblast cell homogenates (Acquaviva, et al., 
2005; Forny, et al., 2016; Lempp, et al., 2007). Based on these observations, the measurable residual 
enzyme activity in vitro and the missense type of the variant used for the generation of the ki allele, 
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we expected that the ki allele would result in a milder phenotype than the ko allele, which is in fact 
a truncating mutation. Indeed, a gene dose-dependent effect was corroborated by all observed data: 
the Mutko/ki mice displayed higher levels of MMA, 2-MC, and C3, more pronounced growth retarda-
tion, and a stronger reaction to dietary challenge than homozygous Mutki/ki animals. Therefore, the 
gene dose effect detected in our study may be reflective of the phenotypic differences in patients 
and has benefitted our study, allowing us to assess milder and more severe forms of MMAuria. 
7.4.3 Response to cobalamin treatment 
It is recommended to evaluate every mut-type MMAuria patient for responsiveness to cobalamin 
treatment (Baumgartner, et al., 2014; Fowler, et al., 2008). However, no systematic study has thus far 
investigated the effectiveness of cofactor treatment in mut-type MMAuria. If effective, the cofactor 
would be expected to ameliorate disease by supporting the enzyme’s activity and/or stability, similar 
to the cofactor response displayed by phenylalanine hydroxylase (Christ, et al., 2013; Ziesch, et al., 
2012). The human mutant p.Met700Lys is an excellent candidate to test cobalamin responsiveness, 
as patient fibroblasts compound heterozygous for this and a premature stop mutation showed ~4.5 
times increased incorporation of 14C propionate into acid precipitable material when supplemented 
with OHCbl (Lempp, et al., 2007), and biochemically this mutation was found to affect the KM of MUT 
for AdoCbl (Forny, et al., 2014). Indeed, in our HP diet study, Mutki/ki mice appear to have been at least 
partly protected by pre-administration of OHCbl. These mice did not show the immediate weight 
loss associated with the initiation of the HP diet, and showed delayed accumulation of metabolites. 
The reduced degree of protection for Mutko/ki mice suggests that with the level of Cbl achieved by 
these injections, both mutant alleles are required to be potentially Cbl-responsive. An even better 
rescue may be facilitated by the application of higher Cbl doses in these mice, potentially reaching 
levels suggested for treatment in human patients (Fowler, et al., 2008). Nevertheless, our results set 
the stage for further exploration of cofactor response – a concept which may be applicable to many 
other missense mutations, since about one quarter of all mut-type mutations show an in vitro re-
sponse to cobalamin (Horster, et al., 2007; Worgan, et al., 2006). 
7.5 MATERIALS AND METHODS 
7.5.1 In vitro cell culture and enzyme activity assay 
Immortalized fibroblast cells of a mut0 patient (carrying the homozygous mutation p.Gln30*) were 
cultivated in cell culture medium (DMEM, Ref. 31966-021, Gibco, Thermo Fisher Scientific) supple-
mented with 10% fetal bovine serum (FBS, Ref. 10270-106, Gibco, Thermo Fisher Scientific) and an-
tibiotics (Ref. 15240-062, Gibco, Thermo Fisher Scientific). Constructs of human (hs) MUT wild-type 
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and mouse (mm) Mut wild-type and the mutants hs-p.M700K and mm-p.M698K were made by site-
directed mutagenesis in the pTracer-CMV2 vector (Invitrogen, Thermo Fisher Scientific). Electro-
poration was used to transiently transfect constructs into the immortalized fibroblasts. Cells were 
harvested 48 hours after electroporation by trypsinization. The cell pellet was washed with phos-
phate buffered saline and stored at -80°. Lysates were obtained by sonication of the frozen pellet in 
5 mM potassium phosphate buffer (pH 7.4) and used for MUT activity assay as described in (Forny, 
et al., 2014). To determine KM for AdoCbl in the cell lysates, the concentration of AdoCbl was varied 
between 0.0025 and 50 μM. Instead of cell lysates, homogenates from mouse tissues were also used 
for the activity assay (preparation see below). 
7.5.2 Mouse tissue preparation 
Liver, kidney, brain, heart, and muscle tissues were removed immediately after the mice were eu-
thanized in a CO2 chamber. Blood was collected in heparin tubes (Microvette 200 LH, Sarstedt) and 
centrifuged for 5 minutes at 2000 xg; supernatant was removed and plasma stored at -80°C. Lysates 
of tissues were prepared as follows: Approximately 50 mg of tissue was homogenized in the tissue 
lyser (TissueLyser II, Qiagen) in 300-600 μl of a lysis buffer dependent on the subsequent usage of 
the sample: Buffer A (TritonX-100 0.5% (v/v), 10 mM HEPES at pH 7.4, 2 mM DTT, 1 tablet of Complete 
Protease Inhibitor Cocktail Tablets (Cat # 11 697 498 001, Roche) per 50 ml of buffer) was used for 
Western blot and activity assay; buffer B (250 mM sucrose, 50 mM KCl, 5 mM MgCl2, 20 mM Tris base, 
adjusted to pH 7.4) for determination of MMA and 2-MC levels The homogenate was centrifuged at 
14’000 rpm for 10 minutes at 4°C. The supernatant was used for protein determination by Bradford 
assay (Cat. #500-0205, BioRad). 
7.5.3 Housing of mice and generation of knock‐in allele 
Animal experiments were performed in accordance with policies of the Veterinary Office of the State 
of Zurich and Swiss law on animal protection. Animal studies were approved by the Cantonal Veter-
inary Office Zurich under the license number 202/2014. Animals were kept in single-ventilated cages 
and under controlled humidity and temperature (21-23°C). Whenever possible littermate controls 
were used to compare experimental groups. 
To generate (in collaboration with Polygene AG, Rümland, Switzerland) mice homozygous for the 
mutation Mut-p.Met698Lys (c.2093T>A on RefSeq NM_008650.3) (C57BL/6 Mutki/ki), a vector was gen-
erated to be used for embryonic stem cell targeting. The neomycin resistance cassette helped to 
select cells for screening by PCR and Southern blotting. Positive clones were used for blastocyst in-
jections and generation of chimeric animals. Backcrossing to C57BL/6 mice allowed the testing of 
the pups for germline transmission. The breeding of the germline-positive animals to Flp-deletor 
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mice lead to the deletion of the FRT-flanked neomycin cassette via recombination. Mutational anal-
ysis by Sanger sequencing confirmed the mutation c.2093T>A. To maintain the knock-in allele, fe-
male Mutki/wt mice were crossed with Mutki/kimales. To generate Mutko/ki mice, female Mutko/wt (Peters, 
et al., 2003) were crossed to Mutki/kimales. 
Mouse genotyping was performed on genomic DNA from ear punch biopsies after previous extrac-
tion (DNAeasy Blood & Tissue Kit, Cat. No. 69506, Qiagen). The primers 5’-GTGGGTGTCAGCACACTTG-
3’ (forward) and 5’-CGTATGACTGGGATGCCT-3’ (reverse) amplified (HotStarTaq DNA Polymerase, 
Cat. No. 203205, Qiagen) a PCR segment which differed in size because of the remaining FRT site 
after recombination. An amplicon of 432 base pairs (bp) corresponded to a wild-type allele, 531 bp 
indicated a knock-in allele. For the genotyping of the knock-out allele, the primers 5’-ACAACTCCTT-
GTGTAGGTC-3’ (forward) and 5’-CCTTTAGGATGTCATTCTG-3’ (reverse primer binding to exon 3) 
were used to generate an amplicon of 507 bp in size. If exon 3 was replaced by a neomycin cassette 
as demonstrated in (Peters, et al., 2003) the same forward primer together with the the reverse pri-
mer 5’-GAATGAACTGCAAGACGAG-3’ resulted in an amplicon of 1138 bp. For the breeding of Mutko/ki 
mice, both genotyping protocols were performed to determine the genotype of the weaned pups 
at the age of 3 weeks. 
7.5.4 Long‐term studies and metabolic cage studies 
Long-term monitoring of mice entailed weekly weight measurements and regular blood collections 
as well as urine collections. Animals were single caged overnight to collect urine and measure indi-
vidual chow and water intake. Urine was collected in the morning, the sediment removed and frozen 
at -80°C. 
7.5.5 Quantitative real time PCR analysis 
Total RNA was extracted from frozen tissue using the QIAmp RNA Blood Mini Kit (Cat. No. 52304, 
Qiagen). Reverse transcription of 300 μg of RNA was performed with the 1st Strand cDNA Synthesis 
Kit (Takara). TaqMan gene expression assays were done in the 7900HT Fast Real-Time PCR System 
(Thermo Fisher Scientific) using TaqMan Gene Expression Master Mix (Thermo Fisher Scientific). Spe-
cific probes (all Thermo Fisher Scientific) for Mut (Mm00485312_m1), Lcn2 (Mm01324470_m1), p62 
(Mm00448091_m1) and Lc3 (Mm00458724_m1) were used. Experiments were performed in tripli-
cates and results were normalized to beta-actin (Mm00607939_s1). Relative gene expression was 
expressed as fold change compared to baseline and was calculated with the 2-ΔΔCT method. 
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7.5.6 Western blot 
Tissue samples were prepared as described above. 30 μg of protein was loaded onto the gel and 
subsequently analyzed by Western blotting using the following antibodies for methylmalonyl-CoA 
mutase (ab67869, 1:500, Abcam) and Lcn2 (ab63929, 1:1000, Abcam). Beta-actin (A2228, Sigma-Al-
drich) was used as loading control at a dilution of 1:4000. Secondary antibodies were horseradish 
peroxidase (HRP)-labelled goat anti-mouse (sc-2302, Santa Cruz) or goat anti-rabbit (sc-2301, Santa 
Cruz) IgG at a dilution of 1:5000. HRP activity was visualized by applying electrochemical lumines-
cence (RPN2109, GE Healthcare). Bands were quantified by normalization to internal beta-actin con-
trol bands. 
7.5.7 Metabolite measurements 
MMA in mice urine was analysed by liquid chromatography mass spectrometry (LC-MS/MS) on a 
Thermo Scientific UltiMate 3000 Rapid Separation LC coupled to an AB Sciex 5500 TripleQuad mass 
spectrometer using a commercial Kit (Recipe ClinMass® advanced). In brief, the urine probes were 
first diluted with Milli-Q water (18.2 MΩ∙cm at 25 °C) at different levels (factor 10 to 20’000) to which 
internal standard (d3-MMA) was added. The samples were vortexed, centrifuged, transferred to 
HPLC vials and 2 μl were injected into the instrument. 
For determination of the concentrations of amino acids, acylcarnitines (C2 and C3) as well as MMA 
in dried blood spots, blood was collected from tail vein onto a filter card and dried. Punches from 
filter cards were analysed by tandem mass spectrometry similar to (Turgeon, et al., 2010). 
For MMA and 2-MC determinations in tissue, 250-300 μl of homogenate were used for liquid–liquid 
extraction. Briefly, 10 μl of 1 mM stable isotope-labeled d3-MMA (Cambridge Isotope Laboratories, 
Inc., Andover, USA) and 100 μl of 1.25 mM d4-nitrophenol (d4-NP; euriso-top GmbH, Saarbrucken, 
Germany) were added as internal standards. Samples were acidified with 300 μl of 5 M HCl and after 
addition of solid sodium chloride extracted twice with 5 ml ethyl acetate each. The combined ethyl 
acetate fractions were dried over sodium sulfate and then evaporated at 40°C under a stream of ni-
trogen. Samples were then derivatized with N-methyl-N-(trimethylsilyl)heptafluorobutyramide 
(MSHFBA, Macherey-Nagel, Düren, Germany) for 1 h at 60°C. For GC/MS analysis, the quadrupole 
mass spectrometer MSD 5975A (Agilent Technologies, USA) was run in the selective ion-monitoring 
mode with electron impact ionization. Gas chromatographic separation was achieved on a capillary 
column (DB-5MS, 30 m x 0.25 mm; film thickness: 0.25 μm; Agilent J&W Scientific, USA) using helium 
as a carrier gas. A volume of 1 μl of the derivatized sample was injected in splitless mode. GC tem-
perature parameters were 80°C for 2 minute, ramp 50°C/minute to 150 °C, then ramp 10°C/minute 
to 300°C. Injector temperature was set to 260°C and interface temperature to 260°C. Fragment ions 
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for quantification were m/z 247 (MMA), m/z 250 (d3-MMA), m/z 200 (d4-NP) and m/z 361 (MCA). A 
dwell time of 50 ms was used for MCA and d4-NP and 100 ms for MMA and d3-MMA. 
Total fatty acid profiles from plasma/serum were determined by direct methylation and gas chroma-
tography, as described (Scheja, et al., 2008). Sphingoid base were analysed in tissue homogenates 
prepared in buffer A (see above) or directly in heparin plasma (100 μl). Proteins were precipitated by 
adding 500 μl MeOH (Honeywell), including 200 pmol internal standards (d7-SA and d7-SO, Avanti 
Polar Lipids, Alabaster CA) and lipids extracted under constant agitation (1h, 1400rpm @ 37°C; Ep-
pendorf Thermomixer Comfort; Eppendorf, Hamburg, Germany). Precipitated proteins were re-
moved by centrifugation (5 min at 16’100 rcf, 22°C; Model 5415, Eppendorf, Hamburg, Germany) and 
the supernatant (500 μl) transferred followed by the addition of 75 μl HCl (32%, Sigma). This mixture 
was incubated at 65°C for 16 h and finally neutralized by the addition of 100 μl KOH [10 M]. Hydro-
lyzed lipids were re-extracted by adding 125 μl CHCl3, followed by the stepwise addition of another 
500 μl CHCl3, 100 μl NH4OH [2 N] and 500 ul alkaline H2O. Phases were separated by centrifugation at 
room temperature (13’000 xg for 5 min). The upper phase was removed and the lower phase washed 
twice with alkaline H2O (1 ml). The remaining CHCl3 phase was evaporated under a flow of N2 (Techne 
Sample Concentrator, Bibby Scientific Ltd, Staffordshire, UK) and lipids stored under N2 at -20°C. For 
LC-MS analysis, lipids were re-dissolved in 75 μl derivatization mix (56.7% MeOH, 33.3% EtOH, 10% 
H2O) and derivatized with 5 μl of OPA working solution (990 μl boric acid [3%] + 10 μl ο-Phthalalde-
hyde [50 mg/ml in EtOH] + 0.5 μl 2-Mercaptoethanol). Samples were separated for 30min on a re-
verse phase C18 column (Uptispere 120 Å, 5μm, 125x2 mm, Interchim, France) with an isocratic mo-
bile phase (50% MeOH + 5 mM Ammonium Acetate (Sigma) at a flowrate of 400 μl/min. After each 
run the column was regenerated for 10 min with 100%MeOH. Spectra were recorded on a triple quad 
MassSpec (TSQ quantum ultra, Thermo scientific) in positive mode using APCI ionization. 
Ammonia levels in whole blood were measured by the PocketChem blood ammonia meter (PA-4140, 
Arkray) after validating the device by certified photometric endpoint measurement. 
Electrolytes in urine were measured by a timed endpoint method (SYNCHRON System kit, Beckman 
Coulter). Kit references are: Magnesium (445360), Sodium (467935), Potassium, Chloride and Calcium 
(467935 & 467915). For urea determination in plasma the SYNCHRON CX3 Delta System was used 
(Beckman Coulter, Nyon), kit no. 443350. 
7.5.8 Histology and immunohistochemistry 
Stainings were performed on sections from brain tissues fixed in formalin and embedded in paraffin. 
After deparaffinization through xylol and graded alcohols, sections were stained with the following 
antibodies: GFAP (1:13000; Dako), IBA1 (1:1000; WAKO) and active Caspase3 (1:200; BD Biosciences). 
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Stainigs for GFAP and IBA1 were performed on an automated BenchMarkTX platform (Ventana) us-
ing the I-View Kit according to the manufacturer's protocol. Stainings for active Caspase3 were done 
on an automated BOND III platform (Leica) using the RefineDetection Kit according to the manufac-
turer's protocol. Hematoxylin counterstain was subsequently applied. Images were acquired using 
the NanoZoomer scanner (Hamamatsu Photonics) and NanoZoomer digital pathology software 
(NDPview;Hamamatsu Photonics). Images were analyzed with Adobe Photoshop and Adobe Illus-
trator. 
7.5.9 Diet and cobalamin therapy 
Two different diets were used and fed to the mice ad libitum. A high protein diet with 70% casein 
(weight per weight) or 61% protein (TD.140830, Harlan) and a precursor-enriched diet (35.4% pro-
tein, of which 20% derived from casein; TD.140829, Harlan) were applied. The precursor-enriched 
diet had specific amino acid levels increased: isoleucine (total of 70 g/kg, 700% compared to refer-
ence diet), valine (84 g/kg, 700%) and threonine (53 g/kg, 700%) because they are precursors of the 
propionate pathway; leucine (19 g/kg, 119%) since its uptake might compete with the update of the 
other amino acids which are increased in the diet; cystine (3.5 g/kg, 700%) to elevate the overall 
sulfur content; methionine was not elevated because of its atherogenic potential and possible effect 
on brain function when applied in excess (McCampbell, et al., 2011; Troen, et al., 2003). 
For the cobalamin treatment studies, mice were pre-treated for one week with daily intraperitoneal 
injections of 0.3 μg hydroxocobalamin (OHCbl) (Streuli Pharma AG) per gram body weight starting 
at the age of 53 days. At day 60 the high protein diet was initiated and i.p. OHCbl treatment contin-
ued. 
7.5.10 Statistical analyses 
All data were analyzed with Prism 6.0 (GraphPad) software. Statistical comparison tests used are 
ANOVA multiple comparisons test and Student’s t test. In sample groups always a minimum of four 
animals was used and the data were calculated as means ±SD or ±SEM, respectively. A p value below 
0.05 was considered significant. 
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7.7 SUPPLEMENTARY MATERIAL 
 
 
Supp. Figure S1. Long-term data in male and female mice. (A) Left panel: Body weight of male mice is monitored over 
time; middle panel: Elevated C3 levels normalized to C2 in Mutki/ki and Mutko/ki mice determined in dried blood spots by 
tandem mass spectrometry; right panel: MMA urine levels measured by LC-MS/MS. (B) Left panel: Chow intake in female 
mice determined by overnight measurements in metabolic cages; middle panel: Weight loss in mice when single-caged 
overnight; right panel: Weights of whole kidney (1 organ) normalized to body weight at different time points. 
 
 
Supp. Figure S2. Amino acid levels expressed in μM at the age of 35 days. Dried blood spots of three different genotypes 
(Mutki/wt, grey; Mutki/ki, red; Mutko/ki, dark red) were used for tandem mass spectrometry measurements of amino acid levels. 
Bars represent mean values; error bars depict SD; n = 5 per group; *: p < 0.05. 
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Supp. Figure S3. (A) Levels of even-chain fatty acids determined in plasma and expressed as percentage of total amount 
of fatty acids. (B) Even-chain sphingoid bases determined in plasma and expressed as pmol per microliter of plasma.
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Supp. Figure S4. Brain histology of Mutko/ki mice and control mice (wt and Mutki/wt). Mutki/wt and Mutko/ki brains are from animals at the age of 1 year, wt control is 140 days old. Apart from 
traditional haematoxylin-eosin staining, slices were stained for glial fibrillary acidic protein (GFAP), ionized calcium-binding adapter molecule 1 (Iba1), and Caspase 3. Scale bars on overview 
pictures are 1 mm, scale bars of insets in the basal ganglia are 100 μm. 
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Supp. Figure 5. Diet modification in male mice at the age of 60 days leads to a severe exacerbation of the phenotype. (A) 
Weight loss induced by high protein (HP) or precursor-enriched (PE) diets in Mutki/ki and Mutko/ki mice. Black arrows indicate 
start of respective diet. Levels of (B) C3 normalized to C2 and (C) ammonia in whole blood before and after the diet was 
initiated. (D) Weight of whole organs normalized to body weight. Bars and points represent means; error bars are SEM. 
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Supp. Figure S6. MMA and 2-MC levels in tissues from mice on high protein (HP) and precursor-enriched (PE) diet com-
pared to levels on reference chow (RC). MMA and 2-MC values in nmol are normalized to wet weight of tissues in gram. The 
panels represent data from (A) heart, (B) muscle, (C) brain, (D) kidney and (E) liver tissues. The female data, which is not 
displayed in panels C, D and E, are shown in Fig. 5F, G and H. Bars are means of n = 5; error bars depict SEM. Groups with 
red bars represent data from female mice, blue bars originate from data on male mice. Genotype according to the following 
colour code: Mutki/wt, grey; Mutki/ki, red or blue; Mutko/ki, dark red or dark blue. If a grey bar is grouped with red bars it repre-
sents a female control, with blue bars it is a male control. 
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Fatty acid name Mut-ki/wt Mut-ki/ki Mut-ko/ki 
Linoleic acid 25.84 27.72 28.61 
Palmitic acid 20.90 21.33 20.51 
Oleic acid 18.52 17.65 15.31 
Arachidonic acid 10.57 9.90 10.49 
Stearic acid 9.47 9.43 10.91 
Vaccenic acid 3.13 2.66 2.21 
Palmitoleic acid 2.68 2.41 1.55 
Docosahexaenoic acid 2.49 2.13 2.27 
alpha-Linolenic acid 1.02 1.20 1.31 
Dihomo-gamma-linolenic acid 1.02 0.86 0.84 
d-7-Hexadecane 0.61 0.59 0.58 
Eicosapentaenoic acid 0.55 0.49 0.39 
Myristic acid 0.51 0.53 0.58 
Eicosenoic acid 0.43 0.43 0.45 
Heptadecanoic acid 0.34 0.55 1.16 
Nervonic acid 0.32 0.33 0.34 
gamma-Linolenic acid 0.26 0.31 0.28 
Docosapentaenoic acid 0.21 0.21 0.25 
Pentadecanoic acid 0.21 0.35 0.89 
Eicosadienoic acid 0.20 0.17 0.18 
Behenic acid 0.19 0.21 0.27 
Eicosatrienoic acid 0.17 0.18 0.21 
Lignoceric acid 0.11 0.13 0.18 
Eicosatetraenoic acid 0.11 0.09 0.08 
Heneicosylic acid 0.05 0.05 0.05 
Erucic acid 0.05 0.05 0.06 
Myristoleic acid 0.03 0.03 0.02 
Tridecylic acid 0.01 0.03 0.03 
 
Supp. Table 1. Specific fatty acids in plasma in percent of total amount of fatty acids. 
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sphingoid 
base 
wt Mut-ki/wt Mut-ki/ki Mut-ko/ki 
     
C19SO     
brain 0.015 0.011 0.047 0.020 
heart 0.002 0.002 0.002 0.002 
kidney 0.007 0.007 0.008 0.010 
liver 0.006 0.007 0.007 0.006 
muscle 0.001 0.000 0.002 0.001 
C16SO     
brain 0.023 0.026 0.060 0.022 
heart 0.018 0.025 0.019 0.017 
kidney 0.022 0.018 0.023 0.018 
liver 0.023 0.028 0.022 0.017 
muscle 0.005 0.002 0.004 0.006 
C18SO     
brain 13.968 13.053 32.065 13.956 
heart 2.573 2.463 2.502 2.021 
kidney 8.373 8.430 8.380 9.673 
liver 3.615 4.327 4.212 3.212 
muscle 0.795 1.037 1.402 1.551 
C20SO     
brain 0.677 0.570 1.300 0.665 
heart 0.012 0.005 0.003 0.004 
kidney 0.022 0.034 0.035 0.035 
liver 0.014 0.021 0.012 0.012 
muscle 0.001 0.002 0.001 0.008 
 
Supp. Table 2. Sphingoid bases in tissues in pmol/μg protein. 
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   Reference chow 
(RC) 
High protein (HP)  Precursor‐en‐
riched (PE) 
Isoleucine, g/Kg  10  35  70 
Leucine, g/Kg  16  56  19 
Valine, g/Kg  12  42  84 
Threonine, g/Kg  7.6  27  53 
Cystine, g/Kg  0.5  1.8  3.5 
Methionine, g/Kg  4.6  16  4.6 
Protein, g/Kg  177  609  354 
Casein, g/Kg  200  700  200 
Cbl, mg/Kg  0.0375  0.0375  0.0375 
 
Supp. Table 3. Composition of reference chow, high protein and precursor-enriched chow. Cbl, cobalamin. 
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8 CONCLUSION AND OUTLOOK 
8.1 MMAURIA PATIENT COHORT ANALYSIS 
We were able to analyse 151 patients and to stratify them according to their genotype, biochemical 
data, and age of onset. We provide information on genotype-phenotype correlation and present 41 
novel mutations in the MUT gene. This study shows that patients of the mut- subclass have a later 
age of disease onset which is in line with the previously shown milder disease course in this sub-
group compared to mut0 (Horster, et al., 2007). Responsiveness to cobalamin was evaluated in vitro 
and a detectable response correlated to the genotype of patients with missense mutations, making 
this mutations type more likely to be responsive compared to other mutation types. Nevertheless, 
we conclude that the prediction of disease severity and responsiveness to cobalamin treatment 
based on biochemical assays and mutations type is not certain. Since a reliable prognosis would be 
very helpful for the health management of the patient and also the patient itself, we suggest further 
studies to improve the understanding of cobalamin responsiveness from a clinical point of view and 
also from a molecular/mechanistic perspective. 
Additionally, we analysed the missense mutations in more detail and performed Western blot anal-
ysis to determine residual protein amount as a surrogate marker of protein stability. We identified 
only a handful of missense mutations which resulted in a considerable amount of residual protein. 
In fact, most missense mutations lead to a destabilized MUT mutant protein, adding mut-type 
MMAuria to the growing list of misfolding disorders. Based on this phenomenon we suggest future 
studies which may involve investigations of specific small molecules in order to improve the stability 
of unstable mutant proteins with these compounds. 
8.2 MUT MUTANTS CHARACTERIZATION 
In addition to the detailed update on all MUT mutations detected in our patient cohort, we selected 
23 missense mutants to perform an in-depth characterization of their biochemical properties. Each 
of the 23 mutants was assigned to a category of biochemical defects: KM defect, catalytic defect, ther-
molabile mutant, or unstable mutant. This categorization improves the understanding of possible 
defects conferred by missense mutations on the MUT protein and can guide future investigations of 
missense changes in MUT. We have shown that MUT is amenable to analysis of temperature stability 
tests by DSF and that it can be used as a target protein in large scale screenings applying this meth-
odology. Therefore, our study establishes MUT as a potential target for chaperone-based therapy, 
constituting a promising novel therapeutic approach in MMAuria. 
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8.3 PHARMACOLOGICAL CHAPERONE SCREENING FOR MUT 
In previous investigations (Forny, et al., 2014) MUT was established as a suitable candidate for high 
throughput screening by DSF . Such screening was performed in order to find stabilizing molecules 
for MUT-wt which may be later also applied to mutants of MUT. In screening of a library, consisting 
of 10,000 compounds, about two dozen molecules were identified to have a stabilizing effect on the 
MUT-wt protein. Validation experiments by biophysical and cell culture experiments could inconsist-
ently confirm some of the hit compounds from the screening. Since some of the orthogonal valida-
tion methods did not support the original screening results, we suggest the following future direc-
tions in PC screening for MUT: 
i. The conditions used in the verification methods should be varied to test different concentra-
tions of the tested compounds and various times of incubation. E.g. cell cultures could be 
incubated with higher concentrations of the compounds and for a longer time. These 
changes of the experimental conditions could lead to other results in the validation experi-
ments. Additionally, careful monitoring of the compounds with regard to their uptake into 
the cell, intracellular localisation, and intracellular or even intra-mitochondrial concentration 
is essential. 
ii. The screened library of 10,000 compounds is rather small compared to existing libraries 
available to the drug industry, which often consist of 10-50 fold more compounds per library. 
If the number of compounds screened would be increased, the likelihood of finding specific 
binders of MUT will dramatically rise. 
iii. The screening was performed based on MUT-wt protein. This might be problematic since the 
protein targets in patients are MUT mutants and not wild-type proteins. As illustrated by the 
E. coli expression experiments, unstable MUT mutants were not rescued by the hit com-
pounds. Despite the convenience of using the wild-type protein, which can be purified at 
high amounts, it might be necessary to use several different mutant proteins as targets of 
the screening process. The difficulty of the instability of MUT mutant proteins could be over-
come by large-scale growth of large amounts of bacterial cultures and the application of 
chemical chaperones, such as glycerol, during the purification process. 
iv. The screening approach applies the DSF method which is based on the stability of the MUT 
protein. Alternative screening approaches, based on read-out criteria different from struc-
tural protein integrity, might be more precise and reveal more promising hit compounds. 
Since the final aim of a potential PC therapy in MMAuria is the increase of enzyme activity at 
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the correct location, future screening methods could be based on enzyme activity and/or 
subcellular distribution and thereby result in identification of more effective hit compounds. 
v. Potential evaluation in mouse models should be monitored carefully. The route of admin-
istration has to be selected based on pilot studies which investigate the uptake and delivery 
of the compounds to the target protein in different organs. Special emphasis should be put 
on the uptake of compounds into brain tissue, since satisfactory MMAuria treatment would 
include therapy of the neurological phenotype. 
8.4 NOVEL MOUSE MODELS OF MMAURIA 
8.4.1 Conclusions on current studies 
In this study novel mouse models of MMAuria were generated and evaluated for their value as tools 
in MMAuria research. 
The conditional brain knock-out of Mut showed that the Cre/loxP recombination system can be ro-
bustly applied in our model. The results presented include basic investigations on the validity of the 
brain-knockout and sets the stage for further characterization of this model with a special emphasis 
on the CNS phenotype. 
The novel Mutki/ki and Mutko/ki models were evaluated regarding the accurate mimicking of human 
MMAuria and found to recapitulate the disease in many biochemical and clinical aspects with a gene-
dose effect. The severity of the disease can be modulated by a modified protein diet, which allows 
the titration of disease symptoms. Additionally, we could evaluate the responsiveness of these mod-
els to classical Cbl treatment and found some parameters, which were ameliorated upon this treat-
ment, suggesting that evaluation of Cbl response is crucial in MMAuria patients. Taken together, the 
results generated in this study encourage further studies on pathomechanisms in kidney and CNS, 
novel treatment approaches, and cofactor response. 
8.4.2 Potential future studies 
Future studies should focus on the exploration of the phenotype, especially organ manifestations, 
of MMAuria with a focus on the pathomechanisms. The following methods allow disease accelera-
tion in both models (conditional brain knock-out and constitutive knock-in): 
i. As exemplified in our study, a protein increase in the diet leads to a stress situation in the 
animals, resulting in massive weight loss after only a couple of days on this modified diet. 
This severe impact of a high-protein or precursor-enriched diet can be titrated to a level, 
where weight loss is not so severe but the disease manifestations are still enhanced. 
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ii. The diet modification approach leads to an increase in the throughput of the propionate 
pathway. The same effect can be achieved by fasting. The absence of food intake leads to 
the breakdown of endogenous protein resources and thus to an elevated production of pro-
pionate. This stress situation, which can also be observed in patients, can induce a metabolic 
crisis which enhances MMAuria symptoms. 
iii. Mice can be observed over a longer time, so phenotypic changes can accumulate and are 
therefore easier to be observed. Aging experiments also allow the study of the dynamics of 
certain processes, e.g. changes of pathomechanistic markers over time. 
When the conditions are determined under which a maximal acceleration of the phenotype can be 
expected, CNS and kidney should be investigated in-depth. In our study, Lcn2 and brain weight was 
elevated in the Mutko/ki mice, indicating phenotypic changes in the brain of those animals. Despite 
these results, brain histology remained unchanged, suggesting that the molecular changes did not 
translate to the macroscopic level of the cell. To observe changes such as basal ganglia lesions or 
white matter disease, additional methods are required to monitor these phenotypic phenomena 
such as magnetic resonance imagining, behavioural studies including gait analysis, and electron mi-
croscopy. Renal investigations may include measurement of glomerular filtration rate and ultrastruc-
tural analysis by electron microscopy in order to monitor the potential development of end stage 
renal disease. Moreover, the kidney can be investigated with the conditional knock-out model, when 
Mutflox/flox mice are crossed with a kidney-specific Cre expressing mouse line, generating a similar 
model to the brain-specific conditional Mut-ko model. In order to study specific tissues, primary cell 
cultures derived from organs of Mutflox/flox mice with subsequent in vitro Cre-mediated deletion of Mut 
can also be developed. 
In addition, metabolomics (and also transcriptomics) approaches may be helpful to identify affected 
pathways in the pathology of MMAuria. Although whole metabolome approaches are getting in-
creasing attention in the field of IEMs, they are often targeted (Janeckova, et al., 2012) or not disease-
specific (Mussap, et al., 2013). In MMAuria knowledge about the metabolome of patients is sparse. 
One study on MMAuria and propionic aciduria patient plasma identified propionylcarnitine as the 
best biomarker of disease (Wikoff, et al., 2007). Non-targeted metabolite profiling is usually carried 
out as comparative analysis between control and patient groups (Miller, et al., 2015). Our mouse 
models serve as an ideal tool for such an approach, allowing the definition of a clearer picture of the 
metabolite pattern in MMAuria. The homogenous genetic background of the samples should allow 
the measurement of a robust data set with little individual variation. The identification of novel bi-
omarkers would elucidate so far unknown pathways involved in MMAuria pathogenesis. 
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8.4.2.1 Pharmacological chaperones 
As described in this thesis, the search for PCs is complicated and requires a step-wise procedure in 
order to screen, verify and implement PCs. I suggest the following future studies/improvements: 
i. Screening processes can be improved by using several methods at once, based on different 
features of the target protein such as structural integrity or enzymatic activity. 
ii. In silico screenings (e.g. by molecular docking methods) may be considered in order to take 
advantage of the available knowledge of the protein structure of MUT. 
iii. Since many disease-causing mutations in the MUT gene are known, different mutant pro-
teins should be used as a substrate of screening, allowing the development of mutation-
tailored molecules. 
iv. Different verification methods should be applied: 
a. Methods which are based on the same feature of the protein as the initial screening 
method (e.g. thermal stability in DSF) in order to confirm the results from the screen-
ing. 
b. Orthogonal verification methods should be based on features of the protein which 
are different from the features used in the initial screening, i.e. if the screening 
method is based on stability (e.g. DSF), the verification method should evaluate the 
effect of the compound on activity (e.g. enzyme assay) or other aspects. 
c. Verification methods should employ different concentrations and incubation times 
of PC molecules. 
d. Verification methods may include studies on the uptake of the compounds into cells 
and their subcellular localisation. 
v. Once candidate PCs for MUT are validated by verification methods, such as cell culture test-
ing or activity assays, they can be tested in the mouse models introduced in this thesis. As a 
proof of principle, molecules should be tailored to the p.Met698Lys mutation in case of the 
ki mouse model introduced here. Further studies may include other mutations which require 
the generation of additional mouse models, carrying different mutations. 
8.4.2.2 Gene therapy 
To replace the defective MUT gene with a healthy copy in all cells of the organism (including the 
CNS) would be the ideal treatment for every mut-type MMAuria patient. Gene therapy in MMAuria 
has been successfully applied in mice (Chandler and Venditti, 2008; Chandler and Venditti, 2010) but 
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human trials have not been initiated yet. In fact, successful gene therapy would be the holy grail for 
all single-gene disorders (including MMAuria) but has seen significant opposition since its effective-
ness needs to be improved and its safety is uncertain at this point.  
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